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Signaling pathways that control cellular responses such as proliferation, quiescence, migration and 
apoptosis are crucial for embryonic development, tissue homeostasis and regeneration. Dysregulation 
of these signaling processes can result in severe human diseases including cancer. Therefore, to 
maintain a balance between the above-mentioned cell fates and to prevent pathological events, an 
interplay between different signaling pathways is indispensable. For instance, mitogenic signaling 
induced by the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)-AKT 
networks is required for cells to enter the cell cycle and divide. However, to prevent uncontrolled 
proliferation, anti-mitogenic signals such as those transmitted by mothers against decapentaplegic 
homologue (SMAD) proteins are essential. To gain a deeper understanding of these pathway 
interactions, I employed quantitative time-resolved measurements of fluorescent reporters and 
computer-aided data analysis.  
In the first part of the present study, I examined how the MAPK and PI3K/AKT pathways synergize to 
regulate cell cycle entry and progression. Although these networks have been well characterized in 
earlier studies, their relative contribution, especially at later cell cycle stages, remains largely 
unexplored. In order to investigate the response of cells outside of an active cell cycle to acute 
mitogenic signals, untransformed human breast epithelial cells were first arrested in a quiescent state 
by growth factor deprivation. Afterwards, epidermal growth factor (EGF)-induced signal processing in 
individual cells was quantified over time, which revealed that both pathways were necessary for initial 
cell cycle entry, whereas only PI3K/AKT affected the duration of S-phase at later stages of mitogenic 
signaling. My results provide evidence that the high metabolic demands of replication are unmet in 
the absence of AKT signaling, which results in a strongly prolonged S-phase of the cell cycle.
In the second part, I investigated how the cell cycle and mitogenic signals influence the SMAD signaling 
pathway. I uncovered that ligands of the transforming growth factor beta (TGFb) superfamily signaled 
very differently in quiescent versus proliferating cells. While TGFb mediated a stronger SMAD2 
response in proliferating cells compared to quiescent cells, the opposite was observed upon growth 
differentiation factor 11 (GDF11) stimulation. I was able to show that MAPK activity was responsible 
for the switch in ligand sensitivity, most likely through regulation of target genes. Therefore, the 
question arose whether a single key player or a complete pathway-rewiring were accountable. As RNA 
sequencing revealed considerable changes in the expression of multiple SMAD-associated genes and 
single perturbations of SMAD signaling regulators could not explain the observed phenomenon, I 




different ligands of the TGFb superfamily. However, further studies using genome-scale knockout or 
activation screenings need to be carried out to validate this idea and recreate the pathway-rewiring in 
proliferating cells. Besides the switch in ligand sensitivity, I observed different SMAD-mediated cell 
fates in proliferating and quiescent cells. While apoptosis was only induced in quiescent cells, epithelial 
to mesenchymal transition (EMT) and cytostasis were found in dividing cells. Interestingly, cellular 
responses correlated well with the dynamics of SMAD signaling, which suggested that ligands mediate 
diverse cellular outcomes through different dynamical patterns of SMAD2 nuclear accumulation. This 






Signalwege, die zelluläre Prozesse wie Proliferation, Quieszenz, Migration und Apoptose steuern, sind 
entscheidend für Embryonalentwicklung, Gewebehomöostase und Regeneration. Eine Fehlregulation 
dieser Signalprozesse kann zu schweren Erkrankungen wie Krebs führen. Daher ist eine 
Wechselwirkung verschiedener Signalwege unerlässlich, um das Gleichgewicht zwischen den oben 
genannten Zellschicksalen aufrechtzuerhalten und pathologische Ereignisse zu verhindern. 
Beispielsweise sind mitogene Signale, die durch das MAPK-Netzwerk vermittelt werden, erforderlich, 
damit Zellen in den Zellzyklus eintreten und sich teilen können. Allerdings sind anti-mitogene Signale, 
wie sie von SMAD-Proteinen übertragen werden, essenziell, um unkontrollierte Zellteilung zu 
verhindern. In der vorliegenden Arbeit wurden quantitative zeitaufgelöste Messungen von 
Reporterzelllinien durchgeführt und die entstandenen Daten mittels computergestützter Analyse 
evaluiert, um ein besseres Verständnis dieser Wechselwirkungen zu erhalten.  
Im ersten Teil meiner Dissertation untersuchte ich wie die MAPK und PI3K/AKT-Signalwege 
zusammenarbeiten, um den Eintritt und das Fortschreiten des Zellzyklus zu regulieren. Obwohl diese 
Netzwerke in früheren Studien gut charakterisiert wurden, ist ihr relativer Beitrag, insbesondere in 
Bezug auf spätere Zellzyklusstadien, noch weitgehend unerforscht. Aus diesem Grund wurde die 
Reaktion quieszenter Zellen auf akute mitogene Stimuli untersucht. Hierfür wurden zunächst nicht 
transformierte humane Brustepithelzellen durch den Entzug von Wachstumsfaktoren in Quieszenz 
gebracht. Danach wurde die EGF-induzierte Signalverarbeitung in einzelnen Zellen über die Zeit 
quantifiziert, was zeigte, dass beide Signalwege für den Eintritt in den Zellzyklus notwendig sind, aber 
nur PI3K/AKT die Dauer der S-Phase beeinflusste. Meine Ergebnisse deuten darauf hin, dass die hohen 
Stoffwechselanforderungen der S-Phase ohne funktionsfähiges AKT nicht erfüllt werden, wodurch es 
zu einer stark verlängerten Zellzyklusphase kommt. 
Im zweiten Teil meiner Arbeit untersuchte ich, wie der Zellzyklus und mitogene Signale den 
SMAD-Signalweg beeinflussen. Dabei ergab sich, dass Liganden der TGFb-Superfamilie in ruhenden 
und sich teilenden Zellen sehr unterschiedliche Auswirkungen haben. Während TGFb eine stärkere 
SMAD2-Antwort in proliferierenden Zellen im Vergleich zu quieszenten Zellen induzierte, hatte GDF11 
einen gegenteiligen Effekt. Ich konnte zeigen, dass der Grund für den Wechsel der 
Liganden-Empfindlichkeit die MAPK-Aktivität war, welche vermutlich die Regulation der Zielgene 
veränderte. Daher stellte sich als nächstes die Frage, ob ein einzelnes Gen oder eine vollständige 
Neuverschaltung des Signalweges für diesen Effekt verantwortlich war. Da RNA-Sequenzierung 




Störungen der SMAD-Signalregulatoren das beobachtete Phänomen nicht nachbilden konnten, stellte 
ich die Hypothese auf, dass eine umfassendere Neuverschaltung des Netzwerks erforderlich ist, um 
die Empfindlichkeit gegenüber verschiedener Liganden zu verändern. Allerdings müssten weitere 
Studien, die beispielsweise Knockout- oder Aktivierungsscreenings im genomischen Maßstab 
verwenden, durchgeführt werden, um diese Hypothese zu validieren. Zusätzlich zur Änderung der 
Liganden-Empfindlichkeit beobachtete ich verschiedene SMAD-vermittelte Zellschicksale in 
proliferierenden und ruhenden Zellen. Während Apoptose nur in Zellen außerhalb eines aktiven 
Zellzyklus festgestellt wurde, wurden EMT und Zytostase nur in sich teilenden Zellen nachgewiesen. 
Die zellulären Reaktionen korrelierten sehr stark mit der Dynamik der SMAD-Signalübertragung, was 
darauf hindeutet, dass Liganden unterschiedliche zelluläre Auswirkungen durch Variationen in den 
SMAD2-Dynamiken vermitteln. Diese quantitativen Eigenschaften des Signalweges wurden später 















1.1 THE DEVELOPMENT OF THE MAMMARY GLAND 
According to current estimations, the human body is composed of 3.72 × 1013 cells (Bianconi et al., 
2013). In adult organisms, most of these cells are non-dividing and outside of an active cell cycle. The 
non-dividing state can be separated into two groups, irreversibly arrested and reactivatable cells. 
Irreversibly arrested cells, such as senescent or terminally differentiated cells, can no longer re-enter 
and progress through the cell cycle. In comparison, reactivatable cells are capable of resuming 
proliferation under appropriate physiological conditions (Figure 1A). These cells are often referred to 
as quiescent or G0 cells and occur, for example, in the liver (hepatocytes), blood (lymphocytes) or 
connective tissue (fibroblasts). Additionally, adult stem cells and some epithelial cells can reside in a 
quiescent cell state. The switch between proliferation and quiescence is essential for regeneration and 
tissue homeostasis of higher organisms (Yao, 2014). For example, hepatocytes are highly differentiated 
cells that are usually in a quiescent state but resume proliferation for liver regeneration and repair 
(Fausto, 2004). Another prime example for a tissue that alternates between proliferation states is the 
mammary gland. The rudiment of the gland is present at birth and remains in a quiescent state until 
the final stages of its development occur during puberty. Under the control of hormones, proliferation 
and migration is induced and enables the gland epithelium to invade into the mammary fat pad 
(Figure 1B). This process is referred to as branching morphogenesis and results in a bilayered ductal 
structure composed of an inner layer of luminal epithelial cells and an outer layer of myoepithelial 
cells. During each estrous cycle, the cells of the bilayered ductal structure proliferate and die. Due to 
hormonal changes throughout pregnancy and lactation, the epithelium is remodeled to form secretory 
alveoli through proliferation and migration. Upon weaning, a process called involution restructures the 
epithelium once again and returns the mammary gland to its quiescent state. This highlights that from 
birth to adulthood, the mammary gland undergoes enormous morphological changes that are 
controlled by hormones and paracrine signals. Each cycle of pregnancy, lactation and involution is 
accompanied by an interplay of proliferation, differentiation, migration and apoptosis (Inman et al., 
2015).  
These developmental features make the mammary gland a versatile tissue, but at the same time prone 
to diseases such as cancer. Apart from some types of skin cancer, breast cancer is the most common 
malignancy in woman. In 2020 it even surpassed lung cancer as the most diagnosed cancer with over 
two million cases worldwide (Sung et al., 2021). In the mammary gland, malignancies arise 
predominantly from the luminal epithelial cells. Given the frequency with which cells divide in this 
tissue, it is not inconceivable that, despite low endogenous mutations rates, around one in eight 




approximately 450 cycles of proliferation and involution in response to hormonal changes induced by 
each menstrual cycle. Another tissue that comprises epithelial cells with a high turnover rate (3-5 days) 
is the intestine. Therefore, it is not surprising that two of the most common cancers in human occur in 
breast and colonic epitheliums (Barker, 2014; Hinck and Näthke, 2014).  
To prevent diseases such as cancer but still enable plasticity and regeneration in tissues like the 
mammary gland, pathways controlling proliferation, cytostasis, apoptosis, adhesion and migration 
need to be tightly and highly regulated. For example, to maintain the balance between quiescence and 
proliferation, the rate and timing of cell divisions need to be precisely coordinated by intracellular 
signaling pathways and extracellular stimuli. Crucial regulators of cell cycle entry and progression are 
the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)-AKT pathways 
(Seger and Krebs, 1995; Liang and Slingerland, 2003). In the breast, hormones such as estradiol and 
progesterone or growth factors like epidermal growth factor (EGF) can stimulate cell proliferation by 
activation of MAPK and PI3K. Moreover, approximately half of breast tumors show increased activity 
of MAPK pathways and around 70 % exhibit mutations of the PI3K network, making the two pathways 
key regulators in breast cancer growth (Simoncini et al., 2000; Santen et al., 2002; Hernandez-Aya and 
Gonzalez-Angulo, 2011). To oppose the effects of mitogenic signaling, anti-proliferative signals such as 
those transmitted by transforming growth factor beta (TGFb) superfamily ligands are indispensable to 
balance proliferation and cytostasis (Massagué and Polyak, 1995). For instance, the branching process 
is inhibited by endogenous production of the cytokine TGFb once the fat pad of the breast is filled with 
the ductal epithelium (Nelson et al., 2006). Besides regulating cell cycle progression, pathways involved 
in mammary gland development coordinate migration and apoptosis to remodel the epithelium. 
Again, TGFb signaling is crucial in regulating these cellular responses. For example, weaning-induced 
involution is TGFb dependent as the cytokine initiates apoptosis and subsequently cell clearance 
through phagocytosis (Nguyen and Pollard, 2000; Kolek et al., 2003; Fornetti et al., 2016; Guo et al., 
2017). Furthermore, TGFb signaling plays an important role in the transdifferentiation of epithelial cells 
to mesenchymal cells (epithelial to mesenchymal transition, EMT), a process that is utilized by the 
mammary gland tissue to facilitate branching morphogenesis (Miettinen et al., 1994; Robson et al., 
2006). As TGFb signaling is essential for the development of the breast, dysregulations of the pathway 
have severe consequences. While cytostatic and apoptosis-inducing effects contribute to a tumor 
suppressive role of TGFb during early oncogenic events, EMT is associated with increased cancer cell 
motility, invasion and metastasis in later stages of tumor progression. Thus, paradoxically, TGFb can 





Figure 1: Schematic representation of proliferation states and the development of the mammary gland. 
(A) Cells are shown that enter a reversible (quiescent) or irreversible (senescent) proliferation state from the G1-phase of the 
cell cycle. Quiescent cells usually require appropriate extrinsic signals to resume proliferation. (B) The development of the 
mammary gland from birth to involution is shown. During puberty and adulthood, the epithelial ductal cells expand into the 
mammary fat pad until it is filled out and the branching process stops. The ducts of the branching structures contain an inner 
layer of luminal epithelial cells and an outer layer of myoepithelial cells. During pregnancy and lactation, hormonal changes 
remodel the mammary gland to form secretory alveoli. Upon weaning, the gland is restructured once again by involution, 
which causes the mammary gland to return to its quiescent state. Each cycle of pregnancy, lactation and involution is 
accompanied by an interplay of cellular responses such as proliferation, migration and apoptosis. The schematic 




1.2 CELL CYCLE PROGRESSION THROUGH PRO-MITOTIC 
SIGNALING 
As indicated above, proliferation is crucial for many biological processes such as the development of 
the mammary gland or regeneration of the liver. For a cell to divide, it needs to enter the cell cycle, a 
complex process in which various regulatory proteins are required to guide a cell through a specific 
sequence of events. In these events, cells increase in size (G1-phase), duplicate their DNA (S-phase), 
prepare to divide (G2-phase) and finally split into two daughter cells (mitosis or M-phase). To prevent 
uncontrolled cell divisions, transitions between consecutive phases need to be strictly regulated by 
different molecular regulators.  
1.2.1 CDK-CYCLIN NETWORK 
Two key protein families that determine this progression through the cell cycle are cyclins and 
cyclin-dependent kinases (CDKs). While cyclin levels increase or decrease over the course of the cell 
cycle, CDK protein levels remain stable. CDKs are serine/threonine kinases that are inactive in the 
absence of partner cyclins. Upon formation of a heterodimer, CDKs are activated and able to mediate 
the phosphorylation of downstream targets to coordinate the transitions of cell cycle phases. Each 
transition is regulated by different cyclin-CDK combinations (Figure 2A) (Schafer, 1998; Vermeulen et 
al., 2003; Suryadinata et al., 2010). In order to facilitate cell cycle entry and the transition from G0 to 
G1, CDK3-cyclin C complexes are required. These complexes initiate the phosphorylation of the 
retinoblastoma protein (RB) at S807/811 and thereby inactivate it. In its active from, RB binds and 
represses the E2F family of transcription factors. Upon phosphorylation of RB, E2F proteins can 
dissociate and induce the expression of genes necessary for G0 exit. Interestingly, S807/811 is also a 
substrate for CDK4-cyclin D complexes, and cells lacking CDK3 but possessing functional CDK4 can still 
undergo the transition from G0 to G1 (Ren and Rollins, 2004; Sage, 2004). Furthermore, a study in 
T-lymphocytes showed that CDK4/6-cyclin D activity is necessary for G0 exit (Lea et al., 2003). After a 
cell enters the G1-phase, it requires continuous mitogenic signals and a steady rate of protein synthesis 
to progress through G1 and prevent it from reverting to a quiescent state. If both conditions are met, 
cells pass a restriction point at which they will continue to progress into S-phase even if growth factors 
are removed (Zetterberg et al., 1995). At the beginning of the G1-phase, and before the restriction 
point, mainly CDK4/6-cyclin D complexes mediate the phosphorylation of RB. Upon phosphorylation, 
E2F transcription factors are activated, which induces the accumulation of cyclin E in later stages of G1 
in cells that have passed the restriction point (Ohtani et al., 1995; Ekholm et al., 2001). Cyclin E then 




Throughout the remainder of the cell cycle, pRB stays hyperphosphorylated and thus in an inactive 
state (Schafer, 1998). The phosphorylation of RB at multiple sites leads to a complete activation of E2F 
and thereby to an even stronger transcriptional activation of the cyclin E gene (Suryadinata et al., 
2010). The CDK2-cyclin E complexes then regulate the progression from G1- to S-phase (Ohtsubo et 
al., 1995). As cells pass into S-phase, cyclin A accumulates and associates with CDK2 while cyclin E is 
degraded by the ubiquitin-proteasome pathway (Clurman et al., 1996; Ekholm et al., 2001). 
Interestingly, cyclin A activates two distinct CDKs and therefore plays an important role not only in 
regulating S-phase, but also in controlling the transition from G2- to M-phase. While the activation of 
CDK2 leads to S-phase progression, the binding to CDK1 promotes the transition from G2- to M-phase 
(Bendris et al., 2011). To precisely time the mitotic entry, the activated CDK1-cyclin A dimers regulate 
the activation and stabilization of CDK1-cyclin B complexes (Boer et al., 2008). Once cyclin B has bound 
CDK1, cyclin A is degraded by ubiquitin-mediated proteolysis (Elzen and Pines, 2001). Depending on 
CDK1-cyclin B, cells progress through mitosis and ultimately exit this cell cycle phase upon proteasomal 
degradation of cyclin B (Hershko, 1999; Suryadinata et al., 2010). Besides mitogenic stimuli that induce 
cyclins and CDKs, there are also anti-mitogenic signals that prevent the progression of the cell cycle, 
for example by inducing cyclin-dependent kinase inhibitors (CKIs) such as p15 and p21 (Quereda et al., 
2016).  
1.2.2 MAPK SIGNALING 
The MAPK pathway is crucial for cell cycle entry and progression as it regulates cyclins and CKIs. To 
activate the MAPK pathway, cells rely on mitogenic stimuli, such as EGF and their respective receptors. 
When EGF binds and activates the EGF receptor (EGFR), the small GTPase RAS induces phosphorylation 
and activation of the kinase rapidly accelerated fibrosarcoma (RAF), which induces a cascade of 
phosphorylation events that include consecutive activation of MAPK/ERK kinase (MEK) and 
extracellular signal-regulated kinase (ERK). Upon phosphorylation, ERK translocates to the nucleus and 
activates transcription of target genes (Figure 2B). Among the first target genes expressed is the 
transcription factor FOS, which is crucial for cellular processes such as proliferation. Thus, FOS is usually 
not expressed in quiescent cells, but its transcription is induced within minutes after stimulation. Once 
the transcription factor is produced, it is rapidly degraded. However, the FOS protein can be stabilized 
through C-terminal phosphorylation which is mediated by nuclear ERK. Therefore, ERK not only 
activates mRNA transcription of FOS, but also prevents the degradation of the corresponding protein. 
Moreover, target genes of the FOS transcription factor, such as FRA1/FOSL1, are stabilized by ERK 
phosphorylation as well. For this reason, a prolonged ERK activity is required to induce FOS and 




addition to this temporal encoding, information in the MAPK pathway may be encoded by the 
amplitude and duration of ERK signaling (Heinrich et al., 2002). Other features like frequency and 
amplitude of cytoplasmic to nuclear ERK oscillation may further affect cellular responses (Shankaran 
et al., 2009). Besides modulating FOS expression, ERK promotes proliferation by inducing expression 
of cyclin D and repression of CKIs (Zhang and Liu, 2002; Rubinfeld and Seger, 2005). As mentioned 
above, activated CDKs phosphorylate RB, which marks the transition from G1- to S-phase of the cell 
cycle. Other signaling-induced processes, such as expression and stabilization of MYC, contribute to 
regulating the G1- to S-phase transition (Leung et al., 2008). 
1.2.3 PI3K/AKT SIGNALING 
In addition to the MAPK pathway, EGFR also activates the PI3K/AKT pathway through direct or indirect 
recruitment and activation of the PI3K subunits p85 and p110. In quiescent cells, the regulatory subunit 
p85 maintains the catalytic subunit p110 in a low-activity state. Through interaction with activated 
growth factor receptors, the basal inhibition of p110 by p85 is disrupted and the subunits are recruited 
to their substrate phosphatidylinositol-4,5-bisphosphate (PIP2) at the plasma membrane. PI3K activity 
then leads to generation of phosphatidylinositol-3,4,5-triphosphate (PIP3), which in turn recruits the 
kinases AKT and phosphoinositide-dependent kinase 1 (PDK1) to the membrane. This brings the 
proteins into proximity and enables phosphorylation and thus activation of AKT by PDK1 (Figure 2B). 
Through activation of mechanistic target of rapamycin kinase (mTOR), AKT influences translation and 
contributes to cyclin D accumulation during cell cycle entry (Cantley, 2002; Hay and Sonenberg, 2004; 
Engelman et al., 2006). In addition, AKT also mediates inhibitory phosphorylation of the cyclin D 
repressor forkhead box O (FOXO) and the kinase glycogen synthase kinase 3 beta (GSK3beta), which 
induces cyclin D degradation (Schmidt et al., 2002; Dong et al., 2005). Furthermore, AKT signaling may 
contribute not only to the transition from G1- to S-phase, but also to other cell cycle transitions by 
affecting the activity and localization of regulatory proteins and by controlling metabolism (Ward and 
Thompson, 2012). 
The PI3K and MAPK pathways interact closely upon mitogenic stimulation (Moelling et al., 2002; Chen 
et al., 2012). It has been suggested that both pathways are compensatory through co-regulated 
proteins (Zwang et al., 2011). Other reports indicate that AKT negatively regulates MAPK activity 
through inactivation of RAF, whereas MEK suppresses PI3K signaling by promoting membrane 
localization of the phosphatase and tensin homologue (PTEN) (Zimmermann and Moelling, 1999; 
Zmajkovicova et al., 2013). PTEN dephosphorylates PIP3 and thus terminates PI3K/AKT signaling 




Taken together, the importance and synergy of ERK and AKT in initiating the cell cycle from G0- to 
S-phase has been well researched, such as the mechanisms by which these pathways interact in 
controlling cyclin D. In contrast, the relative roles of AKT and ERK in controlling later stages of the cell 
cycle are less clear and therefore require further detailed investigations.  
In addition to pro-mitotic signals mediated by the MEK/ERK and PI3K/AKT pathways, there are also 
anti-proliferative signals that prevent uncontrolled cell division. One of the most important signaling 







Figure 2: Schematic representation of CDKs, cyclins and signaling pathways that control the cell cycle. 
(A) Various CDK-cyclin combinations that regulate cell cycle progression are shown. CDK4/6-cyclin D and CDK2-cyclin E 
complexes regulate G1-phase progression and S-phase entry, respectively. To control S-phase progression, cyclin A activates 
CDK2. Afterwards, CDK2 is replaced by CDK1 to mediate the transition from G2- to M-phase through activation and 
stabilization of CDK1-cyclin B complexes. Finally, CDK1 and cyclin B regulate M-phase progression until cyclin B is degraded 
and cells exit the corresponding cell cycle phase. Additionally, the restriction point (R) is marked in the cell cycle. Once cells 
reach the R-point, they are committed to enter S-phase despite a lack of growth factors. (B) The MEK/ERK and PI3K/AKT 
signaling pathways are shown. EGFR stimulation triggers the activation of RAS, RAF, MEK, ERK, PI3K and AKT. Upon activation, 
ERK translocates into the nucleus and regulates expression and stabilization of numerous targets, while activated AKT inhibits 
different kinases and transcription factors such as GSK3 and FOXO, respectively. Green arrows indicate a positive and red 





1.3 SMAD SIGNALING AND ITS PLETHORA OF CELLULAR 
FUNCTIONS 
The SMAD pathway is a crucial signaling network during embryonic development and in the adult 
organism as it controls many cellular processes including cell growth, proliferation, differentiation, 
migration, adhesion and cell death (Schmierer and Hill, 2007; Heldin et al., 2009). Cytokines of the 
TGFb superfamily are inducers of the signaling pathway and regulate this plethora of cellular functions. 
This group of cytokines is comprised of over 30 different ligands, including bone morphogenetic 
proteins (BMPs), growth differentiation factors (GDFs), anti-Muellerian hormones (AMH), activins, 
nodal and TGFbs (Shi and Massagué, 2003). To initiate signaling events, ligands bind to two pairs of 
type I and type II receptor serine/threonine kinases on the cell surface. Upon ligand binding, the 
receptors form a heterotetrameric complex that allows the type II receptors to phosphorylate the 
type I receptors. Activated signaling complexes then mediate phosphorylation of intracellular SMAD 
proteins at their C-terminal domains (Shi and Massagué, 2003; David and Massagué, 2018). This 
phosphorylation process is enhanced or inhibited by the internalization of receptor complexes. While 
endocytosis mediated by clathrin promotes SMAD activation, endocytosis mediated by lipid rafts 
facilitates degradation of ligand-receptor complexes. Internalized receptors that are not degraded can 
be recycled to the cell surface or continue to phosphorylate SMAD proteins from the endosome (Chen, 
2009).  
The SMAD family consists of eight members, which can be classified in three categories: 
receptor-regulated SMADs (R-SMADs; isoforms 1, 2, 3, 5, 8), the common-mediator SMAD (Co-SMAD; 
isoform 4) and inhibitory SMADs (I-SMADs; isoforms 6 and 7) (Massagué et al., 2005). Depending on 
the type of ligand, either SMAD2/3 or SMAD1/5/8 are activated. After phosphorylation, R-SMADs 
heterotrimerize with SMAD4, translocate to the nucleus and interact with transcription factors to 
regulate the expression of SMAD target genes (Feng and Derynck, 2005). Within the nucleus, 
SMAD-specific phosphatases such as protein phosphatase 1A (PPM1A) and pyruvate dehydrogenase 
phosphatase (PDP) dephosphorylate R-SMADs and enable their nuclear export (Chen et al., 2006; Lin 
et al., 2006; Bruce and Sapkota, 2012). Back in the cytoplasm, R-SMADs can be phosphorylated again. 
The cycle of SMAD import and export continues for as long as active receptors are present (Inman et 
al., 2002). Ultimately, SMAD signaling is terminated by a variety of control mechanisms. Besides SMAD 
dephosphorylation in the nucleus, negative feedback regulators of the pathway such as SMAD6 and 7, 
can inhibit and terminate signal transduction through various mechanisms (Schmierer and Hill, 2007). 
For example, I-SMADs interfere with oligomerization or phosphorylation of SMAD molecules. While 




heterotrimerization with SMAD4, SMAD7 recruits the E3 ubiquitin ligase SMURF2 for degradation of 
TGFb receptors (Imamura et al., 1997; Kavsak et al., 2000; David and Massagué, 2018).  
In general, SMAD signaling is a simple and straightforward pathway comprising two signaling branches 
(SMAD2/3 and SMAD1/5/8) as well as a small set of type I and type II receptors. Ligands that signal via 
SMAD2/3 utilize either TGFb receptor 2 (TGFBR2), activin A receptor 2A (ACVR2A), activin A receptor 
2B (ACVR2B) or BMP receptor 2 (BMPR2) as type II receptors and TGFb receptor 1 (TGFBR1), activin A 
receptor 1B (ACVR1B) or activin A receptor 1C (ACVR1C) as type I receptors. To increase signaling 
efficiency, some ligands require a specific co-receptor such as TGFb receptor 3 (TGFBR3), that 
facilitates the binding to their corresponding type I/II receptor complexes. The wide range of cytokines 
and limited selection of receptors lead to multiple ligands sharing the same serine/threonine kinase 
receptors. For instance, activin A and GDF11 both bind to ACVR2A and ACVR2B and mediate the 
phosphorylation of SMAD2/3 through ACVR1B. However, GDF11 can also signal through TGFBR1, the 
type I receptor for TGFb ligands (David and Massagué, 2018). Therefore, activin A, TGFb and GDF11 
not only utilize the same signaling branch, but also partially identical receptors. A schematic 
representation of SMAD signaling after activin A, TGFb and GDF11 treatment is shown below (Figure 3). 
Interestingly, many in vitro and in vivo studies have shown that the different members of the TGFb 
superfamily exert quite distinct biological functions. For example, knockout experiments revealed that 
50 % of TGFb deficient mice died during embryogenesis and survivors developed inflammatory 
disorders, whereas mice with activin A deficiency either died during the perinatal period or showed 
craniofacial defects. Furthermore, knockout of GDF11 induces completely different phenotypes, since 
mice deficient for this growth factor are viable and exhibit posterior displacement of hindlimbs. 
Although the common SMAD2/3 pathway is functional, compensation by other ligands is not possible, 
indicating a divergence of ligand-mediated effects (Chang et al., 2002; Matsuo et al., 2006). Strikingly, 
even strongly related ligands such as myostatin (GDF8) and GDF11 mediate distinct biological 
functions. While GDF8 is best known for inhibiting muscle growth and limiting bone mass, GDF11 
regulates skeletal patterning during embryogenesis and has been proposed as a rejuvenating factor. A 
more recent study even showed that GDF11 counteracts the functions of GDF8 by promoting 
osteogenesis (Katsimpardi et al., 2014; Sinha et al., 2014; Suh et al., 2020). However, the postnatal 
functions of GDF11 are controversially discussed, possibly due to its diverse functionality 
(Simoni-Nieves et al., 2019). Taken together, ligands of the TGFb superfamily can exhibit diverse and 
sometimes contradicting effects on cellular responses, even though they utilize the same signaling 
branch and similar receptor complexes. The molecular mechanisms controlling these biological 




multitude of ligands remains unanswered. The converging signaling pathway and the limited number 
of receptors suggest that the distinction is made on the ligand/receptor level. For example, agonists 
and antagonist of SMAD signaling that control ligand availability and ligand-receptor interactions 
specify signaling input on an extracellular level. Follistatin (FST), a GDF8/11 and activin A inhibitor or 
decorin, a TGFb and GDF8 antagonist, are two of many ligand regulators that add complexity to the 
straightforward signaling pathway (Chang, 2016). Furthermore, co-receptors like TGFBR3, cripto and 
cryptic can promote ligand-specific responses. Besides these additional components influencing 
downstream signaling in a ligand-dependent manner, signals mediated by members of the TGFb 
superfamily might also be spatially and temporally interpreted by the pathway. Thus, ligand-specific 
functions would be encoded by distinct activation patterns (dynamics) of R-SMADs shaped by intrinsic 
properties of ligands and receptors, such as binding affinities, binding kinetics and geometry of 
ligand-receptor complexes (Nickel and Mueller, 2019). As it has been reported that dynamic features 
like amplitude, duration or frequency of pathway activation are able to control cellular responses 
(Purvis and Lahav, 2013; Johnson and Toettcher, 2019), the idea of a quantitative SMAD pathway 





Figure 3: Schematic representation of the SMAD signaling pathway after stimulation with different ligands. 
In the extracellular space, activin A, GDF11 and TGFB1 dimers initiate the signaling events by binding to a pair of their 
corresponding type II receptors. Upon ligand binding, type II receptors form a complex with two type I receptors. Type II 
receptors phosphorylate and thus activate type I receptors, which subsequently activate intracellular SMAD2/3 by 
phosphorylation. Afterwards, activated SMAD2/3 proteins form a heterotetrameric complex with SMAD4 and enter the 
nucleus to regulate gene expression. One of many target genes of the SMAD pathway is SMAD7, which negatively regulates 
the signaling process by engaging E3 ubiquitin ligase and thus initiating receptor degradation. Besides SMAD7, there are also 
ligand-specific antagonists that inhibit SMAD signaling, such as FST and decorin. Both proteins can bind ligands and prevent 
their interaction with corresponding receptors. Within the nucleus, SMAD-specific phosphatases, like PPM1A, 
dephosphorylate SMAD2/3 and initiate the separation of the SMAD complex. Ultimately, SMAD2/3 and SMAD4 split up and 




1.4 MEASUREMENT OF PROTEIN DYNAMICS IN SINGLE CELLS 
Cellular signaling is often investigated with experiments based on populations of cells. While these 
studies provide a useful overview, essential information about the heterogeneity of individual cells is 
usually lost in the average response of the population (Loewer and Lahav, 2011). This was for example 
demonstrated for the p53 tumor suppressor pathway. In response to DNA damage, p53 dynamics were 
described as damped oscillations (Lev Bar-Or et al., 2000). Single-cell experiments, however, revealed 
that individual cells show varying numbers of undamped p53 pulses of fixed amplitude and duration 
(Lahav et al., 2004). In case of SMAD signaling, studies based on individual cells revealed that 
R-SMADs-SMAD4 complex formation and nuclear translocation upon TGFb stimulation occur with 
considerable cell-to-cell variability (Warmflash et al., 2012; Zieba et al., 2012). Thus, when studying 
signaling networks, it is important to investigate not only the population average but also the 
single-cell level. Furthermore, since cell signaling events can occur within seconds, minutes or hours 
after stimulation and often involve translocation of signaling molecules, analyses with high temporal 
and spatial resolution are essential in order to fully understand dynamic behavior of biological 
responses. While techniques such as immunofluorescence microscopy or flow-cytometry enable 
investigations of single cells, they are limited by their inability to analyze the same cell over time. In 
contrast, live-cell time-lapse microscopy provides unmatched temporal resolution and allows to follow 
signaling processes of thousands of individual cells (Figure 4). To utilize this approach, reporter cell 
lines need to be generated, containing fluorescently labeled proteins of interest. Thereby, quantitative 
measurements of protein levels and subcellular localization are facilitated (Ankers et al., 2008). As 
shown in previous studies, cells can encode information in dynamic patterns of signaling molecules. 
For example, while p53 pulses following γ-irradiation are associated with cell cycle arrest, a single 
sustained p53 response upon UV radiation leads to apoptosis (Purvis et al., 2012). Another example is 
the activation of the ERK pathway by nerve growth factors (NGF) and EGF. While NGF mediates a rather 
sustained ERK response that leads to differentiation of rat neuronal precursors, EGF causes a transient 
activation that leads to cell proliferation (Gotoh et al., 1990; Traverse et al., 1992; Nguyen et al., 1993; 
Purvis and Lahav, 2013). Therefore, it is important to examine dynamical patterns of signaling 
molecules.  
Since a key step in SMAD signaling is the rapid translocation of SMAD proteins from the cytoplasm to 
the nucleus upon ligand stimulation, a technique such as live-cell imaging is crucial to gain a better 
understanding of the corresponding pathway. For this reason, we used SMAD2/SMAD4 reporter cell 
lines, time-lapse imaging and automated image analyses in a recent study to quantitatively 




strongly heterogeneous SMAD2 dynamics were observed in TGFb-treated cell populations. By utilizing 
dynamic time-warping, thousands of SMAD2 time courses were clustered to identify six cellular 
sub-populations with qualitatively distinct signaling behavior. For example, cells that do not respond 
to stimulation (non-responders) and cells that show a strong and sustained response were divided in 
different sub-populations. The distribution of the signaling classes were dependent on extracellular 
stimuli. While the fraction of non-responders decreased with increasing TGFb concentrations, the 
fraction of cells showing stronger SMAD2 activation increased. Interestingly, a correlation between the 
sub-populations and cellular responses was observed. In general, SMAD2 activation resulted in 
increased motility and reduced cell division rate in all signaling classes except for non-responders. 
However, cells exhibiting a sustained response, showed more pronounced phenotypic changes 
compared to transiently responding cells. These results emphasize that the cell-specific temporal 







Figure 4: Schematic representation of live-cell time-lapse microscopy and single-cell analysis. 
To utilize time-lapse microscopy, a reporter cell line that contains fluorescently labeled proteins of interest is required. For 
the present study, a transgenic MCF10A SMAD2 reporter cell line was used that expresses a SMAD2 coding sequence fused 
to a yellow fluorescent protein (YFP-SMAD2) and a histone 2B coding sequence fused to a cyan fluorescent protein (H2B-CFP). 
Both transgenes are under control of a constitutive human Ubiquitin C promoter (UbCp). The fluorescently labeled proteins 
can then be measured over several hours with a high temporal and spatial resolution. As a result, large data sets of time 
series images are generated, which are evaluated using automated image analysis. With this approach, hundreds of individual 
cells are tracked over time and protein dynamics of each cell are measured. To study SMAD2 translocation, the ratio between 




1.5 GENE EXPRESSION AND ASSOCIATED CELL FATES OF 
SMAD SIGNALING 
1.5.1 TRANSCRIPTIONAL CONTROL BY SMAD SIGNALING 
As mentioned in the previous sections, the SMAD pathway regulates a diverse array of cellular 
processes including proliferation, migration and cell death. To elicit such a variety of biological 
functions, members of the TGFb superfamily initiate different programs of gene expression. The signal 
transducers for these cytokines are SMAD proteins, which accumulate in the nucleus upon stimulation 
and bind DNA directly or indirectly (Figure 5). By binding to enhancer/promoter sequences in the 
regulatory regions of target genes, activated SMAD complexes can act as transcription factors and 
regulate gene expression positively or negatively (Massagué, 2012; Hill, 2016). The common mediator 
SMAD4 as well as all R-SMADs except for SMAD2 can bind DNA directly. In general, SMADs consist of 
highly conserved N-terminal and C-terminal domains known as mad homology 1 (MH1) and mad 
homology 2 (MH2), respectively (Hill, 2016). The two domains are separated by a flexible linker region 
that contains sites for regulatory phosphorylation by kinases such as MAPKs and CDKs (David and 
Massagué, 2018). While the MH1 domain in R-SMADs can bind DNA, the MH2 domain mediates 
protein-protein interactions with TGFb receptors, SMAD proteins and DNA-binding co-factors (Shi et 
al., 1998; Macias et al., 2015). The MH1 domain of SMAD1, SMAD3, SMAD4 and SMAD5 recognize 
common 5 bp, GC-rich sites (GGCGC and GGCCG), which are considerably enriched in promotor and 
enhancer elements of SMAD target genes. Therefore, at first sight, SMAD complexes seem to be 
limited in their DNA-binding specificity, since most SMADs bind to the same DNA motifs. Yet, 
ligand-activated SMAD2/3 and SMAD1/5/8 can regulate different sets of target genes (David and 
Massagué, 2018). This specificity is usually achieved by SMAD proteins cooperating with other 
DNA-binding transcription factors. Depending on the DNA-binding partner, these interactions occur 
either via the MH1 or MH2 domain. One of the first transcription factors reported to interact with 
SMADs was the forkhead box protein H1 (FOXH1). In case of activin stimulations, activated 
SMAD2-SMAD4 complexes translocate into the nucleus, where FOXH1 binds the MH2 domain of 
SMAD2 and recruits the complexes to an activin-response element to provide ligand-dependent 
transcription (Chen et al., 1997; Zhou et al., 1998; Feng and Derynck, 2005). Further examples are the 
FOXO transcription factors, a subgroup of the forkhead family, which form complexes with 
TGFb-activated SMAD proteins and mediate cytostasis by inducing CDKN1A expression (Seoane et al., 
2004). Interestingly, this process is negatively regulated by the PI3K pathway and thus shows a good 
example of an interplay between proliferative and anti-proliferative signals. In essence, SMAD 




complex cellular responses such as EMT and apoptosis. Therefore, SMAD proteins cooperate with a 
remarkable diversity of transcription factors to initiate different programs of gene expression.  
1.5.2 EMT, CYTOSTASIS AND APOPTOSIS 
During EMT, tightly connected adherent cells lose their cell polarity and cell-cell interactions to acquire 
a motile and migratory phenotype. While the transition from epithelial to mesenchymal cells is an 
essential event during embryonic development and tissue remodeling, it can also lead to aggressive 
tumor progression in cancers (Arima et al., 2008). To facilitate this transition, this process drives cells 
through a progressive adoption of gene expression changes. In brief, upon SMAD activation, cells 
upregulate the expression of transcription factors such as SNAI1 and ZEB1. While SNAI1 initiates EMT 
by decreasing E cadherin (CDH1) expression, ZEB1 downregulates CDH1 expression further to maintain 
the mesenchymal phenotype (Figure 5). Furthermore, markers of mesenchymal cells like N-cadherin 
(CDH2) and vimentin (VIM) are upregulated through this process (Zhang et al., 2014). Besides EMT, 
ligands of the TGFb superfamily mediate anti-proliferative and pro-apoptotic signals. As mentioned 
above, activated SMAD proteins can initiate cytostatic effects by inducing CDKN1A expression. 
Moreover, MYC, a potent regulator of cell cycle progression, has been shown to be a downstream 
target of the SMAD pathway (Yagi et al., 2002). To repress MYC transcription, the MH2 domain of 
SMAD3 forms a complex with the transcription factors E2F4/5 and DP1 as well as the co-repressor 
p107. In response to TGFb stimulation, this complex relocates from the cytoplasm to the nucleus and 
binds the inhibitory element of the MYC promotor to facilitate repression of the corresponding gene 
(Chang et al., 2002). Additionally, it has been shown that TGFb upregulates cell cycle inhibitors such as 
CDKN1B and CDKN2B (Robson et al., 1999). Not only the cytostatic activity, but also the ability to 
induce apoptosis, makes SMAD signaling an important tumor suppressor pathway. The apoptotic 
response to TGFb is well documented in various cell lines and many SMAD-associated events have 
been identified to mediate apoptosis (Schuster and Krieglstein, 2002). One downstream effector of 
TGFb signaling that was repeatedly reported to initiate apoptosis is the zinc-finger transcription factor 
krueppel-like factor 10 (KLF10). Overexpression of this protein has been demonstrated to induce 
apoptosis in hepatocytes and epithelial cells (Chalaux et al., 1999; Ribeiro et al., 1999). Another crucial 
determinant of TGFb-mediated apoptosis is the BIM gene (Wildey et al., 2003; Yu et al., 2008). This 
pro-apoptotic regulator is expressed by SMAD3-induced runt-related transcription factor 1 (Runx1), 
which binds to FOXO3 to upregulate the corresponding gene (Ramesh et al., 2009). A more recent 
publication connected TGFb-initiated apoptosis with an altered regulation of SRY-box transcription 




have also been associated with apoptosis in other studies (Zhao et al., 2008; Hur et al., 2010; Cheng et 
al., 2018).  
Taken together, SMAD proteins modify gene expression by directly binding to the regulatory region of 
target genes or by interacting with various activators and repressors. Due to that, ligands of the TGFb 
superfamily can elicit complex gene expression changes and a variety of biological responses. 
 
Figure 5: Schematic representation of SMAD-mediated gene expression and associated cellular responses. 
Ligand-activated SMAD complexes regulate gene expression by either binding promotor sequences of target genes directly 
or by interacting with specific transcription factors. By initiating different programs of gene expression, stimulus-dependent 
SMAD signaling mediates cell fates, such as cytostasis, EMT and apoptosis. For example, the signaling pathway can induce 
EMT by upregulating the expression of mesenchymal markers like SNAI and VIM and downregulating the expression of 




1.6 AIM OF THIS THESIS 
This study aims to evaluate the interplay of different signaling pathways in regulating cell fate 
decisions. As described above, the physiology of the mammary gland is a prime example for a tissue 
whose development is orchestrated by an interplay of signaling pathways. Cell fate decisions such as 
proliferation, quiescence, migration and apoptosis need to be precisely balanced to ensure a successful 
progression of the mammary gland from birth to involution. As disturbances of the corresponding 
pathways can lead to severe diseases such as cancer, it is of utmost importance to gain a deeper 
understanding of the signaling processes determining these cellular outcomes. Therefore, to approach 
this task, I investigate how signaling networks in individual breast epithelial cells influence each other 
to ultimately control cellular outcomes. To this end, I combined time-resolved single-cell 
measurements of signaling dynamics with pharmacological or genetic perturbations and RNA 
sequencing. 
In the first chapter, the objective is to investigate how the MEK/ERK and PI3K/AKT pathways synergize 
upon EGF stimulation to regulate cell cycle entry and progression. As the importance of ERK and AKT 
in initiating the progression from G0- to S-phase has been researched before, the focus lies on 
examining the relative roles of the corresponding pathways in controlling different stages of the cell 
cycle. 
The objective of the second chapter is to examine how the cell cycle and mitogenic pathways, such as 
those mentioned above, influence stimulus-dependent SMAD signaling in individual cells. Moreover, I 
aim to study gene expression changes and SMAD-associated cell fates such as apoptosis and EMT in 
quiescent and proliferating cells and correlate them to SMAD2 dynamics. Thereby, I intent to answer 
the question whether the corresponding cellular responses are ligand specific or whether the dynamics 





Figure 6: Graphical abstract of this thesis. 
The overall aim of the present study is to investigate the effects of mitogenic signaling pathways on cell cycle entry and 
progression (Part 1) as well as to elucidate the impact of the cell cycle and mitogenic signals on SMAD2 dynamics (Part 2). To 
achieve this objective, I combine live-cell time-lapse imaging of specific reporter cell lines on a single-cell level with 










2 DISENTANGLING PRO-MITOTIC SIGNALING 
Part 1 of this work is based on a study that was recently published in Cell Reports ( Benary*, M., Bohn*, 
S., Lüthen, M., Nolis, I.K., Blüthgen, N., and Loewer, A. (2020). Disentangling Pro-mitotic Signaling 
during Cell Cycle Progression using Time-Resolved Single-Cell Imaging. Cell Reports 31, 107514. 
https://doi.org/10.1016/j.celrep.2020.03.078). All the following experiments, except for rehydration 
and library preparation for single-cell sequencing, were performed by me. Data analysis was carried 
out by Manuela Benary (Charité-Universitätsmedizin Berlin) and the manuscript was written with 
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2.1 RESULTS OF PART 1 
The rate and timing of cell divisions need to be precisely coordinated by intracellular signaling 
pathways and extracellular stimuli to maintain the balance between quiescence and proliferation and 
enable proper cellular homeostasis. To study the influence of signaling pathways on cell cycle entry 
and progression, I quantified EGF-induced mitogenic signaling in quiescent cells and decoded the 
dynamic contributions of downstream signaling pathways by combining time-resolved single-cell 
measurements of ERK activity in an untransformed human breast epithelial cell line with targeted 
pharmacological perturbations, single-cell RNA sequencing (scRNA-seq) and statistical analyses.  
2.1.1 QUANTITATIVE LIVE-CELL IMAGING REVEALS CELL-SPECIFIC 
ACTIVATION PATTERNS OF THE EGFR/ERK PATHWAY 
To analyze EGF-induced signaling in living cells, I used a previously established MCF10A reporter cell 
line termed FIRE (Fra-1-based integrative reporter of ERK). This reporter is based on the fluorescent 
protein mVenus fused to a nuclear localization signal (NLS) and the PEST domain of FRA1, a 
transcription factor stabilized by ERK phosphorylation (Albeck et al., 2013) (Figure 7A and B). In the 
absence of mitogenic stimuli activating the EGFR/ERK pathway, the constitutively expressed reporter 
is rapidly degraded. When cells are treated with the growth factor EGF, FIRE is stabilized through 
ERK-dependent phosphorylation and accumulates in the nucleus (Figure 7C). It therefore provides a 
specific linear measure of the integrated activity of the EGFR/ERK pathway over long, physiologically 
relevant time scales (Gillies et al., 2017). By withdrawing mitogenic growth factors and serum for 48 h 
(2.3.2) before stimulating reporter cells with defined EGF doses (from 0.5 ng/ml to 50 ng/ml) I was able 
to investigate the progression of quiescent cells from G0-phase of the cell cycle to mitosis. I then 
measured the nuclear fluorescence intensity of FIRE for 48 h and generated time-resolved trajectories 
of FIRE intensity, representing more than 850 individual cells per condition by using automated image 
analysis followed by data processing and normalization (Figure 7D and E) (2.3.5). 




Figure 7: Analyzing ERK activity in living cells. 
(A) Scheme of the EGF pathway, where EGFR stimulation triggers the activation of RAF, MEK and ERK by phosphorylation. 
ERK translocates to the nucleus, where it phosphorylates numerous targets, including the transcription factor FRA1. 
Phosphorylation of the PEST domain of FRA1 by ERK leads to stabilization of the protein. I used a fluorescent reporter that 
contains the PEST domain of FRA1 and is stabilized by ERK phosphorylation (FIRE). See also Albeck et al., 2013. (B) Scheme of 
the FIRE activity is shown. The reporter consists of the PEST domain of FRA1 fused to mVenus, a yellow fluorescent protein, 
and a nuclear localization sequence. The reporter is constitutively expressed by the murine stem cell virus long terminal 
repeat (MSCV LTR) and then rapidly degraded. ERK phosphorylates the FRA1 domain at multiple sites and thereby stabilizes 
the reporter. (C) Example images of the FIRE reporter at indicated time points and EGF concentrations. Scale bar: 24 µm. 
(D) Workflow for segmenting and tracking single cells. Cells stably expressed NLS-CFP as a nuclear marker (panel 1), which 
was used to segment the nucleus (panel 2). For tracking single cells, a customized greedy algorithm was used; in panel 3 
tracked cells are labeled with their corresponding identifier. For each tracked cell, the total fluorescence intensity of the FIRE 
reporter was quantified (panel 4). (E) Time courses of five cells are shown (different dashed lines) to exemplify the 
normalization procedure. The raw integrated fluorescence intensities for the FIRE reporter in each cell are depicted over time 
(panel 1). The integrated fluorescence intensity of the FIRE reporter in each cell was normalized by the corresponding 
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fluorescence intensity of the NLS-CFP nuclear marker to remove spurious spikes in single-cell trajectories (panel 2). 
Subsequently, time courses were further normalized by the mean nuclear marker normalized FIRE level of cells in the absence 
of EGF stimulation leading to a measure of FIRE induction upon EGF treatment. 
If cells were not stimulated with EGF, they showed no detectable changes in reporter activity, 
indicating that there was no residual input to the MAPK pathway under my experimental conditions 
(Figure 7C and Figure 8A). By treating the cells with low EGF doses (0.5 ng/ml and 1 ng/ml EGF), I 
observed a transient FIRE accumulation during the first 10-15 h (first phase). When stimulated with 
concentrations above 2.5 ng/ml, cells showed a second phase of FIRE activity with increasing amplitude 
and duration after approximately 15 h (second phase) (Figure 8A and B). On the single-cell level, most 
cells showed a first FIRE response at EGF concentrations of as low as 0.5 ng/ml, while the fraction of 
cells showing a second phase of FIRE signals saturated at EGF concentrations of 5 ng/ml or higher 
(Figure 8C). Additionally, the two phases were analyzed separately by looking at different features like 
amplitude (Amp), fold change (FC), timing of the maximum (Time), duration and area under the curve 
(AUC) (Figure 8D). Again, the results showed that low EGF concentrations did not induce a second 
phase of FIRE activation. Noticeable increases in FC, AUC and Amp of the second phase were only 
achieved by EGF concentrations from 2.5 ng/ml to 50 ng/ml (Figure 8F). In contrast, at early time points 
(first phase) the values of these three features increased regardless of EGF concentrations (Figure 8E). 
Therefore, the features of the first phase allow me to discriminate if the cells were stimulated or not 
and the features of the second phase to discriminate between high and low doses. Taken together, 
using quantitative live-cell imaging I was able to show a bi-phasic ERK activity profile with an early and 
late response at high EGF concentrations. 




Figure 8: Dynamic features of the bi-phasic ERK activity profile. 
(A) Examples of single-cell FIRE reporter time series for randomly selected single cells treated with indicated EGF 
concentrations. Mean time courses (bold lines) and standard deviations (gray ribbons) of all measured cells are indicated. 
Growth factor- and serum-deprived cells were treated with the indicated doses of EGF. Images were acquired every 20 min 
for 46 h. The number of cells analyzed is indicated in 6.3 (Appendix) for each live-cell microscopy experiment. (B) Average 
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FIRE reporter time series for concentrations from 0 ng/ml EGF to 50 ng/ml EGF. Color indicates EGF concentration. 
(C) Percentage of cells showing a response within 16 h (light gray) after stimulation and between 20 h after stimulation and 
the end of measurement (gray). Cells with amplitudes greater than three standard deviations from the average of 
unstimulated cells were considered responders. Error bars indicate 95 % confidence interval based on bootstrapping 
(n = 1,000). (D) Scheme of features describing the FIRE response after EGF treatment. The FIRE response is separated into 
early and late responses, and each phase is characterized by the following features: amplitude (Amp), time of the maximum 
(Time), fold change of the amplitude (FC), duration of the response and area under the curve (AUC). (E) Shown are box plots 
comparing the features of first response, namely amplitude (in arbitrary unit (au)), time of the maximum (in hours), fold 
change of the amplitude (in au), duration of the response (in hours) and area under the curve (in au). The amplitude was 
defined as the mean of the three highest FIRE responses after normalization. The fold change is taken with respect to the 
mean response of FIRE in the same cell before stimulation. The area under the curve has been estimated using a spline 
interpolation and the duration is an estimation of full width at half maximum (2.3.6). Boxes include data between the 25th 
and 75th percentiles. Black lines indicate the median, whiskers extend to maximum values within 1.5× the interquartile range 
and dots represent outliers. The same applies to all following box plots. (F) Corresponding box plots comparing the features 
of the second response (as in (E)). 
2.1.2 ERK ACTIVITY IS NECESSARY BUT NOT SUFFICIENT FOR CELL 
CYCLE ENTRY AND PROGRESSION 
To characterize how EGF signaling controls the phenotypic response of individual cells, I determined if 
and when cells entered S-phase using a fusion of a red fluorescent protein mCherry (RFP) with the first 
110 amino acids of geminin (Albeck et al., 2013) (Figure 9A). As geminin is degraded by APCCdh1 during 
G1-phase and only accumulates during S- and G2-phase (Sakaue-Sawano et al., 2008; Clijsters et al., 
2013), I defined an increase of more than 2× the standard deviation of the basal RFP level as the time 
of S-phase entry (Figure 9B). This method to determine S-phase entry correlated well with 
measurements of actively replicating cells marked by EdU incorporation, even at low stimulation levels 
(Figure 9C-E). At the transition between meta- and anaphase of mitosis, geminin is degraded by 
APCCdc20, which resulted in a sharp decline in the intensity of the geminin reporter (Figure 9B). I will 
refer to the duration of geminin accumulation as the duration of S/G2-phases, whereas the beginning 
of geminin accumulation will be termed S-phase entry. The timing of the meta- to anaphase transition 
will be called cell division. 




Figure 9: Following cell cycle progression in individual cells. 
(A) Scheme of the geminin-based cell cycle reporter. The reporter consists of the first 110 amino acids of geminin fused to a 
red fluorescent protein. The reporter is kept at low levels during G1-phase, accumulates over S/G2/M-phase and is rapidly 
degraded at the transition between meta- and anaphase of mitosis (Clijsters et al., 2013). (B) Time courses of the normalized 
geminin reporter for three cells are shown to exemplify the detection of cell cycle phases (light gray, dark gray and dashed 
lines). The red dotted line indicates the threshold for detecting cell cycle phases. Light orange asterisks show the time points 
for cells entering S-phase and dark orange asterisk show the time points immediately after division. (C) Violin plots showing 
the EdU intensity (log10-normalized) distribution. Cells were stained with EdU 20 h after stimulation with different 
concentration of EGF. Suggested threshold to separate EdU positive from EdU negative cells is indicated as black dashed line. 
(D) Percent of EdU positive cells at indicated concentrations of EGF. Error bars indicate 95 % confidence interval based on 
bootstrapping (n = 1,000). (E) Comparing EdU negative or positive cells with cells in G1- or S-phase, respectively, according to 
geminin levels. Red numbers indicate the percentage of cells in the corresponding cell cycle phase. 
Without EGF stimulation, cells showed neither S-phase entry nor cell division, emphasizing that there 
was no residual mitogenic activity under my experimental conditions and all observed cell cycle 
progression was dependent on EGF-induced signaling. I observed that increasing the EGF 
concentrations resulted in more and more cells entering S-phase, reaching a maximum of roughly 90 % 
of the cells at concentrations of 7.5-10 ng/ml EGF (Figure 10A). I observed a similar increase of cells 
dividing at least once within 48 h. However, the fraction of dividing cells remained considerably lower 
at approximately 70 % (Figure 10A) as the duration of S/G2-phases extended beyond the observation 
period in cells with late S-phase entry. Accordingly, the time of S-phase entry was heterogeneously 
distributed around 20 h post stimulation in individual cells, mostly independent of the strength of the 
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mitogenic stimulus (Figure 10B). Cells responding to low EGF concentrations, however, only entered 
S-phase at earlier time points. This can be explained by the rapid decay of EGF under these conditions 
and thereby a lack of mitogenic signaling at later times. The duration of S/G2-phases was similarly 
distributed with a median around 18 h (Figure 10C). Interestingly, there was no clear correlation 
between time of S-phase entry and duration of S/G2-phases (Figure 10D). 
Only about half of the cells entered S-phase when stimulated with low EGF concentrations 
(Figure 10A). For this reason, I wanted to see if cells that entered S-phase differed in their integrated 
ERK activity profile compared to cells that remained in a quiescent state. When analyzing cells that 
have been treated with 1 ng/ml EGF, a concentration at which about 50 % of the cells entered the cell 
cycle, the median FIRE signal during the first response was only slightly higher in cells entering S-phase 
than those that remained in G0/G1, indicating that the FIRE signal has low predictive power for the cell 
cycle fate of a cell (Figure 10F). Additionally, actively replicating cells marked by EdU incorporation 
showed only minor increases in FIRE levels at various time points (Figure 10E). Cells treated with higher 
EGF concentrations displayed no noticeable differences in the shape and amplitude between cells 
entering S-phase and those which did not (Figure 10F). Even when I align the single-cell FIRE 
trajectories to the time of S-phase entry to correct for asynchronies in the response and compared 
these trajectories to FIRE trajectories of quiescent cells aligned to a matched time distribution, I again 
detected only marginal differences (Figure 10F). 
As I could not observe a strong correlation between the FIRE signal and S-phase entry, I analyzed if cell 
divisions were affected by integrated ERK activity. Comparing the fold change in FIRE levels during the 
first response in dividing and non-dividing cells, I observed a similar trend as for S-phase entry 
(Figure 10G). Interestingly, a more pronounced difference between cycling and quiescent cells was 
only observed when FIRE levels in the 16 h prior to cell division were analyzed. However, as this 
difference was only visible in cells treated with high doses of EGF, the measurements did not provide 
support for a decisive influence of ERK signaling in the completion of the cell cycle. Another interesting 
observation was that integrated ERK activity was not increased at low doses of EGF in the hours before 
cell division. This suggested that ERK activity might occur at late S-phase when EGF is present but may 
not be necessary to complete the cell cycle. Generally, my findings corroborated that ERK activity is 
required for quiescent cells to re-enter the cell cycle as previously reported (Zhang and Liu, 2002; 
Sharrocks, 2006), but since the variability of cellular responses cannot be explained, it is likely that 
additional mitogenic inputs are transmitted upon ligand stimulation. 




Figure 10: The role of ERK activity for cell cycle entry and progression. 
(A) Percentage of cells entering S-phase (light gray) and dividing (white) at indicated concentrations of EGF. Error bars indicate 
95 % confidence interval estimated with bootstrapping (n = 1,000). (B) Distribution of the time at which S-phase starts after 
stimulation with indicated concentrations of EGF. (C) Estimates of the length of S/G2-phase distribution (time from beginning 
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of S-phase to division) for three different concentrations of EGF (1 ng/ml, 7.5 ng/ml, and 50 ng/ml) using Kaplan-Meier 
analysis (2.3.7). (D) Scatterplot comparing the time at which S-phase starts after stimulation and length of S/G2-phase for 
two different concentrations of EGF (1 ng/ml and 7.5 ng/ml). Ellipses indicate area that include 95 % of the cells. (E) 
Normalized FIRE intensity at different time points (1 h, 8 h and 19 h 40 min) before EdU staining. Cells were labeled with EdU 
(for 40 min) 20 h after EGF treatment. Violin plots with EdU positive cells are dark gray and populations with EdU negative 
cells are light gray. Horizontal lines indicate the median FIRE intensity. (F-G) Average (bold line) and standard deviation 
(ribbon) of reporter time series (normalized to unstimulated control) of cells entering S-phase (yellow) and cells that do not 
enter S-phase (gray) stimulated with indicated concentrations of EGF. Left graphs show the first 16.5 h after stimulation; right 
graphs show 16.5 h before the onset of S-phase or equivalently sampled time series for non-responding cells (F). Comparison 
of dividing cells (orange) and non-dividing cells (gray) for the first 16.5 h after stimulation or before division (G). 
2.1.3 PI3K SIGNALING CONTRIBUTES A NECESSARY MITOGENIC 
STIMULUS UPON EGF TREATMENT 
Next, I systematically perturbed components of the MAPK signaling pathway (2.3.3) while monitoring 
integrated ERK activity, time of S-phase entry and duration of the S/G2-phase to determine the extent 
to which the ERK/MAPK pathway transmits pro-mitotic signals from EGFR activation (Figure 11A). By 
using the small molecule inhibitor gefitinib, the activity of EGFR was blocked, which abrogated all ERK 
signaling activity as well as cell cycle entry and progression (Figure 11B and C). This re-emphasized that 
in this model, EGFR signaling is essential for cell cycle entry. Although MEK inhibition prevented FIRE 
activation to a similar extent as the EGFR inhibitor (Figure 11B), about 10 % of cells started cycling in 
this condition (Figure 11C). Interestingly, the duration of S/G2-phases of those cells that entered the 
cell cycle was unaffected by MEK inhibition (Figure 11D). Although MEK appeared to be an important 
factor in cell cycle progression, inhibition of the kinase did not completely block cell cycle entry as it 
was observed with EGFR inhibition. This suggested that parallel pathways contribute significantly to 
mitogenic signaling. Therefore, I pharmacologically inhibited kinases from interacting pathways like 
p38 (SB203580), c-Jun N-terminal kinase (JNK) (JNK inhibitor VI) and GSK3 (SB216763). JNK and GSK3 
inhibition had no effect on ERK activity and only led to minor changes in the cellular response 
(Figure 11B-D). However, I observed an increased FIRE signaling upon p38 inhibition (Figure 11B). 
Interestingly, this did not lead to an increase in the fraction of cells entering S-phase or dividing 
(Figure 11C). In contrast, I observed a longer duration of S/G2-phases as well as a concomitant 
decrease in the number of cells dividing (Figure 11C and D). This again indicated that ERK activity is not 
limiting for cell cycle regulation. Finally, I inhibited the PI3K pathway using a pharmacological inhibitor 
(LY29402). As the PI3K pathway is activated in parallel to MAPK signaling through the EGF receptor, it 
is an obvious candidate for transmitting additional mitogenic input. Indeed, inhibiting the kinase led 
to almost a complete block of cell cycle entry and progression. Interestingly, those few cells that 
entered the cell cycle had prolonged S/G2-phases (Figure 11C and D). When assayed with the FIRE 
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reporter, ERK was still as active as in control cells (Figure 11B). The effect of inhibiting the downstream 
kinase AKT with the small molecule MK-2206 led to similar effects on the cell cycle as PI3K inhibition 
(Figure 11B-D). 
 
Figure 11: Pharmacological perturbation reveals relative contributions of MEK/ERK and PI3K/AKT pathways during 
mitogenic signaling. 
(A) Scheme of the EGF pathway indicating the targets (colored asterisks) of pharmacological inhibitors used in this study. 
Dashed lines indicate indirect activation. (B) Average time courses of the FIRE reporter after stimulation with EGF for controls 
(gray) and after pre-incubation with the indicated inhibitors. For controls, the standard deviation around the mean of five 
experiments is shown (gray ribbon) (6.3). (C) Effect of inhibitors on the percentage of cells entering S-phase (top panel) or 
dividing (bottom panel) at the indicated concentration of EGF. Error bars indicate 95 % confidence interval based on 
bootstrapping (n = 1,000). (D) Effect of inhibitors on the duration of S/G2-phases for two different EGF (1 ng/ml and 7.5 ng/ml) 
concentrations by using Kaplan-Meier analysis.  
Strikingly, I observed strong FIRE levels upon p38, PI3K and AKT inhibition. As blockage of these three 
kinases led to less cell cycle entry and increased FIRE activity, it was plausible that inhibited cell cycle 
progression might affect ERK activity. To test this hypothesis, I inhibited cell cycle progression using 
the CDK4/6 inhibitor palbociclib and CDK1 inhibitor RO3306. While CDK4/6 inhibition completely 
prevented S-phase entry and cell division, CDK1 inactivation only reduced the number of cells dividing. 
Nevertheless, as FIRE levels were not amplified in both conditions, a direct influence of cell cycle 
blockage on ERK activity seemed unlikely (Figure 12A-D). 




Figure 12: Inhibited cell cycle progression does not affect ERK activity. 
(A) Average time courses of the FIRE reporter after stimulation with different concentrations of EGF and preincubation with 
CDK inhibitors. (B) Effect of CDK inhibitors on the percent of cells entering S-phase (solid bars) or undergoing division (open 
bars). Error bars indicate 95 % confidence interval based on bootstrapping (n = 1,000). (C) Start of S-phase within 47 h after 
stimulation with different concentrations of EGF and CDK inhibition. (D) Effect of CDK inhibition on the duration of S/G2-
phases upon stimulation with different concentrations of EGF using Kaplan-Meier analysis. 
2.1.4 CELL CYCLE ENTRY AND PROGRESSION HAVE DIVERGING 
TEMPORAL REQUIREMENTS FOR MAPK AND PI3K SIGNALING 
The next step was to better understand the contribution of MAPK and PI3K signaling for regulating cell 
cycle entry and progression. To this end, I inhibited the corresponding pathways as well as EGFR activity 
at different time points after EGF stimulation (Figure 13A). When EGFR-dependent signaling was 
blocked entirely 10 h after EGF treatment by gefitinib treatment, FIRE signals rapidly decreased, and 
cell cycle entry was prevented in nearly all cells (Figure 13B-E). Sustaining EGFR activity for 15 or 20 h 
led to an increasing fraction of cells entering and progressing through the cell cycle. As expected, the 
duration of ERK activity was extended as well. When I inhibited MEK at different time points after EGF 
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stimulation, a similar decay of the FIRE response was observed (Figure 13B). However, more cells 
entered S-phase when the MEK inhibitor was added at 10 h compared to gefitinib. Even more striking 
was the relative increase in cells dividing compared with EGFR inhibition at all time points tested 
(Figure 13C). In contrast, PI3K inhibition at 10 h, 15 h or 20 h post EGF treatment showed a comparable 
suppression of S-phase entry and cell division as EGFR inhibition despite only temporarily attenuating 
ERK activity (Figure 13B and C). Blocking EGFR, MEK or PI3K signaling for different periods at the 
beginning of the experiment led to delayed FIRE accumulation and S-phase entry as expected 
(Figure 13F-I). However, cells still entered S-phase in comparable numbers after inhibitors were 
washed away (Figure 13J and K). A decrease in dividing cells was only observed when inhibitors were 
present for 15 h due to the limited observation period. These results corroborate that both ERK and 
PI3K activity are necessary for S-Phase entry (Jones and Kazlauskas, 2001). 
A close look at the cells that progressed into S-phase upon PI3K inhibition revealed higher geminin 
levels at the time of treatment, indicating that they already passed the restriction point and initiated 
the transition from G1- to S-phase prior to the loss of PI3K activity (Figure 13D). Importantly, the 
duration of S/G2-phases in cycling cells was strongly increased when PI3K signaling was blocked 
10-20 h after EGF treatment (Figure 13E). The same decreased rate of cell cycle progression was 
observed upon EGFR inactivation. However, preventing ERK activation through MEK inhibition had no 
effect once cells entered the cell cycle (Figure 13E). 




Figure 13: Temporal requirements for ERK and AKT activity differ during cell cycle progression. 
(A) Scheme of experiment. EGFR, MEK, and PI3K inhibitors were added either at time of stimulation or 10 h, 15 h, or 20 h 
after stimulation. (B) Average time courses of the FIRE reporter after stimulation with 7.5 ng/ml EGF and incubation with the 
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indicated pharmacological inhibitors at different time points or controls (gray). For controls, the standard deviation around 
the mean of three experiments is shown (gray ribbon). (C) Effect of inhibitors on the percentage of cells entering S-phase 
(left) or dividing (right) for the indicated time of inhibition after stimulation. Error bars indicate 95 % confidence interval 
based on bootstrapping (n = 1,000). (D) Comparison of geminin levels at time of inhibitor treatment (as indicated) between 
cells entering S-phase (right, dark gray) and cells that do not enter S-phase (left, light gray) within the time of measurement. 
Numbers of cells for each condition are indicated. (E) Effect of the time of inhibitor treatment (as indicated) on the duration 
of S/G2-phases after stimulation with 7.5 ng/ml EGF compared to controls using Kaplan-Meier analysis. (F) Average time 
courses of the normalized FIRE reporter after stimulation with 7.5 ng/ml EGF alone or in combination with a MEK inhibitor or 
PI3K inhibitor. The inhibitors were washed from the medium 5 h, 10 h or 15 h later. (G) Average time course of the normalized 
FIRE reporter stimulation with 7.5 ng/ml EGF in combination with an EGFR inhibitor. The inhibitor was either kept during the 
complete experiment (dark) or washed off after 15 h (light). (H) Comparing the effect of pulsed inhibition using a MEK or a 
PI3K inhibitor on the timing of S-phase entry. (I) Comparing the effect of pulsed inhibition using an EGFR inhibitor on the 
timing of S-phase entry. (J) Effect of pulsed inhibition on the percent of cells entering S-phase (solid bars) or dividing (open 
bars). Error bars indicate 95 % confidence interval based on bootstrapping (n = 1,000). (K) Same approach as in (J), but the 
EGFR inhibitor was used instead. 
To further investigate the role of PI3K signaling for S- and G2-phase progression, I aimed to initiate ERK 
activation for a short period of time and then additionally activate PI3K by additional ligands. To do so, 
I used EGF at a low dose (0.5 ng/ml) that, due to ligand degradation, is expected to induce only 
transient signaling. I additionally stimulated cells with insulin-like growth factor (IGF) (2.5 µg/ml), 
which is expected to preferentially initiate the phosphorylation and thus activation of AKT (Zheng and 
Quirion, 2006; Ma and Bai, 2012) (Figure 14A). By using the FIRE reporter, transient ERK activation at 
low doses of EGF that was unaffected by the addition of IGF was confirmed (Figure 14B). Moreover, 
IGF treatment alone did not induce FIRE accumulation (Figure 14C). Although the transient ERK 
activation was sufficient to induce cell cycle entry in approximately 25 % of cells (Figure 14D), these 
cells needed longer to complete S/G2-phase than cells with high EGF inputs (Figure 14E). However, 
when I combined low EGF input with IGF stimulation, which predominantly activates the PI3K pathway, 
it rescued the phenotype and resulted in cell cycle progression rates comparable to high EGF stimuli 
(Figure 14E).  Importantly, IGF treatment alone did not result in appreciable cell cycle entry 
(Figure 14F), whereas a combination of low EGF and strong IGF inputs led to a modest increase in the 
fraction of cells entering S-phase and dividing (Figure 14D). Consistently, actively replicating cells 
incorporating EdU showed slightly increased levels of phosphorylated AKT compared to cells remaining 
in G1 upon treatment with both EGF alone and EGF together with IGF (Figure 14G and H). Similar results 
were obtained when combining low doses of EGF with insulin (5 µg/ml), which also activates the PI3K 
pathway (Engelman et al., 2006) (Figure 14I-K). 




Figure 14: AKT activation rescued delayed cell cycle progression at low EGF concentrations. 
(A) Scheme of the EGF and IGF pathways and the rescue approach. (B) Average time courses of the FIRE reporter after 
stimulation with different concentrations of EGF as well as co-stimulation with IGF (2.5 µg/ml). (C) Average time courses of 
the FIRE reporter after stimulation with different concentrations of IGF alone. (D) Percentage of cells entering S-phase (solid 
bars) or dividing (open bars) after stimulation. Error bars indicate 95 % confidence interval based on bootstrapping (n = 1,000). 
(E) Comparing the effect of IGF stimulation on the duration of S/G2-phases using Kaplan-Meier analysis. (F) Effect of IGF 
stimulations alone on the percent of cells entering S-phase (solid bars) or undergoing division (open bars). Error bars indicate 
95 % confidence interval based on bootstrapping (n = 1,000). (G) Percentage of EdU positive cells. Cells were first stimulated 
with different concentrations of EGF (green bars) alone or in combination with 2.5 µg/ml IGF (blue bar) and after 20 h stained 
with EdU. Error bars indicate 95 % confidence interval based on bootstrapping (n = 1,000). (H) Comparing the distribution of 
cytoplasmic pAKT levels between EdU negative (light gray) and EdU positive cells (dark gray) using immunofluorescence 
(2.3.8). P-values based on a t-test are indicated with asterisk (ns: p > 0.05, *: p <= 0.05, **: p <= 0.01, ***: p <= 0.001, ****: 
p <= 0.0001). (I) Average time courses of the FIRE reporter after stimulation with different concentrations of EGF in 
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comparison to a rescue experiment with additional insulin. (J) Effect of insulin stimulation on the percent of cells entering 
S-phase (solid bars) or dividing (open bars). Error bars indicate 95 % confidence interval based on bootstrapping (n = 1,000). 
(K) Comparing the effect of insulin stimulation on the duration of S/G2-phases using Kaplan-Meier analysis. 
To strengthen the understanding of PI3K signaling and its role during S- and G2-phase, I stimulated 
cells with EGF and inhibited MEK and PI3K activity 15 h later. I then employed scRNA-seq to determine 
expression profiles of individual cells 20 h and 30 h after addition of the growth factor (Figure 15A, 
2.3.9-2.3.11). Visualization of the resulting data by dimensionality reduction using uniform manifold 
approximation and projection (UMAP) showed clear separation of quiescent and EGF-stimulated cells 
(Figure 15B, gray and blue dots). Blocking PI3K and MEK signaling led to distinct expression profiles 
that clustered separately from cells treated with EGF only (Figure 15B, green and red dots). 
Interestingly, expression profiles of inhibitor-treated cells differed at the 20 h and 30 h time points. 
Similar results were obtained in a replicate experiment and by using a different dimensionality 
reduction method (principal component analysis, (Figure 15D and E)). To correlate expression profiles 
of individual cells with cell cycle progression, the cell cycle state of each cell was mapped by using 
characterized marker genes (Stuart et al., 2019) (2.3.11). With this approach I was able to determine 
cell cycle distributions for each condition and time point that were comparable to previous analyses 
using time-lapse microscopy (Figure 15F). Combining the UMAP projection with cell cycle information 
revealed a clear progression of EGF-stimulated cells from G1- to S- and G2/M-phase (compare 
Figure 15B and C). Importantly, cells progressing into S- and G2/M-phase in the presence of PI3K and 
MEK inhibitors showed clearly distinguishable expression profiles. Using the pathway activity scores 
calculated by the PROGENy method (Schubert et al., 2018), I validated that inhibitor treatment led to 
the expected changes in MAPK and PI3K signaling (Figure 15G). 




Figure 15: Cell cycle resolved expression analysis of single cells upon mitogenic stimulation. 
(A) Scheme of scRNA-seq experiments. Cells were stimulated with 7.5 ng/ml EGF. MEK or PI3K inhibitors were added after 
15 h and cells were sampled for scRNA-seq at the indicated time points. (B) UMAP for one experiment. Cells are barcoded for 
experimental condition. (C) UMAP as in (B) with cells barcoded for cell cycle phases. (D) Principal component analysis (PCA) 
of highly variable genes based on scRNA-seq from the first replicate. The first two principal components (PC) are plotted; dots 
indicate individual cells; colors correspond to stimulation with EGF (blue), additional inhibition with MEK (orange) or PI3K 
(green) inhibitor. As indicated, cells were sampled at different time points. (E) PCA of highly variable genes based on 
scRNA-seq from a replicate experiment. (F) Stacked bar plot indicating the number and fractions of cells in G1-phase (gray), 
S-phase (yellow) and G2/M-phase (purple) for different conditions and for two replicates. (G) PROGENy pathway activity 
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scores for MAPK pathway (upper panel) and PI3K pathway (lower panel) over time and for the different conditions. Each dot 
indicates one replicate and dashed lines connect the corresponding mean values as guidance. 
As a next step, differentially expressed genes upon inhibitor treatment depending on cell cycle state 
and time point were determined and the corresponding molecular pathways using gene ontology (GO) 
term analysis were resolved (Figure 16). In G1-phase cells, I mainly observed changes in the expected 
molecular pathways, such as response to growth factors. In S-phase cells, only PI3Ki-treated cells 
showed significant changes, which mainly affected pathways involved in metabolic processes, such as 
mitochondrial respiration, translation and ribonucleotide synthesis. In G2/M-phase cells at 30 h post 
EGF stimulation, MEK and PI3K inhibition induced distinct alterations in pathway activity. For PI3K 
inhibition, changes in G2/M-phase cells partially overlapped with those observed during S-phase 
(Figure 16). 
 
Figure 16: Pathway enrichment analysis upon pharmacological inhibition of MEK and PI3K. 
Pathway enrichment using differential gene expression for samples treated with MEK or PI3K inhibitor in comparison to EGF 
stimulation at the indicated time points and cell cycle phases. 
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I further analyzed cell cycle distributions to determine if the observed delay in cell cycle progression 
upon PI3Ki treatment was due to an increased duration of S- or G2/M-phase. As expected, I observed 
a decreased fraction of cells in S-, G2- or M-phase 20 h after EGF treatment when MEK or PI3K activity 
was inhibited 15 h post stimulation (Figure 17A). The fraction of S/G2M-phase cells further decreased 
at the 30 h time point, as no additional cells could enter S-phase in the absence of MAPK or PI3K 
signaling, whereas others successfully completed cell division. By analyzing the ratio between S- and 
G2/M-phase cells under both conditions, I observed that most cells without active MEK completed 
S-phase between the 20 h and 30 h time point (Figure 17B). However, upon PI3Ki treatment, a 
noticeable fraction of cells remained in S-phase at the 30 h time point, suggesting a delay in S-phase 
progression. To further validate these findings, I imaged FIRE reporter cells upon EGF treatment by 
time-lapse microscopy, inhibited MEK and PI3K activity after 15 h and labeled the cells with EdU (2.3.4) 
at 22.5 h and 32.5 h post stimulation, respectively (Figure 17C). Consistent with the scRNA-seq analysis, 
most geminin-positive cells were EdU positive and thereby actively replicating at the 22.5 h time point 
(Figure 17D). After 32.5 h, most MEKi treated cells completed S-phase and entered G2-phase. As 
expected, control conditions showed active replicating cells at 32.5 h as cells were still able to enter 
S- from G1-phase. However, although no additional cells were able to enter S-phase upon PI3K 
inhibition, I observed that most of the treated cells were still EdU positive at the later time point.  To 
estimate the corresponding time of S-phase progression, cells were binned according to the time of 
S-phase entry, as indicated by geminin accumulation relative to the time of metabolic labeling, and the 
corresponding fraction of EdU-positive cells was determined (Figure 17E). Nearly all control and 
MEKi-treated cells completed S-phase within 16 h, whereas most cells without active PI3K remained 
in S-phase for over 20 h. This severe delay in S-phase progression was further supported by a slower 
rate of EdU incorporation in PI3Ki- than in MEKi-treated cells (Figure 17F).  
Taken together, quantitative time-resolved analysis at the single-cell level uncovered that the 
mitogenic EGF signal is transmitted both via the MAPK and PI3K signaling pathway. Activation of both 
pathways together is necessary for cell cycle entry. However, timely progression through S-Phase is 
mainly dependent on a sustained PI3K signaling to adjust to the metabolic needs of the cells during 
replication. 




Figure 17: PI3K signaling is required for timely progression through S-Phase. 
(A) Percentage of cells in S/G2M-phase based on cell cycle markers (dots, replicates; lines, mean). (B) Effect of MEK or PI3K 
inhibitors, respectively, on percentage of cells in S-phase. (C) Scheme of live-cell imaging experiments with EdU stainings at 
different time points. (D) Percent of EdU-positive cells that started S-phase before EdU staining based on analysis of geminin 
levels. Error bars indicate 95 % confidence interval based on bootstrapping (n = 1,000). (E) Effect of MEK or PI3K inhibitor on 
the number of EdU-positive cells labeled at indicated time points. Cells were binned according to the time since entering 
S-phase (based on geminin). Error bars indicate 95 % confidence interval based on bootstrapping (n = 1,000). (F) Effect of 
MEK (orange) and PI3K inhibitor (green) on the extent of EdU incorporation. 
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2.2 DISCUSSION OF PART 1 
Mitogenic signaling gives multicellular organisms the opportunity to regulate the rate and timing of 
cell division. To ensure precise control over cell cycle entry and progression, the information flow 
through multiple signaling pathways needs to be integrated dynamically to coordinate the different 
components of the cell cycle machinery (Chambard et al., 2007). By combining live-cell microscopy, 
scRNA-seq, pharmacological perturbations and computer-aided data analysis, I was able to disentangle 
the contributions of the MAPK and PI3K/AKT pathways to mitogenic signaling during different cell cycle 
phases. By using a specific fluorescent reporter cell line, I measured signaling activity in single cells. In 
addition to unrivaled temporal resolution, live-cell microscopy allows resolving non-genetic 
heterogeneity that can strongly influence the outcome of signaling events (Spiller et al., 2010). Several 
strategies have been developed to monitor MAPK pathway activity in living cells: fluorescence 
resonance energy transfer (FRET)-based reporters allow direct measurements of substrate 
phosphorylation but are limited by a low signal-to-noise ratio and are prone to saturation (Komatsu et 
al., 2011; Selimkhanov et al., 2014; Ryu et al., 2015; Gillies et al., 2017). Translocation-based reporters 
provide a similar, but more robust ratio-metric measure (Regot et al., 2014). However, their sensitivity 
is also restricted to certain segments of the ERK dynamic range (Gillies et al., 2017). Nuclear localization 
of an ERK-YFP fusion correlates with its activity on short time scales but can be affected by other 
cellular processes (Cohen-Saidon et al., 2009). Finally, as I was interested in understanding how and 
when total ERK activity affects cell cycle progression, I decided to employ the FIRE reporter that linearly 
reflects integrated ERK activity (Albeck et al., 2013; Gillies et al., 2017). When my results are compared 
to previously reported data from Albeck et al., 2013, it is important to note that different experimental 
conditions were used. I primarily focused on the response of quiescent cells to acute growth factor 
stimulation, whereas previous studies focused on steady-state EGF signaling under sustained 
stimulations. Additionally, only signaling effects of the MAPK-pathway in the nucleus were considered, 
since the FIRE reporter is not able to capture cytoplasmic activity (Murphy et al., 2002). This might 
explain why under some conditions, such as PI3K and AKT inhibition, FIRE response and 
phosphorylation diverge.  
Using computer-aided data analysis, I extracted time series of ERK activity over two days for thousands 
of cells treated with varying concentrations of EGF. Thereby, I was able to show a bi-phasic ERK activity 
profile with an early and late response at high EGF concentrations. The continuous measurements 
from unperturbed individual cells, thus, confirmed previous observations from biochemical studies of 
cell populations (Meloche et al., 1992). From this data, it was proposed that initial ERK activity is 
necessary to mediate the transition from the G0 state of the cell cycle to G1. During G1-phase, reduced 
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nuclear ERK activity promotes cell cycle progression, as the transcription factor FOS is degraded and 
replaced by FRA1 (Burch et al., 2004). Sufficiently strong activation of ERK during late G1-phase is finally 
necessary to induce transcription factors such as early growth response protein 1 (EGR1), which 
mediate the all-or-none decision to enter S-phase and divide (Zwang et al., 2011). I could confirm that 
ERK signaling is required for S-phase entry by using pharmacological inhibitors to artificially abbreviate 
ERK activity (Figure 13). However, I did not detect a clear correlation between ERK activity and S-phase 
entry at low EGF doses in simultaneous measurements of FIRE and cell cycle reporters (Figure 10F). 
Consistently, there was no direct correlation between S-phase entry and the occurrence of a second 
signaling phase (Figure 8C and Figure 10A). One possible explanation could be that entering S-phase is 
similar to a stochastic decision that requires sustained ERK activity. Depending on the duration of 
G1-phase, transient ERK signaling may be sufficient in one cell to enter S-phase, while in other cells 
both phases of ERK signaling may be required. Another explanation for the observed heterogeneity in 
S-phase entry might be varying levels of cell cycle inhibitors such as p21. In previous single-cell 
experiments, it was shown that the decision between proliferation and quiescence in cycling MCF10A 
cells is controlled by a bifurcation in CDK2 activity due to varying levels of p21 as a consequence of 
endogenous DNA damage during replication (Spencer et al., 2013; Arora et al., 2017; Barr et al., 2017). 
It will now be interesting to investigate if p21 heterogeneity persists during growth factor 
deprivation-induced quiescence or if other molecular mechanisms are responsible for the 
heterogeneous responses to low EGF concentrations. For example, it could be possible that 
heterogeneous expression of inhibitors of the PI3K pathway, which I showed to be required for cell 
cycle entry as well, contributes to the proliferation–quiescence decision.  
In addition to quantifying the decision to enter the cell cycle, the frequency and timing of cell division 
were determined by following the phenotypic response of each cell. Using pharmacological 
perturbations, I showed that ERK signaling is dispensable after the restriction point has been exceeded, 
while PI3K/AKT activity was required both for entering S-phase and for timely progression to mitosis. 
However, it was not possible to induce cell cycle entry by activation of AKT through IGF or insulin alone. 
During G1, it is known that ERK and AKT signaling interact at the level of cell cycle inhibitors, although 
the precise effects may depend on the cell line studied (Zwang et al., 2011; Worster et al., 2012). My 
experiments using inhibitors at different time points after EGF stimulation revealed that PI3K inhibition 
completely blocked S-phase entry, whereas with MEK inhibition some cells still entered S-phase. These 
results are consistent with previous studies, which showed that G1 progression requires PI3K/AKT and 
ERK signaling, whereas S-phase entry itself is mainly dependent of PI3K/AKT (Jones and Kazlauskas, 
2001). As AKT activity can suppress anti-proliferative gene products induced during early G1-phase, it 
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may render cells permissive for ERK-driven S-phase entry (Zwang et al., 2011). However, the role of 
AKT in controlling S/G2 progression is less well documented. It was shown that blocking PI3K/AKT 
signaling prolongs progression through S/G2-phase, but it remained unclear which of the two phases 
is prolonged (Dangi et al., 2003). Employing scRNA-seq and life-cell imaging combined with metabolic 
labeling showed that inhibition of AKT signaling strongly prolongs S-phase (Figure 15 and Figure 17). 
One proposed mechanism is that AKT phosphorylates CDK2 and regulates its subcellular localization 
during S-phase (Maddika et al., 2008). The resulting nucleo-cytoplasmic shuttling of CDK2 may be 
important for cell cycle progression. Therefore, in further studies it could be interesting to research 
AKT activity and CDK2 localization simultaneously in living cells. Additionally, high metabolic demands 
of S-phase may require strong AKT signaling. The AKT signaling pathway is crucial for cellular 
metabolism, including glycolysis and nucleotide biosynthesis (Ward and Thompson, 2012). Analysis of 
the differentially expressed genes in the scRNA-seq data showed that, indeed, PI3K inhibition 
deregulates genes involved in metabolic processes during S-phase (Figure 16). This provides evidence 
that high metabolic demands are not fulfilled in the absence of AKT activity, which contributes to 
prolonged S-phase progression. Additionally, AKT signaling also influences cell growth via mTOR 
signaling (Ward and Thompson, 2012), and cell size, in turn, might influence the length of S-phase 
(Lloyd, 2013). However, it is currently unknown if and how cell size and cell cycle are coupled (Lloyd, 
2013).  
One of the most important cell fate decisions is the control of proliferation and perturbation of this 
process can be involved in severe pathologies. For instance, amplification of EGF receptors in breast 
cancer cells or mutations in the PI3K pathway, such as PTEN deletion, can lead to increased mitogenic 
signaling. While single perturbations will not lead to changes in cell proliferation in most cases, the 
accumulation of alterations observed during tumorigenesis can cause hypersensitivity to growth 
factors. A detailed understanding of temporal requirements and synergies between major mitogenic 
mechanisms could be advantageous in developing therapeutic interventions that prevent altered cell 
signaling. Instead of treatments with single agents such as gefitinib, a thoughtful schedule of 
combination therapies might be more efficient in targeting both proliferating and quiescent cells. 
Additional studies utilizing quantitative experimental data and computer-aided analysis will provide 
the necessary molecular insights for such next-generation therapies. 
  
2 Disentangling Pro-mitotic Signaling 
 
46 
2.3 MATERIAL AND METHODS OF PART 1 
2.3.1 CELL LINES 
MCF10A cells were grown in Dulbecco's Modified Eagle Medium (DMEM/F12, Thermo Fisher Scientific) 
supplemented with 5 % horse serum (Thermo Fisher Scientific), 20 ng/ml EGF (PeptroTech), 0.5 µg/ml 
hydrocortisone (Sigma Aldrich), 100 ng/ml cholera toxin (Sigma Aldrich), 10 µg/ml insulin (Sigma 
Aldrich), 2 mM glutamax (Thermo Fisher Scientific), 100 U/ml penicillin and 100 µg/ml streptomycin 
(Thermo Fisher Scientific). From now on this medium is referred to as growth-medium. The FIRE 
reporter has been previously described (Albeck et al., 2013). In brief, it is an indirect reporter of ERK 
activity, which consists of the PEST domain of FRA1 fused to YFP. Expression is driven by the MSCV LTR. 
The reporter cell line also stably expresses NLS-CFP (mCerulian) as a nuclear marker to facilitate 
automatically tracking and segmenting cells. In addition, the reporter cell line also expresses geminin 
as a marker for the transition from G1- into S-phase and for division. 
2.3.2 GROWTH FACTOR DEPRIVATION AND LIVE-CELL TIME-LAPSE 
IMAGING 
For live-cell imaging experiments, I used 24-well imaging plates (ibidi). I seeded 3.75 × 104 cells per well 
and incubated them in growth-medium for 36 h before the medium was exchanged to DMEM/F12 
containing 0.3 % tissue culture grade BSA (Sigma Aldrich), 0.5 µg/ml hydrocortisone, 100 ng/ml cholera 
toxin, 100 U/ml penicillin and 100 µg/ml streptomycin. From now on this medium is referred to as 
deprivation-medium. Cells were incubated for 48 h in the serum- and growth factor-free medium to 
ensure that cells go into a quiescent state. At least 2 h before the experiment, I changed medium to 
phenol red-free FluoroBrite medium (Thermo Fisher) containing 0.3 % tissue culture grade BSA, 
0.5 µg/ml hydrocortisone, 100 ng/ml cholera toxin, 2 mM glutamax, 10 mM HEPES (Thermo Fisher 
scientific), 100 U/ml penicillin and 100 µg/ml streptomycin (from now on referred to as 
deprivation-microscopy-medium). Cells were imaged with a Nikon Eclipse Ti-E inverted microscope 
with perfect focus system. All experiments were performed using a 20 × CFI Plan Fluor objective and a 
Nikon DS-Qi2 digital camera. Fluorescent proteins were excited with a X-Cite 120 LED illumination 
system (Lumen Dynamics) at 540 nm for YFP and 485 nm for CFP. The used filter sets were: 500/20 nm 
excitation, 515 nm beam splitter and 480/40 nm emission filter for YFP and 436/20 nm excitation, 
455 nm beam splitter and 480/40 nm emission filter for CFP. Over 48 h images were taken every 
20 min. The monitoring and acquisition of the images was controlled by Nikon NIS Elements AR 
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software. To ensure a stable environment, the microscope was enclosed with an incubation chamber 
controlling temperature, atmosphere (5 % CO2) and humidity (Okolab). 
2.3.3 LIGAND AND INHIBITOR TREATMENT 
Inhibitor and ligand treatments were performed in the appropriate deprivation-(microscopy)-medium. 
In stimulation experiments, cells were imaged for 1 h prior to growth factor stimulation.  If not marked 
differently, inhibitors were diluted in DMSO and used as indicated below. Control cells were treated 
with medium only or medium containing DMSO. 
Inhibitors and ligands Used concentration 
CHIR-98014 GSK3b inhibitor (Selleckchem)  1 µM 
Gefitinib EGFR inhibitor (Cayman Chemical) 10 µM 
IKK2 inhibitor (Calbiochem) 5 µM 
JNK inhibitor VIII (Cayman Chemical) 10 µM 
Ly294002 PI3K inhibitor (Alexis Biochemicals) 50 µM 
MK-2206 AKT1/2/3 inhibitor (Selleckchem) 5 µM 
Palbociclib CDK4/6 inhibitor in Sodium DL-Lactate 
(MedchemExpress) 
10 µM 
RO-3306 CDK1 inhibitor (Axon Medchem 10 µM 
SB203580 p38 inhibitor (Selleckchem) 10 µM 
SB216763 GSK-3 inhibitor (Sigma Aldrich) 1 µM 
Selumetinib (AZD6244) MEK1/2 inhibitor (Selleckchem) 1 µM 
Sorafenib RAF kinases inhibitor (Selleckchem) 10 µM 
U0126 MEK1/2 inhibitor (Selleckchem) 10 µM 
EGF (Peprotech) various concentrations 
IGF (Peprotech) various concentrations 
Insulin (Peprotech) 10 µg/ml  
2.3.4 EDU STAINING 
For EdU staining in live-cell imaging, cells were incubated with 10 mM EdU (EdU Click-647, Thermo 
Fisher Scientific) at defined time points. After 40 min, EdU was washed off with 
deprivation-microscopy-medium and the supernatant of a backup plate, which was treated equally, 
was utilized to ensure appropriate EGF concentrations. Immediately after the experiment, cells were 
fixed with 2 % paraformaldehyde (Sigma-Aldrich) in PBS. Afterwards, cells were washed with PBS, 
permeabilized with 0.1 % Triton X-100 (Carl Roth) in PBS and blocked with 10 % goat serum 
(PAN-Biotech GmbH) in PBS. For EdU detection, a reaction cocktail was prepared according to the 
manufacturer’s instructions and added to the cells. After 30 min incubation at room temperature, cells 
were washed with 0.1 % Triton X-100 in PBS and counterstained with 2 mg/ml Hoechst (Invitrogen) in 
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0.1 % Triton X-100/PBS. Using the same positions, cells were imaged for one additional loop in the 
microscope and correlated with the previous captured images. 
2.3.5 DATA ANALYSIS OF LIVE-CELL MICROSCOPY EXPERIMENTS 
Cells were tracked throughout the duration of the experiment using custom-written MATLAB 
(MathWorks, Natick, MA) scripts based on code developed by the Alon lab (Cohen et al., 2008) and the 
Cell Profiler project (Carpenter et al., 2006) as previously described (Strasen et al., 2018). In brief, I 
applied flat-field correction and background subtraction to raw images before segmenting individual 
nuclei from images of the NLS-CFP reporter using adaptive thresholding and seeded watershed 
algorithms. Segmented cells were assigned to corresponding cells in subsequent images using a greedy 
match algorithm based on a cost function, which included the velocity and direction of movement for 
a cell. Only cells tracked from the first to last time point were considered. Additionally, the 
fluorescence intensity of the nuclear marker was used to ensure consistency. I then quantified the 
nuclear fluorescence intensity of the FIRE reporter for each cell over time and normalized the resulting 
single-cell trajectories by dividing with the nuclear fluorescence of the NLS-CFP reporter to account for 
changes in nuclear shape. This normalization eliminated spurious peaks and disturbances by cell 
division. The measurements of unstimulated control cells included in each experiment were used for 
further normalization resulting in a fold change of FIRE levels compared to unstimulated means 
(Figure 7E). Specifically, for each cell the FIRE levels at each time point were divided by the mean FIRE 
level of the unstimulated control at that time point. Cells with an amplitude greater than three 
standard deviations (sd) from the average amplitude of unstimulated cells were considered to be 
responders. To identify cell cycle states using geminin, the time courses were first normalized by the 
mean of the unstimulated control. Time points with a geminin response smaller than a threshold 
(mean + 2*sd of unstimulated control) were defined as part of the G1-phase, when geminin is not 
expressed (Figure 9B). Using run-length encoding, the duration of S/G2-phase and the time point of 
division could be identified. To avoid false positive detection of cell cycle phases, only cells were 
included in the analysis in which the time between beginning of S-phase and division was at least 4 h. 
Percent of dividing cells was used to compare effects between different concentrations of EGF or 
different types of inhibitors. The standard error was calculated with bootstrapping (n = 1,000, 
R package: boot). 
2.3.6 FEATURE ANALYSIS 
The time courses were separated into early (less than 16 h after stimulation) and late response (more 
than 20 h after stimulation). For each signaling phase, the amplitude was defined as the mean of the 
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three highest FIRE responses after normalization and the time of response as the mean time for the 
three highest FIRE responses. The fold change was taken with respect to the mean response of FIRE in 
the same cell before stimulation. The duration was measured as full width at half maximum, limited to 
the maximum possible observation period. The area under the curve was estimated using a spline 
interpolation (R package: MESS). To identify responding cells, the amplitude of the first response and 
the second response was compared to the distribution of the respective amplitude in the control 
experiment (without EGF). 
2.3.7 KAPLAN-MEIER ANALYSIS 
The analysis of duration of the S/G2-phase might be affected as cells are not monitored indefinitely 
and thus, the data was incomplete. This shortcoming was overcome by calculating Kaplan-Meier 
curves. Kaplan-Meier curves are a way to analyze times-to-event with incomplete data. This type of 
analysis is commonly used in clinical studies (Bewick et al., 2004) to account for patient drop-outs. In 
the analysis of S/G2-phase duration, cells which passed into S-phase were characterized in terms of 
whether they underwent division (event occurrence) in the measured time course or not (censored 
data). The cumulative events (completion of division) over time were shown (R package: survival, 
survminer). 
2.3.8 IMMUNOFLUORESCENCE 
Cells were seeded and treated equally to live-cell microscopy experiments. After a 48-h growth factor 
and serum deprivation, cells were stimulated with EGF at specific time points to fix all conditions with 
2 % paraformaldehyde in PBS simultaneously. After cells were fixed for 10 min at room temperature, 
the paraformaldehyde was washed away with PBS. Next, cells were permeabilized with 
0.1 % Triton X-100 in PBS for 20 min, blocked with 10 % goat serum in PBS for 30 min and incubated 
with primary antibodies (listed below) in 1 % BSA/PBS for 1 h. Afterwards, cells were washed using 
0.1 % Triton X-100 in PBS and incubated with a secondary antibody (listed below) in 1 % BSA/PBS. After 
further washing steps, cells were stained with 2 mg/ml Hoechst in 0.1 % Triton X-100 in PBS.  Cells 
were washed and subsequently stored in PBS. Images were acquired with the same objective and filter 
sets as described in 2.3.2. Again, automated segmentation was performed in MATLAB with algorithms 
from CellProfiler (Carpenter et al., 2006). 




Mouse monoclonal anti-pAKT (Thermo Fisher Scientific) 
Rabbit monoclonal anti-pRB (Cell Signaling Technology) 
Goat polyclonal anti-mouse AlexaFluorTM 488 (Thermo Fisher Scientific) 






2.3.9 CELL PREPARATION FOR SINGLE-CELL RNA SEQUENCING 
For scRNA-seq, 6-cm plates were used with 4.3 × 105 cells per plate and treated equally to the live-cell 
microscopy experiments. After a 48-h growth factor and serum deprivation, cells were stimulated with 
EGF at specific time points to trypsinize them simultaneously and adjust the cell number to 5 × 105 cells 
per condition. Each sample was resuspended in 50 µl BD Stain Buffer and labeled with a specific Sample 
Tag (10 µl) (both from BD Single-Cell Multiplexing Kit - Human) for 20 min at room temperature. After 
adding 100 µl BD Stain Buffer, cells were mixed, centrifuged and washed with 500 µl BD Stain Buffer. 
Using 500 µl RNase free PBS, all cells were pooled in a single tube and counted to ensure a sufficient 
cell number. After centrifugation and resuspension in 800 µl RNase free PBS, 3.2 ml pre-chilled 
methanol was added dropwise to the sample while mildly vortexing. Cells were kept on ice for 15 min, 
mixed, divided into 1 mL aliquots and stored at -80 °C.  
2.3.10 REHYDRATION AND LIBRARY PREPARATION FOR SINGLE-CELL 
RNA SEQUENCING 
Rehydration was done at 4 °C; cells were pelleted and washed twice in rehydration buffer (DPBS, 
10 % BSA, 0.5 U/ml RNase Inhibitor), then filtered and counted. The 3’ RNA library was prepared 
according to the Chromium Single Cell 3’ Reagent Kits v3-protocol (CG000183 Rev A) with a targeted 
cell recovery of 10,000 cells. At step 2.3.d of cDNA cleanup, the supernatant was removed and used 
for sample tag library preparation according to the BD Single-Cell Multiplexing Kit-Human protocol 
(Reagent Kit v2). The cDNA library was complemented with 5 % of its corresponding sample tag library 
to be run in the same sequencing run. Samples were sequenced on an HiSeq 4000 sequencer (Illumina). 
Commercial kits used for rehydration and library preparation 
Chromium Single Cell 3ʹ GEM, Library & Gel Bead Kit v3 (10x Genomics) 
Chromium Single Cell B Chip Kit (10x Genomics) 
Chromium i7 Multiplex Kit (10x Genomics) 
2.3.11 SINGLE-CELL RNA SEQUENCING ANALYSIS 
Read mapping and counting was done using Cell Ranger version 3.0.2 (10x Genomics) and a dual 
genome reference consisting of the human genome GRCh38 as supplied by Cell Ranger. Additionally, 
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an artificial genome containing the BD sequence tags was utilized. Demultiplexing was done using a 
custom script that reads the BAM file and counts sequences that map to the artificial BD sequence tags 
genome and removes duplicate UMIs per cell. Subsequently, cells were assigned to samples (or 
duplets) using the HTODemux() function of Seurat (Stuart et al., 2019) after normalization (as described 
in the Seurat manual). Transcriptome analysis of the scRNA-seq samples was done using Seurat. In 
brief, low quality cells were removed based on mitochondrial contamination and number of unique 
genes. Each gene was normalized by the total expression in the cell, scaled by 10,000 and 
log-transformed. Cell cycle status was defined using a list of cell cycle markers from Tirosh et al., 2016, 
as provided by Seurat. For the analysis of the differential gene expression, cells were grouped by 
experiment, condition and cell cycle phase to generate pseudo-bulk samples. This analysis was done 
using DESeq2 (Love et al., 2014). To identify the effect of inhibitors on pathway activity, 
variance-stabilized data as provided by DESeq2 and applied PROGENy were used (Schubert et al., 
2018). The differentially expressed genes in the pseudo-bulk samples were further analyzed using GO 
enrichment (R package: clusterProfiler; (Yu et al., 2012)). The identified GO terms were simplified using 
a semantic similarity measure, which depends on the frequencies of two GO terms involved and that 
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3.1 RESULTS OF PART 2 
After investigating the interplay between the MAPK and PI3K/AKT pathways and their relative 
contributions to cell cycle entry and progression, I examined how such mitogenic signals affect the 
SMAD pathway. In general, these networks interact to precisely regulate the switch between dividing 
and non-dividing cells, thereby enabling tissue repair and regeneration. As SMAD signaling opposes 
the effects of mitogenic signaling and thus prevents uncontrolled cell divisions, it plays a major role in 
this regulatory process. To study the crosstalk between the different signaling pathways, I quantified 
ligand-induced SMAD signaling in quiescent and proliferating MCF10A SMAD2 reporter (S2-R) cells by 
combining time-resolved single-cell measurements with targeted genetic and pharmacological 
perturbation as well as computer-aided analyses. 
3.1.1 SMAD SIGNALING IN QUIESCENT AND PROLIFERATING CELLS 
3.1.1.1 TGFB-MEDIATED SMAD SIGNALING IS ATTENUATED IN QUIESCENT 
CELLS 
To investigate how SMAD signaling is affected by the cell state, I stimulated proliferating and quiescent 
cells with high doses of TGFB1 (from now on referred to as TGFb) and monitored the translocation of 
SMAD transcription factor complexes from the cytoplasm to the nucleus by time-lapse microscopy 
(3.3.12). To follow this translocation in single cells with high temporal and spatial resolution, an 
established S2-R cell line expressing a YFP-SMAD2 fusion protein as well as histone H2B-CFP as a 
nuclear marker was used (Strasen et al., 2018). To force the reporter cells into a quiescent state, I 
withdrew serum and growth factors from the growth-medium for 48 h. Afterwards, the number of cell 
divisions was determined (3.3.14.1). While cycling cells were dividing approximately once in 24 h, 
quiescent cells showed nearly no division at all (Figure 18A). By measuring the cell cycle distribution 
(3.3.16), a clear G0/1 arrest was observed, indicating that a 48-h growth factor deprivation was 
sufficient to put the reporter cells into quiescence (Figure 18B). After validating the proliferation state, 
SMAD2 responses were measured using live-cell microscopy and automated image analysis (3.3.14). 
Over 24 h, images were acquired at regular intervals (6 min) to provide a high temporal resolution. 
This approach allowed to follow hundreds of cells and measure the H2B-CFP and SMAD2-YFP 
fluorescence throughout the entire experiment. With the acquired data, median trajectories, reflecting 
the ratio between nuclear and cytoplasmic SMAD2 (nuc/cyt SMAD2 ratio), were generated. The results 
revealed that SMAD2 in proliferating cells was predominantly located in the cytoplasm in absence of 
TGFb and strongly accumulated in the nucleus 1-2 h post stimulation. After the first response, SMAD2 
relocalized to the cytoplasm until the nuc/cyt SMAD2 ratio adapted to a lower signaling plateau and 
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stayed above initial values throughout the experiment (second/sustained response). Interestingly, if 
quiescent cells were stimulated with the cytokine TGFb, less SMAD2 translocated from the cytoplasm 
into the nucleus compared to cycling cells (Figure 18C-E). Not only the first response but also the 
sustained signaling seemed to be strongly attenuated (Figure 18G and H). This effect was validated for 
endogenous SMAD2 in wild-type MCF10A cells using immunofluorescence (3.3.15) (Figure 18F). 
Additionally, levels of phosphorylated SMAD2 in wild-type and reporter cells confirmed this 
phenomenon (3.3.17) (Figure 18I). In essence, the dynamic behavior of SMAD2 switched from a strong 
and sustained to a weak and transient signaling response by growth factor and serum deprivation. 
 
Figure 18: TGFb-mediated SMAD signaling is strongly influenced by the cell state. 
(A) Cell proliferation of the S2-R cell line shown as number of cell divisions per cell within 24 h after a 48-h growth factor 
deprivation (quiescent). To identify mitosis, cells were imaged in live-cell microscopy and the integrated H2B-CFP 
fluorescence intensity was analyzed. A decrease of ~50 % in intensity indicated a successful cell division. Cells cultured in 
normal growth-medium (proliferating) served as control. (B) Distribution of cell cycle phases of growth factor-deprived and 
dividing cells. To determine the number of cells in G0/1-, S-, and G2-phase, the cell cycle distribution generated by MetaCyte 
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was used. DEL represents cells that could not be assigned to a cell cycle phase. (C) Live-cell time-lapse images of quiescent 
and proliferating S2-R cells treated with 100 pM TGFb (3.3.13). Pictures were taken before treatment (0 h) and 1.5 h or 8 h 
after treatment. Scale: 24 µM. (D-E) Analysis of the nuc/cyt SMAD2 ratio upon stimulation with 100 pM TGFb in proliferating 
(D) and quiescent (E) cells. Cells were imaged 1 h prior to TGFb stimulation. Solid lines represent median trajectories and 
shaded areas indicate 25th and 75th percentiles. The number of cells analyzed in time-lapse microscopy experiments is 
indicated in 6.7 (Appendix). (F) Quantification of nuc/cyt SMAD2 ratio 3 h after treatment with 100 pM TGFb in proliferating 
and quiescent wild-type MCF10A cells using immunofluorescence. The generated boxes include data between the 25th and 
75th percentiles. The black line indicates the median and whiskers extend to maximum values within 1.5× the interquartile 
range. (G-H) Single-cell analysis of quiescent and proliferating S2-R cells. The generated boxes include data between the 25th 
and 75th percentiles. The black line indicates the median and whiskers extend to maximum values within 1.5× the interquartile 
range. (G) Quantification of the highest nuc/cyt SMAD2 ratio within the first 5 h after stimulation with 100 pM TGFb (first 
response). (H) Quantification of the lowest nuc/cyt SMAD2 ratio within 6 h after the first peak (second response). (I) Western 
blot analysis of SMAD2 activation in quiescent and proliferating S2-R or wild-type (WT) MCF10A cells. Cells were stimulated 
with 100 pM TGFb and SMAD2 phosphorylation was analyzed at indicated time points. Endogenous pSMAD2 with a molecular 
weight of ~60 kDa and transgenic pYFP-SMAD2 with a molecular weight of ~75 kDa were observed. Actin and glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) were used as loading controls. 
As several factors like EGF, insulin and horse serum were missing from the quiescence-inducing 
medium, the question arose which extracellular signals were necessary to form a strong sustained 
SMAD2 response upon TGFb stimulation. Since EGF is a potent mitogen and capable of re-introducing 
quiescent cells into the cell cycle (Part 1 of this study), I first added EGF back to the medium and 
incubated the cells for different periods of time. As shown in Figure 19A, a 6-8 h preincubation with 
EGF was sufficient to rescue the first response of the TGFb-induced SMAD2 translocation. To test if the 
attenuation of the signaling response was caused by an altered cell cycle state or changes in mitogenic 
signaling itself, quiescent cells were treated with the CDK4/6 inhibitor palbociclib to keep cells in a 
non-dividing state despite the stimulation with EGF (Figure 19B). Interestingly, 8 h of EGF 
preincubation was still sufficient to rescue SMAD2 dynamics even though cells could not progress 
through the cell cycle, indicating that rather a loss of mitogenic signaling was responsible for SMAD2 
attenuation instead of progression through the cell cycle (Figure 19C). To further validate this 
observation, I mimicked growth factor deprivation by pharmacologically inhibiting MEK/ERK and 
PI3K/AKT signaling in proliferating cells for 48 h. Indeed, as shown in Figure 19D, a sustained MEK/ERK, 
but not PI3K/AKT activity was required for a strong SMAD2 response. These findings suggested a 
crosstalk of MAPK signaling and the SMAD pathway. Since the rescue of SMAD2 dynamics by EGF took 
several hours, these interactions might rather be mediated by MEK/ERK target genes instead of a 
post-translational modification (PTM)-based direct crosstalk of SMAD and MAPK signaling. 




Figure 19: TGFb-mediated SMAD signaling is attenuated if MAPK activity is switched off. 
(A) Single-cell analysis of quiescent S2-R cells. Quantification of the highest nuc/cyt SMAD2 ratio after treatment with 
50 ng/ml EGF for the indicated duration followed by a stimulation with 100 pM TGFb. The generated boxes include data 
between the 25th and 75th percentiles. The black line indicates the median and whiskers extend to maximum values within 
1.5× the interquartile range. (B) Cell proliferation of quiescent MCF10A FIRE reporter cells shown as number of cell divisions 
per cell within 48 h. Cells were either treated with a CDK4/6 inhibitor (t = 0 h) and 50 ng/ml EGF (t = 1 h) or DMSO (t = 0 h) 
and EGF (t = 1 h). CDK4/6 inhibitor was used to prevent cell cycle progression despite EGF stimulation. (C) Analysis of the 
nuc/cyt SMAD2 ratio in quiescent cells after modulation by various treatments. Cells were stimulated with EGF and CDK4/6 
inhibitor as described in (B) followed by a 100 pM TGFb treatment at t = 9 h. Despite the lack of CDK4/6 activity EGF 
preincubation still rescued the SMAD2 dynamics. (D) Single-cell analysis of S2-R cells treated with different inhibitors. 
Quantification of the highest nuc/cyt SMAD2 ratio within the first 5 h after stimulation with 100 pM TGFb. Proliferating cells 
were treated with EGFR, MEK or PI3K inhibitors (same inhibitors as in Part 1 of this study) 48 h before treatment with TGFb 
and compared to quiescent cells. The generated boxes include data between the 25th and 75th percentiles. The black line 
indicates the median and whiskers extend to maximum values within 1.5× the interquartile range. 
3.1.1.2 GDF11-MEDIATED SMAD SIGNALING IS INCREASED IN QUIESCENT 
CELLS 
After uncovering that TGFb-mediated SMAD signaling is attenuated in quiescent cells, I performed a 
small-scale ligand screening in S2-R cells to determine if the response to other ligands of the TGFb 
superfamily was dampened as well. Proliferating and quiescent cells were stimulated with different 
ligands (activin A, GDF3, GDF8 and GDF11) which are known for their activation of SMAD2/3 via the 
use of alternative receptor complexes. Despite activating the same signaling molecules, the strength 
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of the first response differed greatly. While TGFb and activin A mediated a strong SMAD2 translocation 
in proliferating cells, the other ligands, GDF3, GDF8 and GDF11 barely initiated SMAD signaling. 
Interestingly, GDF8 and GDF11 induced an amplified first response in quiescent cells and thereby 
showed the opposite effect previously observed for TGFb (Figure 20A). Therefore, the tested ligands 
could be categorized in three groups: Attenuated in quiescent cells (TGFb), amplified in quiescent cells 
(GDF8 and GDF11) and unaffected by the cell state (activin A). Since GDF11 revealed a contrasting 
effect to TGFb and induced the strongest response after growth factor deprivation, I chose GDF11 for 
further experiments in this study. To compare GDF11- and TGFb-mediated SMAD2 dynamics in more 
detail, an experiment with different ligand concentrations was performed and the median trajectories 
of nuc/cyt SMAD2 ratios were determined. Both ligands showed a dose-dependent effect in quiescent 
and proliferating cells (Figure 20B-E). Interestingly, the first response of GDF11-mediated SMAD 
signaling was increased upon growth factor deprivation. However, a sustained response as seen in 
proliferating cells treated with high doses of TGFb could not be detected (Figure 20C and D). While I 
saw a different dynamical pattern in these two experimental conditions, SMAD2 dynamics in quiescent 
cells treated with TGFb and proliferating cells stimulated with GDF11 behaved very similarly 
(Figure 20B and E). After discovering that cells switched from a high sensitivity for TGFb ligands to 
increased sensitivity for GDF11 ligands upon growth factor deprivation, this phenomenon was verified 
for endogenous SMAD2 utilizing western blot analysis and immunofluorescence. Again, increased 
GDF11-mediated SMAD2 activation in quiescent cells was observed (Figure 20F and G). Like in previous 
experiments (Figure 19D), I investigated if a sustained loss of MAPK activity is responsible for this 
effect. Indeed, pharmacologically inhibiting MEK and EGFR for 48 h perfectly replicated the effect of 
the growth factor deprivation on SMAD signaling (Figure 20H). Taken together, quiescent and 
proliferating cells reacted with differing degrees of sensitivity to ligand stimulations due to an 
interaction with the MAPK pathway. 




Figure 20: GDF11-mediated SMAD signaling is amplified if MAPK activity is switched off. 
(A) Single-cell analysis of S2-R cells stimulated with different ligands of the TGFb superfamily.  Quantification of the highest 
nuc/cyt SMAD2 ratio in quiescent and proliferating cells within the first 5 h. Ligands other than TGFb were used with a 
concentration of 1 nM and 20 nM. The generated boxes include data between the 25th and 75th percentiles. The black line 
indicates the median and whiskers extend to maximum values within 1.5× the interquartile range. (B-C) Median nuc/cyt 
SMAD2 ratio of quiescent (B) and proliferating (C) cells stimulated with varying concentrations of TGFb over 24 h. Cells were 
imaged 1 h prior to TGFb stimulation. (D-E) Median nuc/cyt SMAD2 ratio of quiescent (D) and proliferating (E) cells stimulated 
with varying concentrations of GDF11 over 24 h. Cells were imaged 1 h prior to GDF11 stimulation. (F) Quantification of 
nuc/cyt SMAD2 ratio 3 h after treatment with 10 nM GDF11 in proliferating and quiescent wild-type MCF10A cells using 
immunofluorescence. The generated boxes include data between the 25th and 75th percentiles. The black line indicates the 
median and whiskers extend to maximum values within 1.5× the interquartile range. (G) Western blot analysis of SMAD2 
activation in quiescent and proliferating S2-R cells. Cells were stimulated with 10 nM GDF11 and SMAD2 phosphorylation was 
analyzed at indicated time points. Endogenous pSMAD2 with a molecular weight of ~60 kDa and transgenic pYFP-SMAD2 with 
a molecular weight of ~75 kDa were observed. Actin was used as a loading control. (H) Single-cell analysis of S2-R cells treated 
with different inhibitors. Quantification of the highest nuc/cyt SMAD2 ratio within the first 5 h after stimulation with 
5 nM GDF11. Proliferating cells were treated with EGFR, MEK or PI3K inhibitors 48 h before treatment with GDF11 and 
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compared to quiescent cells. The generated boxes include data between the 25th and 75th percentiles. The black line indicates 
the median and whiskers extend to maximum values within 1.5× the interquartile range. 
3.1.1.3 LACK OF MAPK ACTIVITY INDUCES REWIRING OF THE SMAD NETWORK 
The obtained results showed that, depending on the activity of MAPK, ligands from the TGFb 
superfamily can signal very differently in quiescent and proliferating cells. A long-term MEK/ERK 
activity was required for strong and sustained SMAD signaling induced by TGFb, whereas for GDF11 it 
was the reverse effect, as a sustained lack of MEK/ERK activity substantially increased the strength of 
the signaling. A comprehensive understanding of the crosstalk between the two signaling networks 
would be necessary to decode possible interaction points. As previous experiments suggested that the 
SMAD network was rewired on a slow time scale of several hours to switch ligand sensitivity a direct 
interaction of MEK/ERK with the SMAD pathway seemed unlikely. Instead, I assumed that the rewiring 
was mediated through changes of target genes. Therefore, gene expression in proliferating and 
quiescent cells was analyzed at a genome-wide level by RNA sequencing (3.3.20). Since growth factor 
deprivation changes the physiological condition of a given cell, the expression of a great number of 
genes is expected to change with the cell state. To narrow down potential key players of this rewiring, 
I used all information gathered from previous experiments. For example, it was shown that a 48-h MEK 
inhibition had the same effect on SMAD signaling as a 48-h growth factor deprivation and that 
restimulation of quiescent cells with EGF was sufficient to rescue TGFb-mediated SMAD2 activation. 
Thus, not only mRNAs from proliferating and quiescent cells were sequenced but also multiple control 
conditions like proliferating cells treated with a MEK inhibitor for 48 h, quiescent cells stimulated with 
EGF for 8 h or quiescent cells treated with a MEK inhibitor and EGF for 8 h. This limited the number of 
potential candidates responsible for the ligand sensitivity switch, as now the genes had to fulfill the 
following criteria: upregulated expression in non-dividing conditions (quiescent cells, 
MEK inhibitor-treated cells and MEK inhibitor- and EGF-treated cells) and downregulated expression 
in dividing conditions (proliferating cells and EGF rescue cells) or vice versa. To apply this approach to 
all analyzed genes, first the RPKM values for each condition were calculated (3.3.20). Then, a two-step 
filter system was applied. First, the gene had to exhibit a fold change of at least 1.5 between 
proliferating and quiescent cells. Second, if growth factor deprivation negatively regulated the gene, 
the lowest RPKM value of the dividing conditions and the highest RPKM value of the non-dividing 
conditions were compared and had to exhibit a fold change of at least 1.5. If the gene was positively 
regulated in growth factor-deprived cells, the highest RPKM value of the dividing conditions was 
compared to the lowest RPKM value of the non-dividing conditions (Figure 21A). With this approach, 
the list of 13,251 differentially expressed genes was narrowed down to 1,900 genes that fulfilled all 
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criteria. To further limit the number of possible candidates, a list of SMAD pathway-associated genes 
was composed using different database resources (6.6) and compared with the filtered genes of the 
RNA sequencing (Figure 21B). Finally, a set of 63 genes was identified, which were differentially 
regulated and associated with SMAD signaling (Figure 21C). From this list, ten examples were selected 
and illustrated. As can be seen in Figure 21D, even after a rigorous selection procedure, there were 
still many genes that fitted perfectly in the filtering pattern. The multitude of suitable candidates 
suggested that a pathway-rewiring, in which many SMAD-associated genes were modulated, could be 
responsible for switching the ligand sensitivity. Thus, instead of modifying one key player, it might 
require orchestrated gene expression changes. Nonetheless, the genes of the final list were 
researched, and interesting candidates were determined. 




Figure 21: Global gene expression analysis identified potential key regulators of SMAD signaling. 
The analysis was performed in close collaboration with Lorenz Ripka (IMB Mainz). (A) Schematic representation of how gene 
filtering was applied to identify key players. First, proliferating (control) cells were compared to growth factor-deprived cells 
to determine if the gene is up- or downregulated. The fold change had to be at least 1.5. Next, if the gene was downregulated, 
the lowest RPKM value of the dividing conditions and the highest RPKM value of the non-dividing conditions were compared. 
Again, the fold change had to be at least 1.5. If the gene was upregulated in growth factor-deprived cells, the highest RPKM 
value of the dividing conditions was compared to the lowest RPKM value of the non-dividing conditions. 
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(B) Scaled Venn diagram showing the number of genes after each filtering step. (C) List of filtered genes which could be 
associated with the SMAD pathway. Arrows indicating if the gene was up- or downregulated upon growth factor deprivation. 
(D) Examples of genes listed in (C) shown as bar graphs. Order of the conditions (x-axis) as shown in (A). 
3.1.1.4 GENERATING A FST KNOCKOUT AND TGFBR3 OVEREXPRESSION CELL 
LINE 
Literature research uncovered that FST is a known antagonist of GDF11 (Gamer et al., 1999) but not 
TGFb signaling. Thereby, the downregulation of FST in quiescent cells (Figure 21D) could potentially 
explain the increase in GDF11-mediated SMAD signaling as previously observed. Additionally, 
references were found, which showed that TGFBR3 negatively influences TGFb-mediated signaling 
through ectodomain shedding. In short, cells can release soluble TGFBR3 which binds and sequesters 
ligands to inhibit TGFb signaling (Elderbroom et al., 2014). Furthermore, TGFBR3 is reported to co-vary 
with GDF11 (Wang et al., 2014) and enhance GDF11-mediated SMAD2 activation (Bajikar et al., 2017). 
Taken together, both proteins might have the potential to change SMAD signaling and explain the 
observed differences in quiescent and proliferating cells.  
To further validate the hypothesis of FST as a key player, I investigated GDF11 signaling in proliferating 
U-2 OS and HEK293T cells by western blot analysis. These cell lines were chosen because both express 
the corresponding receptors but only U-2 OS cells produce FST. Therefore, it was expected that 
GDF11-mediated SMAD signaling is stronger in HEK293T cells. Indeed, HEK293T cells showed 
comparatively high quantities of phosphorylated SMAD2 upon treatment with 4 nM GDF11 
(Figure 22A). To ensure that FST is responsible for the observed differences, the next step was to 
introduce FST into HEK293T cells. To this end, cells were transfected with a plasmid expressing FST 
under the control of the constitutive CMV promotor as well as a hygromycin B resistance gene 
(pCMV3-FST). After cells were selected for two weeks, RT-qPCR was performed to quantify FST mRNA 
levels (3.3.19). As shown in Figure 22B, the transfection was successful and HEK293T cells were 
expressing the GDF11 antagonist. Again, western blot analysis of pSMAD2 was carried out and revealed 
that FST overexpression almost completely abolished GDF11 signaling, which further strengthened my 
hypothesis (Figure 22C). However, it should be kept in mind that different cell lines were compared 
that vary from one another in many ways. 




Figure 22: GDF11-mediated SMAD signaling could be attenuated by FST overexpression in HEK293T cells. 
(A) Western blot analysis of SMAD2 activation in proliferating S2-R, U-2 OS and HEK293T cells. Cells were stimulated with 
4 nM GDF11 and SMAD2 phosphorylation was analyzed at indicated time points. Endogenous pSMAD2 with a molecular 
weight of ~60 kDa was observed. GAPDH was used as a loading control. (B) Quantification of FST mRNA in HEK293T cells 
stably expressing transgenic FST (HEK293T FST-OE) by RT-qPCR. Wild-type HEK293T cells served as a control. Actin was used 
as an internal control. Error bars indicate standard deviation of technical triplicates. (C) Western blot analysis of SMAD2 
activation in wild-type HEK293T and FST overexpression cells. Cells were stimulated with 4 nM GDF11 and SMAD2 
phosphorylation was analyzed at indicated time points. Endogenous pSMAD2 with a molecular weight of ~60 kDa was 
observed. GAPDH was used as a loading control. 
To investigate the role of FST in MCF10A cells, a stable FST knockout in the S2-R cell line was created 
utilizing the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 
(Cas9) system (3.3.2). The knockout of FST has to affect both alleles of the gene to ensure a complete 
loss of the corresponding protein. To this end, a template DNA, for inserting a blasticidin resistance 
with a constitutive simian virus 40 (SV40) promoter (SV40-Blast_R) and a plasmid expressing a single 
guide RNA (sgRNA) were cloned and transfected together with a plasmid expressing a Cas9 
endonuclease into S2-R cells. SV40-Blast_R was inserted into the gene locus (exon 2) near the start 
codon to disrupt the gene as early as possible (Figure 23A). After transfection, cells were selected with 
blasticidin for up to three weeks and single colonies were picked to generate clonal cell lines (3.3.3). 
To ensure that the interrupted FST sequence led to a non-functional protein, western blot analysis was 
performed (Figure 23B). All clones without detectable FST (1, 9, 10, 21, 25, 26 and 28) were identified 
and then screened with PCR to check if the blasticidin resistance was inserted in one (heterozygous) 
or both (homozygous) alleles. Clones 1, 10 and 26 were heterozygous while clone 21 showed the 
correct band sizes for a homozygous insertion (Figure 23C). Sequencing of clone 1 and 26 (6.5) revealed 
a deletion after the Cas9 endonuclease cleavage site, explaining the complete loss of FST protein in 
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western blot analysis. Additionally, little to no FST mRNA was detected in RT-qPCR for clone 1, 21 and 
26 (Figure 23D). In the end, these three candidates fulfilled all criteria for a defined knockout of the 
FST gene and were suitable for subsequent live-cell microscopy experiments.  
Besides FST, TGFBR3 emerged as potential key player for the switch in ligand sensitivity. For the 
overexpression of TGFBR3 in proliferating cells, the approach from Konermann et al., 2015, was 
followed where instead of a functional Cas9 a dead Cas9 (dCas9) fused to the transcription activation 
domain VP64 was used (3.3.4). With the help of a specific sgRNA, this complex was guided to the 
endogenous locus of TGFBR3 (within 200 bp upstream of the transcriptional start site (TSS)) and 
initiated the upregulation of the receptor expression. For a stronger overexpression, the activation 
efficiency could be further improved by adding additional activation domains (p65 and HSF1) which 
bind to the scaffold of the sgRNA via specific aptamers and RNA binding domains, respectively 
(Figure 23E). Since the goal was to mimic growth factor deprivation, I aimed to raise the TGFBR3 level 
to the same amount observed in quiescent cells. First, both overexpression approaches were tested in 
wild-type MCF10A cells. To this end, two stable cell lines were created by lentiviral transduction, one 
expressing only dCas9-VP64 and the other additionally expressing the MS2-p65-HSF1 transcriptional 
activator. As a negative control, an sgRNA targeting the ACVR2B instead of the TGFBR3 locus was used. 
The western blot analysis revealed that the overexpression of TGFBR3 was successful and the 
transcriptional activation with VP64 alone was sufficient to raise the TGFBR3 level to the same amount 
observed in quiescent cells. Therefore, S2-R cells were only transduced with the lentiviral vector 
lentiSAMv2, containing sgRNA and dCas9-VP64 complex. As shown in the western blot analysis, the 
TGFBR3 level had more than doubled upon transduction and again reached values similar to those 
observed in quiescent cells (Figure 23F). Besides the two single perturbations, I wanted to investigate 
combinatory effects as well. To this end, the overexpression of TGFBR3 was also carried out in FST 
knockout cells. Finally, the different cell lines were used for time-lapse microscopy. 




Figure 23: Knockout of FST and overexpression of TGFBR3 were successfully introduced into S2-R cells. 
(A) Schematic representation of the CRISPR/Cas9 knockout of FST. To generate the vector containing the repair template, 
homology arms were amplified from genomic DNA of MCF10A and the SV40-Blast_R sequence was amplified from the vector 
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pVE10 (6.4). Through overlapping ends and assembly cloning (3.3.7), the sequences were joined together. The vector 
pDONR221-Blast_R (6.4) was then cut with the restriction enzyme NotI, releasing the donor DNA from the backbone. 
Afterwards, the linearized donor DNA, vectors encoding Cas9 endonuclease and the sgRNA were transfected into S2-R cells. 
In the presence of a repair template, the Cas9-induced double-strand breaks (DSB) could be repaired precisely by 
homology-directed repair (HDR), resulting in the desired knock-in of SV40-Blast_R into the FST locus. Interrupting the gene 
close to the start codon will result in a non-functional protein or the protein will not be translated at all. (B) Western blot 
analysis of different knock-in clones and S2-R cells (control). FST bands with a molecular weight of ~65 kDa were observed in 
S2-R cells and multiple knock-in clones. FST was not detectable in clone 1, 9, 10, 21, 25, 26 and 28. GAPDH with a molecular 
weight of ~37 kDa served as loading control. (C) PCR products of potential FST knockout clones. Agarose gels showing the 
DNA fragments produced by PCR amplification. The primers FST_gen forward and reverse (marked in (A)) were utilized to 
amplify the genomic region containing the Cas9 endonuclease site (first band XA). If the donor DNA was inserted into the FST 
locus, the PCR amplification generated one fragment (3.4 kbp) for homozygous and two fragments (3.4 kbp + 2.2 kbp) for 
heterozygous genotypes. The primers FST_gen forward and Direct_blast reverse (marked in (A)) were utilized to amplify a 
part of the inserted blasticidin (second band XB). Upon successful integration of the donor DNA, the PCR amplification 
generated a fragment of 1.7 kbp size. Genomic DNA of S2-R cells served as a control. DNA Ladder 1 kb Plus (New England 
BioLabs) was used as a marker. (D) Quantification of FST expression after blasticidin knock-in by RT-qPCR. S2-R cells served 
as a control. Actin was used as an internal control. Error bars indicate standard deviation of technical triplicates. (E) Schematic 
representation of the transcriptional activation through dCas9 (modified after Konermann et al., 2015). The dCas9 is fused to 
the activation domain VP64 and can be guided to the TSS of the target gene by sgRNAs. The additional activation domains 
p65 and HSF1 can bind to the MS2-binding loop in the sgRNA backbone to further increase transcriptional upregulation. (F) 
Western blot analysis of TGFBR3 after transcriptional activation in wild-type MCF10A and S2-R cells. Utilizing a lentiviral 
system, cells were either transduced only with the dCas9-VP64-sgRNA vector (lentiSAMv2) or with lentiSAMv2 and the 
additional activation domains p65 and HSF1 (lentiMPHv2). Besides an sgRNA targeting the TGFBR3 locus, an sgRNA targeting 
the ACVR2B locus was used as a control. TGFBR3 bands with a molecular weight of ~110 kDa were observed. GAPDH was 
used as a loading control. Quantification of densitometric band intensities with ImageJ shows a similar receptor level between 
quiescent cells and proliferating cells transduced with the lentiSAMv2-TGFBR3 vector. To control for technical variability 
target protein signals were normalized to the loading control. 
3.1.1.5 PERTURBATIONS OF FST AND TGFBR3 ARE NOT SUFFICIENT TO 
EMULATE GROWTH FACTOR DEPRIVATION 
After generating the three different cell lines S2-R-FST-/-, -TGFBR3-OE and -FST-/--TGFBR3-OE, I 
investigated SMAD2 dynamics to determine if the single or combined perturbations have the same 
effect on the signaling pathway as a 48-h growth factor deprivation.  To this end, cells were stimulated 
with TGFb or GDF11 and imaged using time-lapse microscopy. Additionally, the impact of 
transcriptional feedbacks on SMAD dynamics was tested in S2-R and FST knockout cells by utilizing the 
transcription inhibitor 5,6-dichlorobenzimidazole 1-β-D-ribofuranoside (DRB). Afterwards, I 
determined the nuc/cyt SMAD2 ratio and compared the effect sizes (differences of medians) of the 
perturbations and the growth factor deprivation (Figure 24A). As previously observed, 
GDF11-mediated SMAD signaling was amplified while TGFb-mediated SMAD signaling was attenuated 
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in quiescent cells. Surprisingly, the perturbations had only minor effects on SMAD signaling. In contrast 
to my expectations, the knockout of FST and the overexpression of TGFBR3 did not enhance 
GDF11-mediated SMAD signaling. Only the treatment with DRB slightly increased SMAD2 activation. 
Since DRB has toxic effects, cells treated with the transcription inhibitor could only be followed for 6 h 
instead of 24 h. In cells stimulated with TGFb, a slight attenuation of the signaling was observed after 
overexpressing TGFBR3. Furthermore, the DRB treatment showed an amplification of the TGFb 
signaling (Figure 24A). As I was looking for potential key players that could explain the switch in ligand 
sensitivity, only DRB treatment in GDF11-stimulated cells and TGFBR3 overexpression in TGFb-treated 
cells changed SMAD signaling in the desired direction (Figure 24B and C). To investigate whether the 
observed effects were significant, I performed permutation testing and determined the confidence 
intervals of the effect sizes over time (Figure 24D and E). Even though the perturbations altered the 
signaling output statistically significantly, the extent of the effects caused by growth factor deprivation 
could not be emulated, suggesting that either another key protein or a complete network rewiring was 
responsible. However, since a change of over 60 genes involved in SMAD signaling was observed in the 
RNA sequencing and the single/dual perturbation of FST and TGFBR3 had only minor effects, a 
complete pathway-rewiring seemed more likely. In addition, a single protein would not only have to 
increase GDF11-mediated signaling but also decrease TGFb-mediated signaling at the same time. To 
summarize, the FST knockout and the TGFBR3 overexpression in S2-R cells were successful, however, 
SMAD2 translocation was only slightly affected by these modifications, although both proteins are 
direct regulators of the pathway. Therefore, my results indicated that SMAD signaling is very robust 
against single perturbations and that a more wide-ranging rewiring of the network is necessary to alter 
dynamics to the extent of a growth factor deprivation. Nonetheless, it should be noted that only two 
gene perturbations were tested and the hypothesis of a key player regulating this phenomenon could 
not be rejected. 




Figure 24: Single and combined perturbations changed SMAD2 signaling dynamics only slightly. 
(A) Heatmap showing the effect sizes of different perturbations on SMAD2 translocation over time upon TGFb and GDF11 
stimulation. Cells were imaged in live-cell microscopy for 24 h and stimulated with 100 pM TGFb or 10 nM GDF11. Cells were 
imaged 1 h prior to ligand stimulation. Cells treated with DRB were only tracked for 6 h instead of 24 h. Each vertical line 
represents one time point, and the effect sizes (differences of medians) are shown as indicated in the legend. Effect sizes 
represent the magnitude of the experimental effect. (B) Median nuc/cyt SMAD2 ratio of proliferating S2-R cells treated with 
100 µM DRB and 10 nM GDF11 or 10 nM GDF11 alone over 6 h. (C) Median nuc/cyt SMAD2 ratio of proliferating 
S2-R-TGFBR3-OE cells and S2-R cells treated with 100 pM TGFb over 24 h. (D-E) Effect size (bold line) and 95 % confidence 
intervals (thin lines) are shown for the experiments described in (B-C). To estimate the confidence intervals, permutation 
testing (1,000 permutations) was performed. 
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3.1.2 SMAD-MEDIATED CELL FATES IN QUIESCENT AND 
PROLIFERATING CELLS 
After revealing that MCF10A cells adjust their sensitivity for ligands of the TGFb superfamily according 
to the proliferation state, the question has been raised whether different ligands also have different 
consequences for the physiological response of the cell. Ligands of the TGFb superfamily regulate cell 
fate decisions during embryogenesis and in the adult organism. Cellular responses like apoptosis, cell 
cycle arrest and EMT are often associated with SMAD signaling. However, it is poorly understood how 
the simple and straight forward pathway can determine such a broad range of cell fate decisions. 
Additionally, it has yet to be answered whether and how the pathway differentiates between varying 
ligands. I hypothesized that SMAD signaling is rather quantitative than qualitative and that ligands can 
only be distinguished by SMAD dynamics they initiate. 
3.1.2.1 DYNAMICS OF SMAD2 CORRELATE WITH CELLULAR RESPONSES 
To investigate cellular outcomes and correlate them with SMAD2 dynamics, long-term stimulations 
were carried out. Since phenotypic changes are often governed by complex gene regulatory programs 
and can take several days to develop (Katakura et al., 1999; Zhang et al., 2014; Peixoto et al., 2019), I 
imaged proliferating and quiescent S2-R cells for up to 120 h in live-cell microscopy. By using high and 
low concentrations of GDF11 and TGFb, a strong and weak SMAD2 activation for each ligand was 
achieved. To ensure sustained ligand stimulations, every 48 h the medium was replaced with freshly 
prepared medium containing GDF11 or TGFb. As shown in Figure 25B, stimulation with 250 pM TGFb 
caused a strong and sustained SMAD2 response over 120 h, while treatment with 5 pM TGFb initiated 
a transient response in proliferating cells. Expectedly, for both GDF11 concentrations only minor 
activation of the signaling pathway was observed. In quiescent cells, responsiveness was reversed 
resulting in strong GDF11-mediated signaling and weak TGFb-mediated signaling (Figure 25A). After 
determining the dynamics of SMAD2, the next step was to associate them with phenotypic changes. 
To this end, cell divisions, motility and cell death were quantified and investigated. One of the first and 
most striking observations was the increase of dying cells in the quiescent condition treated with 
GDF11. Usually, only a small fraction of cells died during a 120-h microscopy experiment, however, if 
stimulated with high doses GDF11, more than 60 % of the cells died (Figure 25C). The same effect, but 
to a lesser extent, was observed for cells treated with low GDF11 and high TGFb concentrations. 
Interestingly, the phenomenon was not seen in proliferating cells. In order to further characterize the 
observed cell death and ensure that cells underwent apoptosis and not necrosis, a western blot 
analysis of cleaved caspase 7 was carried out. Similar to the live-cell microscopy experiment, cells were 
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growth factor deprived and stimulated with GDF11 or TGFb. To make sure that all dead cells were 
included in the analysis, the supernatant was centrifuged and lysed as well. Measuring the amount of 
cleaved caspase 7 showed that indeed cells underwent apoptosis and that GDF11 treatment had the 
biggest effect on cell death (Figure 25E). Judging from this experiment alone, the amount of ligand and 
strength of the signaling seemed to be more decisive than the type of ligand. After characterizing 
apoptosis, the motility of the cells was analyzed as an increase in movement can be an indicator for 
EMT (Lamouille and Derynck, 2007). By calculating the motility score (3.3.14.2), I observed an increase 
for all stimulated cells except for the condition with 100 pM GDF11. Again, the cellular response 
showed a high correlation with SMAD2 dynamics, as a stronger pathway activation led to more cell 
movement (Figure 25D). However, this time, the phenotypic changes were only apparent in 
proliferating cells and not in quiescent cells. One possible reason could be that cells that experienced 
higher SMAD2 activation underwent apoptosis before exhibiting signs of EMT. To further characterize 
the increase in motility, I analyzed known biomarkers for EMT such as SNAI1, VIM and CDH1 (Zeisberg 
and Neilson, 2009) by RT-qPCR. All three genes were considerably up- or downregulated if cells were 
treated with TGFb for a long period of time, indicating that indeed EMT led to increased levels of 
motility. GDF11-treated cells showed only minor changes in gene expression, which explains the 
moderate increase in cell motion (Figure 25F). As now two out of three cell fates were observed, I 
measured the number of cell divisions over time to look for evidence of cytostasis. Interestingly, only 
the condition with a high TGFb stimulation displayed a decrease in cell division rate, suggesting that 
strong and sustained SMAD2 activation is necessary to trigger this outcome (Figure 25D). However, it 
should be noted that cells did not completely stop dividing but rather slowed down cell cycle 
progression. One potential explanation could be the decrease of MYC in TGFb-treated cells 
(Figure 25F), as MYC promotes the cell cycle by inducing cyclins and CDKs (García-Gutiérrez et al., 
2019). Ultimately, I was able to quantify all three phenotypic changes in MCF10A cells by performing 
long-term ligand stimulations with TGFb and GDF11. 




Figure 25: Long-term stimulation and associated cellular responses correlated with SMAD2 dynamics. 
(A-B) Median nuc/cyt SMAD2 ratio of quiescent (A) and proliferating (B) S2-R cells treated with different GDF11 or TGFb 
concentrations over 120 h. Cells were imaged 1 h prior to ligand stimulation. Every 48 h, medium was exchanged with fresh 
medium containing respective ligand concentrations. (C) Fraction of quiescent cells that died during the 120-h experiment. A 
dead cell was identified in cell tracks by measuring the diameter of the nucleus. If a nucleus was fragmented during apoptosis 
and the diameter of the nucleus fell below a certain threshold, it was determined as a dying cell. The data of two biological 
replicates was used. Bold line represents the median fraction of dead cells and the thin lines represent the standard deviation. 
(D) Movement and cell divisions over time in proliferating cells. Mean distance moved per cell in a fixed time interval (20 min) 
is shown in the first boxplot. Motility score is shown in pixels (0.24 µm/pixel). Number of cell divisions for each cell over time 
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was calculated and shown in the second boxplot. The data of two biological replicates was used. The generated boxes include 
data between the 25th and 75th percentiles. The black line indicates the mean and whiskers extend to maximum values within 
1.5× the interquartile range. (E) Western blot analysis of cleaved caspase 7 in quiescent S2-R cells. Cells were stimulated with 
5 nM GDF11 or 250 pM TGFb for 24 h, 72 h and 120 h. Cleaved caspase 7 bands with a molecular weight of ~20 kDa were 
observed. Cells treated with cisplatin (25 µM or 50 µM) served as positive control. Actin was used as a loading control. (F) 
Quantification of SNAI1, VIM, CDH1 and MYC mRNA by RT-qPCR. The RNA for the cDNA synthesis was isolated from 
proliferating S2-R cells stimulated with 5 nM GDF11 or 250 pM TGFb for 24 h, 72 h and 120 h. Actin was used as an internal 
control. Error bars indicate standard deviation of technical triplicates. 
To further investigate the hypothesis that the strength of the signaling is the most important factor for 
the cellular outcome, single-cell analyses of the long-term experiments were carried out next. To this 
end, the area under the curve (AUC) of the nuc/cyt SMAD2 ratio for each individual cell was 
determined. Afterwards, AUCs were associated with cellular responses like motility and cell divisions. 
As shown in Figure 26A and B, the AUC correlated well with the cell movement. Cells with a higher AUC 
also covered more distance over 120 h. For instance, TGFb-treated cells displayed high motility and 
high AUCs, whereas GDF11-treated cells showed only minor increases. Regarding cell divisions, again 
a correlation with the signaling strength was observed. For example, it could be shown that, without 
considering the different treatments, the cells with the 400 highest AUCs were dividing less frequently 
than the cells with the 400 lowest AUCs (Figure 26C). These results hinted once more at 
dynamic-dependent, rather than ligand-dependent cell fates as TGFb- and GDF11-treated cells were 
represented in both, the high and low AUC group. However, it should be noted that only a small 
fraction of TGFb- and GDF11-treated cells were among the 400 lowest and highest AUCs, respectively 
(Figure 26D). Since in dividing cells the response to GDF11 is much lower compared to the response to 
TGFb, this distribution was to be expected. To perform a statistically significant analysis, the number 
of GDF11-treated cells in the high AUC group and the number of TGFb-treated cells in the low AUC 
group would have to be increased. As none of the three SMAD-associated cell fates were observed in 
both proliferation states, it was also not possible to compare quiescent cells showing a strong response 
to GDF11 with proliferating cells showing a strong response to TGFb. Therefore, it was considered that 
the analysis of global gene expression in quiescent and proliferating cells could be carried out to 
investigate whether gene induction mediated by SMAD signaling is rather quantitative than qualitative. 
For example, if SMAD signaling does indeed not differentiate between different ligands, a similar set 
of genes would be regulated in GDF11- and TGFb-treated cells and a strong correlation between gene 
induction and SMAD2 dynamics would be observed.  
Taken together, apoptosis, EMT and cytostasis, all cellular fates often associated with SMAD signaling, 
were observed in MCF10A cells. Interestingly, while apoptosis was only detected in quiescent cells, 
EMT and cell cycle slowdown were measured exclusively in proliferating cells. All phenotypic changes 
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showed a high correlation with the amount of activated SMAD2, which indicated that cell fate decisions 
are mainly determined by dynamic patterns of SMAD2. However, to uncover if the signaling pathway 
is rather simple and does not differentiate between different ligands, genome-wide changes in gene 
expression in response to TGFb and GDF11 stimulations were investigated next. 
 
Figure 26: Single-cell analysis of motility and cell division in proliferating cells showed correlations between SMAD2 
dynamics and cellular responses. 
The analysis was performed in close collaboration with Lorenz Ripka (IMB Mainz). (A-B) Scatter plot showing the motility 
score of each cell analyzed in the long-term microscopy experiments and the AUC of the nuc/cyt SMAD2 ratio. Each dot 
represents one single cell. Left TGFb-treated cells (A) and right GDF11-treated cells (B) are shown. (C) The number of divisions 
of cells with the 400 lowest and 400 highest AUCs was determined without considering the different treatments. The reason 
why the 400 highest/lowest cells were chosen was that when the distribution of the AUCs was examined, the strongest 
outliers from both experiments corresponded to about 400 cells. (D) Pie charts showing the distribution of the different 
conditions among the 400 highest and lowest AUCs. All plots include the data of two biological replicates. 
3.1.2.2 SMAD SIGNALING IS A QUANTITATIVE RATHER THAN QUALITATIVE 
PATHWAY 
My previous results suggested that SMAD signaling does not differentiate between ligands but rather 
mediates a response in dependence of the amount and duration of SMAD2 in the nucleus. To 
strengthen this hypothesis, instead of phenotypic changes, the modulation of gene expression would 
be used as a readout to study the physiological consequences of ligand stimulations. As a proof of 
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concept, the gene expression of EMT and cell cycle markers in quiescent cells treated with GDF11 was 
investigated by RT-qPCR. It was speculated that even though the non-dividing cells did not exhibit 
these cell fates, the corresponding genes would still be modulated due to the quantitative nature of 
the SMAD signaling pathway. Indeed, as shown in Figure 27A, genes that were only slightly regulated 
by GDF11-mediated signaling in proliferating cells (Figure 25F) were now strongly modulated by the 
stimulus. Based on these findings, a large-scale approach to globally study gene expression patterns in 
quiescent and proliferating cells was carried out by using RNA sequencing. To this end, S2-R cells were 
treated with high doses of TGFb or GDF11 for 3 h and 6 h. Considering the SMAD2 dynamics observed 
in live-cell microscopy (Figure 20B-E), these time points should represent the period between the first 
peak and the onset of the second SMAD2 activation. Thereby, the effects of both responses on gene 
expression were analyzed. To investigate if a similar set of genes was regulated by the two ligands, 
scatter plots were generated showing the log2 fold change of all genes. Since the GDF11 condition was 
plotted against the TGFb condition, all genes along the diagonal are equally regulated by the different 
stimuli. Additionally, a linear model was incorporated. The slope of this linear model (m) is an indicator 
of the relative strength of the overall signal induction. A slope greater than 1 indicates a stronger 
induction through GDF11 than TGFb and vice versa. To test for statistical significance, the combined 
p-values of both conditions were used, which refer to the differential expression compared to control 
cells. The combined p-values were also included in the linear model. Thereby, genes with lower 
p-values were emphasized more strongly. Also, the correlation coefficient (r) was calculated, indicating 
the strength of association between GDF11- and TGFb-mediated gene regulation. Strikingly, in all 
conditions, almost every gene was close to the diagonal and the correlation coefficient was always 
above 0.6 (Figure 27B-E). Usually, values between 0.7 and 0.9 are described as strongly associated 
(Mukaka, 2012). This already showed that most genes were regulated similarly by the two ligands. 
Taking a closer look at the linear model revealed that in proliferating cells the gene expression is 
stronger induced by the TGFb treatment as the slope is below 1 (Figure 27B and C). In accordance with 
the SMAD2 dynamics, the opposite was observed when cells were growth factor deprived (Figure 27D 
and E). Interestingly, when quiescent cells treated with GDF11 and proliferating cells stimulated with 
TGFb were compared, gene expression seemed to be stronger induced in the TGFb condition even 
though both exhibit an equally great first SMAD2 response (Figure 27F and G). This might be due to 
the stronger second response mediated by TGFb or fundamental differences between the two cell 
states. Taken together, the results again suggested that SMAD signaling is quantitative rather than 
qualitative. Not only were the same genes regulated, but SMAD2 dynamics were also strongly 
correlated with gene expression. Together with the previous observation of the phenotypic changes, I 
concluded that the dynamic behavior of SMAD2 is more decisive than the type of ligand and that 
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ligands of the TGFb superfamily mediate diverse cellular outcomes through different dynamical 
patterns of SMAD molecules. 
 
Figure 27: RNA sequencing revealed strong correlation of TGFb- and GDF11-induced gene expression. 
The analysis was performed in close collaboration with Lorenz Ripka (IMB Mainz) (A) Quantification of SNAI1, VIM, CDH1 and 
MYC mRNA by RT-qPCR. The RNA for the cDNA synthesis was isolated from quiescent S2-R cells stimulated with 5 nM GDF11 
or 250 pM TGFb for 24 h, 72 h and 120 h. Actin was used as an internal control. Error bars indicate standard deviation of 
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technical triplicates. (B-G) Scatterplots showing the log2 fold change of the measured genes after stimulation with 
10 nM GDF11 or 100 pM TGFb. Genes in proliferating (B-C) and quiescent (D-E) S2-R cells were analyzed. Additionally, the 
gene expression of quiescent cells treated with GDF11 and proliferating cells stimulated with TGFb was compared (F-G).  Each 
dot represents one gene. X-axis shows the log2 fold change of genes from TGFb-treated cells. Y-axis shows the log2 fold 
change of genes from GDF11-treated cells. Since a strong correlation of the fold changes between the two conditions was 
observed, it was possible to predict the fold change under GDF11 stimulation from the fold change under TGFb stimulation 
for the same gene with a linear model. The slope of this linear fit indicates the relative strength of the gene regulation 
mediated by both ligands. A slope greater than 1 indicates a stronger gene expression through GDF11 and a slope less than 
1 indicates a stronger gene expression through TGFb. To test for statistical significance, the combined p-values of both 
conditions were calculated and shown as indicated in the legend. Also, the combined p-values were included in the linear 
model. To this end, 1-p was used as a weight for each data point. Thereby, genes with a low p-value were considered more 
than genes with a high p-value. P-values refer to the differential expression compared to control cells. 
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3.2 DISCUSSION OF PART 2 
In adult organisms most cells are in a quiescent state, but some can re-enter the cell cycle under the 
right mitogenic conditions. The switch between cell states is important to enable tissue repair and 
regeneration (Cheung and Rando, 2013; Yao, 2014). However, it needs to be strictly regulated by 
proliferative and anti-proliferative signals. SMAD signaling is one of the pathways that is crucial for this 
regulation as perturbation of the pathway can result in an imbalance of proliferation and quiescence 
and ultimately in severe diseases such as cancer (Kretzschmar, 2000; Nelson et al., 2006; Inman et al., 
2015). For this reason, it is important to gain a better understanding of this pathway not only in 
proliferating but also in quiescent cells. In the present study, I focused on characterizing the dynamics 
of TGFb- and GDF11-mediated SMAD signaling as well as the associated physiological responses in both 
proliferation states, using time-resolved measurements at the single-cell level and computer-aided 
data analysis. 
3.2.1 SMAD SIGNALING IN QUIESCENT AND PROLIFERATING CELLS 
Quiescent or G0 cells are described as cells outside of the replicative cell cycle that can resume 
proliferation under the right physiological conditions. Through a 48-h growth factor deprivation, it was 
possible to bring MCF10A cells into a non-dividing state (Figure 18A) and, as shown in Figure 19B, 
re-introduction of EGF into the medium caused cells to proliferate again. While I observed that nearly 
95 % of the cells were in G0- or G1-phase upon growth factor deprivation (Figure 18B), it was difficult 
to differentiate between the two cell cycle phases. In general, quiescent cells have not been well 
characterized and markers canonically used to distinguish between G0- and G1-phase have been 
questioned (Oki et al., 2014). For example, Ki67 is often used as a marker for proliferation, as initial 
studies indicated that the protein is absent in quiescent cells and only detectable in G1-, S- and 
G2-phase (Gerdes et al., 1984). However, more recent studies revealed that Ki67 levels are highly 
heterogeneous in individual cells and dependent on the time a cell is remaining in G0. Therefore, Ki67 
is not suitable as a binary marker of proliferation versus quiescence (Miller et al., 2018). Since I showed 
that cells were arrested in G0/G1 after removal of growth factors and that they proliferated again 
when stimulated with EGF, I labeled these conditions as quiescent, even though I did not distinguish 
between the two cell cycle phases. 
After validating that 48 h in growth factor-deprived medium was sufficient to arrest cells in a quiescent 
state, I performed western blot analysis, immunofluorescence and live-cell time-lapse microscopy 
experiments to investigate how SMAD signaling is affected by the cell state. The dynamic behavior of 
SMAD in proliferating MCF10A cells was already well described in previous studies (Strasen et al., 
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2018), however, how SMAD signaling behaves in quiescent cells was mostly undiscovered. Surprisingly, 
the response to TGFb was much higher in proliferating cells compared to quiescent cells (Figure 18D 
and E). As quiescence was mainly induced by EGF deprivation (Part 1 of this study and Chou et al., 
1999), I examined if re-introduction of the growth factor is sufficient to reverse the observed effects 
on SMAD signaling. Indeed, stimulation with EGF was sufficient to rescue TGFb signaling (Figure 19A). 
Therefore, absent EGF was not only responsible for the G0/G1 arrest but also for the attenuation of 
SMAD activation. This raised the question whether the EGF pathway had a direct effect on SMAD 
signaling, for example through MAPK, or whether an altered cell cycle state influenced SMAD 
dynamics. As I compared a dividing population, including cells in G1-, S- and G2-phase, with a 
population that contained almost exclusively cells in G0/G1-phase, cell cycle phase-specific effects 
seemed plausible. Moreover, the cell cycle has wide-ranging effects on cellular physiology and can 
modulate gene expression levels (Buettner et al., 2015). To test this hypothesis, I treated quiescent 
cells with the CDK4/6 inhibitor palbociclib to keep cells in G0/G1-phase despite the re-introduction of 
EGF. Even though cells could not progress through the cell cycle, EGF treatment rescued SMAD 
dynamics, indicating that a loss of mitogenic signaling was responsible for SMAD attenuation instead 
of cell cycle effects (Figure 19C). Using pharmacological inhibitors, I was able to show that a sustained 
MEK/ERK activity was necessary for full SMAD signaling activity. Interestingly, inhibition of the 
PI3K/AKT pathway, which is also activated by EGF and necessary for cell cycle entry and S-phase 
progression (Part 1 of this study), did not alter SMAD dynamics (Figure 19D). This proved again that 
arresting cells in G0/G1-phase alone does not influence the signaling as pharmacological PI3K 
inhibition usually results in G1 accumulation (Fekete et al., 2012). The interaction between MEK/ERK 
and SMAD signaling was already discovered in earlier studies. Non-canonical SMAD signaling includes 
various branches of MAPK pathways and can increase MEK and ERK gene expression (Xie et al., 2004; 
Zhang, 2009). Furthermore, MEK/ERK can have a direct influence on SMAD signaling through 
phosphorylation of the SMAD linker region. For instance, the accumulation of SMAD molecules in the 
nucleus can be disturbed by linker phosphorylations (Kretzschmar et al., 1997; Kretzschmar et al., 
1999; Massague, 2003). While this would argue against my results that a sustained MEK/ERK activity 
is essential for strong and sustained TGFb-mediated SMAD signaling, other studies reported a positive 
crosstalk between the ERK and SMAD pathway (Hayashida et al., 2003) and that the linker 
phosphorylation can increase the half-life of receptor phosphorylated SMADs (Hough et al., 2012). 
Concerning my results, the lack of MEK/ERK activity and the resulting lack of linker phosphorylation 
could be considered as a reason for the attenuation of SMAD signaling. In our laboratory, work is in 
progress to create specific cell lines containing mutations in different linker regions of SMAD. These 
cells could then be used to further validate this hypothesis. However, as the rescue of SMAD dynamics 
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by EGF took several hours, I assumed that the interaction of SMAD and MAPK signaling was rather 
mediated by MEK/ERK target genes instead of a direct crosstalk.  
Before investigating changes in gene expression, I performed a small-scale ligand screening to 
determine if the effects of other ligands of the TGFb family were influenced by growth factor 
deprivation as well. The screening revealed that the response to activin A was not affected by the cell 
state. Interestingly, myostatin (GDF8)- and GDF11-treated cells showed opposite effects on SMAD 
signaling compared to cells stimulated with TGFb (Figure 20A). The high analogy between GDF8 and 
GDF11 could explain why both ligands mediated a similar effect on SMAD signaling (Walker et al., 
2016). However, since the SMAD network is a simple and straight forward pathway, the vastly different 
dynamics upon TGFb, activin A and GDF8/11 treatment were not expected. All tested ligands are 
known to signal via SMAD2/3  (Rebbapragada et al., 2003; Andersson et al., 2006; Tsuchida et al., 
2009), which leaves only a few possible differences between the signaling processes that could explain 
this phenomenon. One distinction is on the receptor level as they utilize different receptor 
combinations to initiate SMAD2/3 phosphorylation. For the ligands tested in this study, TGFBR2 (TGFb) 
and ACVR2A/ACVR2B (activin A, GDF8 and GDF11) serve as type II receptors, whereas TGFBR1 (TGFb, 
GDF8 and GDF11), ACVR1B (activin A, GDF8 and GDF11) and ACVR1C (activin A) serve as type I 
receptors. Additionally, some ligands require a co-receptor like TGFBR3 (TGFb and GDF11) for full 
signaling activity (David and Massagué, 2018). Therefore, a regulation on the receptor level could 
explain the distinct dynamics despite the same downstream signaling. Another possibility are 
ligand-specific antagonists like FST or follistatin-like 3 (FSTL3), which can bind and neutralize GDF8, 
GDF11 and activin A but not TGFb (Schneyer et al., 2008). However, as the ligands mediated such 
opposing effects on the signaling, I assumed that most likely multiple components of the SMAD 
pathway need to be altered through growth factor deprivation. To gain a better understanding how 
cells can switch their ligand sensitivity, I chose GDF11 for further experiments in this study. By 
investigating the median nuc/cyt SMAD2 ratio of quiescent and proliferating cells upon stimulation 
with varying concentrations of TGFb and GDF11, the dynamic behavior of SMAD2 was further 
characterized. As shown in Figure 20B-E, dividing cells treated with GDF11 and non-dividing cells 
treated with TGFb exhibited similar dynamics, however, quiescent cells stimulated with GDF11 showed 
only a weak second response instead of a strong sustained response which was usually observed for 
proliferating cells treated with high TGFb concentrations. To investigate if ligand-depletion is the 
reason for the transient response, I tested higher concentrations of GDF11 (data not shown), but even 
a dose of 50 nM did not increase the second response. Again, regulation on the receptor level or 
specific ligand antagonists could be an explanation. The RNA sequencing revealed that ACVR2B 
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expression (RPKM ~0.6) was extremely low in MCF10A cells compared to TGFBR2 (RPKM ~20). Thereby, 
degradation of TGFb- and activin-receptors through negative feedbacks like SMAD7 (Kavsak et al., 
2000; Winbanks et al., 2016) could lead to transient responses to GDF11, as only small quantities of 
ACVR2B were available. Overexpression of ACVR2A and ACVR2B in MCF10A cells could be carried out 
to examine this hypothesis.  
Interestingly, pharmacological inhibition of MEK and EGFR revealed that a sustained lack of MAPK 
activity was responsible for the increase of GDF11-mediated SMAD signaling in quiescent cells 
(Figure 20H). This means that MEK activity can increase the response to TGFb and simultaneously 
decrease the response to GDF11. As both ligands signal via the same molecule SMAD2, a direct 
interaction by linker phosphorylation again seems less likely than an indirect effect mediated by 
MEK/ERK target genes. For this reason, and because the rescue with EGF suggested that the SMAD 
network was rewired on a slow time scale, a global gene expression analysis in proliferating and 
quiescent cells was performed. After evaluating the RNA sequencing, 63 SMAD pathway-associated 
genes were identified that fulfilled all criteria of the filtering procedure. Among them, several direct 
regulators of SMAD signaling such as TGFBR3, FST, GDF11 or AKT1 emerged (Figure 21). 
After researching the top genes on the list, it was possible to exclude several candidates. For example, 
genes that are involved in the maturation of ligands, like latent-transforming growth factor 
beta-binding protein 1  (LTBP1) (Robertson et al., 2015), or genes expressing the ligands itself, like 
GDF11 and GDF8 (MSTN), could be neglected as I used high quantities of recombinant TGFb and 
GDF11. Furthermore, genes that are associated with the SMAD pathway but do not directly influence 
the signaling were excluded for now. In this way, two candidates of particular interest were identified. 
For instance, FST, a potent GDF8 and GDF11 antagonist  (Gamer et al., 1999; Lee and McPherron, 2001; 
Khalil et al., 2016) was strongly downregulated in the non-dividing conditions (Figure 21D). To rebuild 
the rewiring caused by growth factor deprivation, I knocked out FST in S2-R cells. All three isoforms of 
FST (FST288, FST303 and FST315) that have similar binding affinities to ligands (Sidis et al., 2006) were 
targeted and I validated the corresponding clones with western blot analysis, PCR, RT-qPCR and 
sequencing (Figure 23B-D, 6.5). Surprisingly, the loss of FST did not alter GDF11 signaling at all 
(Figure 24A). Clonal effects could be excluded since multiple clones were examined in live-cell 
microscopy and all showed similar GDF11-mediated SMAD2 dynamics (data not shown). Taken 
together, I concluded that the generated cell lines do not express any form of FST, which indicated that 
the knockout of FST alone does not affect GDF11 signaling. However, genetic compensations could 
also be responsible for the unchanged SMAD2 dynamics. The compensation through other genes in 
response to a knockout/knockdown is a common phenomenon (El-Brolosy and Stainier, 2017). For 
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example, histone deacetylase 1 (HDAC1) and HDAC2 can compensate each other. When HDAC1 is 
inactivated, increased levels of HDAC2 were observed or vice versa (Jurkin et al., 2011).  Another 
example is the compensation of cyclin D2 through cyclin D3 upregulation in B-lymphocytes from cyclin 
D2 -/- mice (Lam et al., 2000). The loss of a functional gene is often compensated via a closely related 
gene. This makes FSTL3 an interesting candidate for the compensation of the FST knockout. Both share 
several functional properties, as well as a 40–50 % overall primary sequence homology (Schneyer et 
al., 2001; Saito et al., 2005). To test this hypothesis, FST-KO cells could be analyzed for FSTL3 
overexpression. Furthermore, there are other antagonists for GDF11 signaling, like GDF-associated 
serum protein 1 (GASP1) and GASP2 (Kondás et al., 2008; Khalil et al., 2016), which could also be 
checked for increased levels. 
The other interesting candidate was TGFBR3, a co-receptor modulating TGFb presentation to its type II 
receptor (Wang et al., 1991). It has been reported that the co-receptor can undergo ectodomain 
shedding and negatively regulate TGFb-induced SMAD2 activation. During this process, cells release 
soluble TGFBR3 that binds and sequesters ligands to inhibit TGFb signaling (Elderbroom et al., 2014). 
Strikingly, TGFBR3 has also been reported to co-occur with GDF11 (Wang et al., 2014) and enhance 
GDF11-mediated SMAD2 activation (Bajikar et al., 2017). Therefore, an abundance of TGFBR3 could 
not only decrease TGFb signaling but also increase GDF11 signaling at the same time. For this reason, 
TGFBR3 was overexpressed in the S2-R cell line. To ensure that the type III receptor is functional and 
to avoid common problems of exogenous overexpression, I increased expression levels of the 
endogenous gene using the CRISPR/Cas9 system (Figure 23E). Moreover, it was verified that the 
protein level of TGFBR3 was similar between quiescent cells and the overexpression cell line 
(Figure 23F). However, the increased levels of TGFBR3 did not achieve the desired effect. Even though 
the upregulation of the receptor decreased TGFb signaling, the effect was negligible (Figure 24C). 
Taken together, the transcriptional activation of TGFBR3 was successful, but the minor effects on 
signaling outcomes suggested that the switch in ligand sensitivity cannot be explained by changes in 
the TGFBR3 level. However, it should be considered that the decrease of TGFb signaling due to 
ectodomain shedding might also require the upregulation of additional co-factors rather than just 
higher quantities of TGFBR3. For example, it was reported that the shedding of the type III receptor 
requires metalloproteases and pervanadate (Velasco-Loyden et al., 2004). To test this hypothesis, the 
supernatant of the overexpression cell line could be screened for soluble TGFBR3. If the amount of 
soluble receptor is not considerably higher than in control cells, the protein level of potential co-factors 
could be increased by transcriptional upregulation.  
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Generally, SMAD signaling seems to be very robust against single perturbations. For instance, the 
knockout of SMAD7, one of the main feedback regulators of the pathway (Moustakas and Heldin, 
2009), increased the overall SMAD2 dynamics but did not change dynamical patterns in MCF10A cells 
(Strasen et al., 2018). Similar effects were observed after knocking out PPM1A (data not shown), a 
SMAD phosphatase which terminates TGFb signaling (Lin et al., 2006). Even with a complete loss of the 
phosphatase, only slight increases of the overall signaling strength were determined. The minor 
changes detected upon perturbation of TGFBR3 and FST in this work are consistent with these earlier 
observations. Moreover, even when all transcriptional feedbacks were inhibited by DRB treatments, 
only small adjustments in SMAD2 dynamics were observed. Interestingly, also the combined 
perturbations (FST knockout and TGFBR3 overexpression or FST knockout and DRB treatment) did not 
considerably change signaling outcomes (Figure 24A). Taken together, these results suggest that single 
and double perturbations might not be sufficient to reproduce the divergent signaling response of 
proliferating and quiescent cells. Therefore, maybe a more comprehensive rewiring of the network 
involving the modulation of multiple components of SMAD signaling is necessary to shift ligand 
sensitivity. The up- and downregulation of 63 SMAD-associated genes in quiescent cells further 
strengthens the hypothesis of a wide-ranging pathway-rewiring. To investigate this idea, gene 
expression of multiple genes would have to be changed. In recent years, more and more genome-scale 
knockout or activation screenings using CRISPR/Cas9 were developed (Konermann et al., 2015; 
Feldman et al., 2019; Ihry et al., 2019). For multiplexed regulation of several genes, a library could be 
generated containing sgRNAs that target the SMAD-associated genes identified by the RNA 
sequencing. For example, Konermann et al., 2015, showed that the simultaneous activation of ten 
genes using ten different sgRNAs is possible. However, it would still be challenging to up- and 
downregulate dozens of genes in one cell line to prove a pathway-rewiring. Eventually, it is also 
possible that the correct key protein responsible for the ligand sensitivity switch was not identified yet. 
Nonetheless, a large-scale screening could again help to determine this key player. 
3.2.2 SMAD-MEDIATED CELL FATES IN QUIESCENT AND 
PROLIFERATING CELLS 
After revealing that MCF10A cells adjust their sensitivity for ligands of the TGFb superfamily according 
to the proliferation state, the question has been raised whether different ligands also have different 
consequences for the physiological response of the cell. Even though multiple studies uncovered a 
wealth of information about the SMAD network, it is still poorly understood how the simple and 
straight forward pathway controls such a broad range of phenotypic outcomes. Moreover, it is unclear 
if and how the signaling network can differentiate between varying ligands. While there are two 
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signaling branches with SMAD2/3 and SMAD1/5/8 as well as a small set of serine-threonine receptors, 
the more than 30 different ligands of the TGFb superfamily suggest a rather converging pathway that 
cannot distinguish between each ligand. However, the diverse functions reported for the different 
ligands contradict this hypothesis. Also, it seems irrational to have a wide variety of growth factors but 
no ligand-specific outcome (Nickel and Mueller, 2019). The promiscuity of ligand-receptor interactions 
was recently discussed for the BMP signaling pathway (SMAD1/5/8). It was suggested that the effect 
of a particular ligand on pathway activity depends on which other ligands are present. For example, it 
was shown that BMP3 antagonistically interacts with almost every other ligand that was tested in this 
context and that BMP4 and BMP7 can exhibit antagonistic and synergistic interactions. Moreover, 
BMP4 and BMP10, two potent activators of the pathway, became inhibitory in the presence of the 
other ligand (Antebi et al., 2017). These complex multi-ligand responses could explain how the 
converging pathway mediates diverse cellular outcomes and it would be intriguing to extend this 
approach to cytokines activating SMAD2/3. Another possible hypothesis was that the dynamic 
behavior of SMADs is more decisive than the type of ligand and that ligands mediate diverse cellular 
outcomes through different dynamical patterns of SMADs. Thus, ligands would not necessarily need a 
more complex pathway to mediate a variety of functions but rather intrinsic properties, like different 
binding affinities or binding kinetics that would change signaling dynamics (Nickel and Mueller, 2019). 
Since previous studies already revealed that signaling dynamics are associated with cellular responses 
(Purvis and Lahav, 2013), this seemed to be a possibility. To test this hypothesis, proliferating and 
quiescent S2-R cells were stimulated with TGFb or GDF11 and screened for cellular outcomes in 
time-lapse live-cell microscopy (Figure 25). I focused on EMT, apoptosis and cytostasis, three cell fates 
that are often associated with SMAD signaling (Heldin et al., 2009). To determine changes in these cell 
fates, I quantified phenotypic features like motility, cell death and cell division. Motility can be used as 
a readout for EMT, as EMT usually results in enhanced cell movement (Lamouille and Derynck, 2007). 
After imaging stimulated S2-R cells for 120 h, I was able to observe changes in all three cell fates. While 
an increase in motility and a decrease in cell division rate were only monitored in proliferating cells, a 
high fraction of cell death was exclusively observed in quiescent cells. To further characterize the 
phenotypes, biomarkers of the different cell fates were investigated (Figure 25E and F). For example, 
CDH1, VIM and SNAI1 were selected for EMT (Zeisberg and Neilson, 2009), MYC for cytostasis (Rabbitts 
et al., 1985) and cleaved caspase 7 for apoptosis (Fernandes-Alnemri et al., 1995). Indeed, biomarkers 
changed according to the observed phenotypes. After providing evidence for all three SMAD-related 
cell fates, the objective was to associate them with the SMAD2 dynamics. Interestingly, the strength 
of the signaling correlated well with the cellular outcome, as an increasing pathway activation led to 
increasing cell death and motility (Figure 25C and D). For the decrease in cell division rate strong 
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sustained dynamics were necessary (Figure 25D), which is consistent with previous studies in cancer 
cell lines showing that transient SMAD activation was sufficient to alter cellular motility, while 
sustained signaling was required to induce cytostasis (Nicolás and Hill, 2003; Giampieri et al., 2009). 
My results suggested that SMAD signaling is indeed quantitative rather than qualitative. Additionally, 
single-cell analyses of the 120-h experiments revealed a strong correlation between dynamics and cell 
fate decisions since cells with a higher AUC also covered a greater distance and divided less frequently 
(Figure 26A-C). Even though the results indicated a dynamic-dependent cell fate, the question whether 
ligands are a deciding factor for cellular outcomes had yet to be answered. For instance, in Figure 26C 
the 400 highest and lowest AUCs were analyzed without considering the different treatments to show 
that the ligand is of secondary importance. However, because of the different ligand sensitivity in 
proliferating cells, only a few TGFb- and GDF11-treated cells were among the 400 lowest and highest 
AUCs, respectively (Figure 26D). Due to this, only a handful of cells that had been treated with different 
ligands, but exhibited similar dynamics/AUCs, could be analyzed. As all SMAD-associated cell fates 
were only observed in one of the two proliferation states, it was also not possible to compare the 
cellular outcome of GDF11 signaling in quiescent cells with the cellular outcome of TGFb signaling in 
proliferating cells, or vice versa. One way to address this problem could be to research other 
phenotypic changes which are present in both cell states. For example, SMAD signaling is also involved 
in the regulation of autophagy, a critical cellular response to environmental changes (Kiyono et al., 
2009). Therefore, if this cellular outcome is displayed in both proliferation states, proliferating and 
quiescent cells could be screened for the accumulation of autophagosomes via a GFP-LC3 reporter 
(Kabeya et al., 2000). Moreover, it has been reported that A549 cells treated with TGFb for 7 days 
undergo senescence (Katakura et al., 1999). To differentiate between quiescence and senescence, it 
could be investigated if cells start to divide again upon EGF stimulation. It would be expected that 
senescent cells, despite growth factor re-introduction, will not resume proliferation. This approach 
could be combined with the senescence associated β-galactosidase (SA-bG) assay as it has been shown 
that SA-bG activity was irreversibly increased in senescent cells but was reversible in quiescent cells 
that re-entered the cell cycle (Yang and Hu, 2005). Thereby, senescence could possibly serve as another 
readout. However, it should be kept in mind that long-term stimulations in quiescent cells caused 
apoptosis, which complicates the investigation of other cell fate decisions. Another possibility to 
address the uneven distribution of the AUCs, would be to increase GDF11-mediated signaling in 
proliferating cells through modifications of the SMAD pathway. This would lead to more 
GDF11-treated cells with high AUCs, which could then be screened for increasing motility and 
decreasing cell division rate. If ligands are insignificant for the cellular outcome, changes similar to 
those observed in TGFb-treated cells would be expected. However, as seen in my previous 
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experiments, SMAD signaling seemed to be quite robust against perturbations. For this reason, I 
decided to approach this problem by analyzing gene expression patterns in stimulated quiescent and 
proliferating cells. Thus, instead of phenotypic changes, the modulation of gene expression was used 
as a readout to study the physiological consequences of ligand stimulations. As a proof of concept, the 
gene expression of EMT and cell cycle markers in quiescent cells treated with GDF11 was investigated 
by RT-qPCR. It was speculated that even though non-dividing cells did not exhibit SMAD-associated cell 
fates, the corresponding genes would still be modulated due to the quantitative nature of the SMAD 
signaling pathway. Indeed, while these genes were barely up- or downregulated in proliferating cells 
treated with GDF11, they now showed a high fold change compared to the unstimulated control 
(Figure 27A). However, the fold change of some of the biomarkers was not as high as in proliferating 
cells treated with TGFb (Figure 25F and Figure 27A). This might be due to the fact that quiescent cells 
with strong SMAD2 activation die or that GDF11-mediated SMAD2 dynamics show a rather weak 
second response. Interestingly, despite the clear regulation of EMT markers in quiescent cells, they did 
not show any corresponding phenotypic changes. One possible explanation for this phenomenon could 
be lethal EMT, an event that remodels the transcription factor landscape for EMT-associated apoptosis 
(David et al., 2016). Thus, instead of increased motility and a mesenchymal phenotype, cell death 
would be observed in quiescent cells. But why quiescent cells are more likely to promote apoptosis 
than EMT compared to proliferating cells remains to be answered. Nonetheless, a similar regulation of 
EMT markers in quiescent cells treated with GDF11 and proliferating cells stimulated with TGFb 
suggested once more that the SMAD pathway does not directly differentiate between ligands but 
rather mediates cellular outcomes through dynamical patterns of SMADs. To further validate the 
quantitative nature of SMAD signaling, gene expression patterns in stimulated quiescent and 
proliferating cells were globally studied utilizing RNA sequencing. To this end, S2-R cells were 
stimulated with high doses of TGFb or GDF11 for 3 h and 6 h. Since the first peak of SMAD2 activation 
usually appeared 2 h upon treatment and the sustained response began approximately 4 h after 
stimulation (Figure 20C and D), these time points should reflect the effects of both responses on gene 
expression. Strikingly, in nearly all conditions, a similar set of genes was regulated by TGFb and GDF11 
signaling. Moreover, dynamics correlated well with the level of gene induction, as all conditions 
showed correlation coefficients above 0.6, some even over 0.9 (Figure 27B-G). As a rule of thumb, 
correlation coefficients between 0.7 and 0.9 are usually described as strongly correlated (Mukaka, 
2012). Since also genes with very low fold changes were included in the scatterplots, it would be 
interesting to use a filter system that only considers genes that are associated with SMAD signaling 
and that have a minimal fold change. To be more specific, genes that contain SMAD binding elements 
such as GGCGC and related 5 bp motifs as well as known motifs for SMAD-specific transcription factors 
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(David and Massagué, 2018) could be selected and then analyzed again. Thereby, only genes that are 
directly regulated would be investigated and indirect effects of SMAD signaling on gene expression 
could be excluded. To assess whether genes were more strongly regulated by TGFb or GDF11 
stimulations, a linear model was added to the scatterplots. In the linear fit, genes with a higher fold 
change were indirectly considered more since the combined p-values referring to the differential 
expression compared to the control were used as a weight for each data point. Usually, genes with an 
extremely low fold change also had higher p-values and thereby were less relevant for the linear fit. 
Corresponding to the SMAD2 dynamics, genes were more strongly induced by TGFb stimulation in 
proliferating cells than by GDF11 stimulation and vice versa in quiescent cells. Interestingly, the gene 
expression of multiple genes in non-dividing cells was still severely modulated by TGFb treatment, 
although SMAD2 activation was usually very low (Figure 27D and E). However, this was not the case 
for GDF11-mediated gene expression in proliferating cells, as can be seen from the moderate slope of 
the linear model (Figure 27B and C). There could be different explanations for this. First, although 
GDF11 signaling is strongly increased by growth factor deprivation, a secondary response, similar to 
that obtained with TGFb stimulation, was never observed. Thus, the sustained response in 
TGFb-treated cells could be responsible for the decreasing slope of the linear model in proliferating 
cells. In other words, the lack of a strong GDF11-mediated second response in quiescent cells 
prevented the linear model from trending more towards GDF11-induced gene expression. Second, 
GDF11 might require an additional transcription factor to induce its full effect, which is not expressed 
in proliferating cells. For example, it has been reported that ID2, a helix-loop-helix inhibitor important 
for mammary gland development (Mori et al., 2000), is required for GDF11-mediated cellular 
responses (Bajikar et al., 2017). Interestingly, ID2 was considerably upregulated in quiescent cells and 
fulfilled all requirements of the filtering system (Figure 21A-C), which would support this hypothesis. 
However, it would argue against the idea of a quantitative signaling and raise the question how ID2 
can differentiate between TGFb and GDF11. The transcriptional activation of ID2 via CRISPR/Cas9 in 
proliferating cells could be utilized to further characterize the role of ID2 in GDF11 signaling. In general, 
the results of the RNA sequencing strongly suggested that SMAD signaling is quantitative rather than 
qualitative, as the same genes were regulated upon GDF11 and TGFb stimulation and the strength of 
the signal correlated well with the level of gene expression. However, it should be noted that only two 
ligands of the TGFb superfamily were investigated. Thereby, it would be intriguing to investigate other 
ligands as well. For example, activin A could be used for further validations since it also initiated the 
activation of SMAD2 in MCF10A cells (Figure 20A). Moreover, as activin A signaling was not influenced 
by growth factor deprivation, the question whether the proliferation state itself affects gene 
expression could be answered. In case the cell state does not play an essential role, genes would 
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correlate almost perfectly between quiescent and proliferating cells stimulated with activin A as they 
exhibit similar nuc/cyt SMAD2 ratios. 
Furthermore, it would be interesting to test the idea of a quantitative signaling by using a mathematical 
model. For instance, the information about TGFb-mediated dynamics and gene expression could be 
used to predict the gene induction by GDF11. Hypothetically, if the pathway does not differentiate 
between different ligands, the dynamics of SMAD2 should be sufficient to predict changes in gene 
expression. Again, dynamics and gene induction of multiple TGFb superfamily members could help to 
create and validate a sophisticated model. Besides more comprehensive RNA sequencing and 
mathematical modeling, the influence of the individual ligands could also be investigated in other 
ways. For example, instead of comparing more growth factors and their cellular outcomes, ligands 
could also be completely removed from the equation. One way to achieve this could be the 
optogenetic regulation of SMAD signaling. With this approach, SMAD molecules can be 
spatiotemporally controlled without the use of ligands (Li et al., 2018; Humphreys et al., 2020). SMAD2 
dynamics like those mediated by GDF11 and TGFb treatment could be replicated by light stimulations 
and subsequent cellular responses could be investigated.  It would be intriguing to see if SMAD 
signaling would still be able to cause cytostasis, apoptosis, EMT or changes in gene expression to the 
same extent. 
Taken together, through quantitative and time-resolved dissection of the SMAD signaling pathway at 
the single-cell level, I uncovered that TGFb mediated a much higher SMAD2 response in proliferating 
cells compared to quiescent cells and that it was exactly the opposite for GDF11. Furthermore, I 
observed different SMAD-associated cell fates that correlated well with SMAD2 dynamics, indicating 
that the signaling pathway is quantitative rather than qualitative. In essence, these discoveries 
contribute to a better understanding of the interplay of SMAD signaling and the cell cycle as well as to 
a deeper insight of SMAD-associated cell fates. But why is a profound knowledge of this network so 
important? Efficient information processing by the SMAD signaling pathway is essential during 
embryogenesis and in the adult organism as dysregulations of the signaling contribute to severe 
diseases such as cancer or fibrosis. Moreover, the pathway plays an important role in the regulatory 
process of quiescence and proliferation to enable tissue repair and regeneration. Thereby, a 
quantitative understanding of how cells encode and decode information about extracellular ligands 
and elicit appropriate responses in both cell states is mandatory for therapeutic targeting of the 
pathway. This study showed the variety of cellular responses that can be mediated by the SMAD 
signaling pathway and which requirements must be fulfilled for each cell fate. For instance, for TGFb 
and GDF11, the cells must be quiescent to initiate apoptosis. For cells to undergo EMT, however, the 
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cells must be proliferating. In view of the dual role of SMAD signaling in cancer, these findings are 
interesting. Usually, ligands like TGFb can prevent uncontrolled tissue growth by inducing cytostasis 
and apoptosis, however, in later stages of tumor progression they lose the suppressive abilities but 
regain EMT-promoting functions which can lead to metastases (Ikushima and Miyazono, 2010). As 
cancer cells are characterized by permanent and uncontrolled cell division, it corresponds to my 
observation that these cells undergo EMT rather than apoptosis. A molecular understanding of how 
the proliferation state influences the decision between EMT and cell death could help to target and 
inhibit the cancer promoting effects of SMAD signaling. Moreover, the findings that GDF11 induces a 
considerable degree of apoptosis in quiescent cells might be interesting for cancer therapies in general. 
For instance, quiescent cancer stem cells have been observed in many human malignancies and are 
accountable for the resistance against current treatments, such as cytotoxic chemotherapy. While 
chemotherapy was effective in killing cancer cells in S/G2/M-phases, there was only little effects on 
cancer cells in G0/G1-phase (Yano et al., 2014; Chen et al., 2016). Thereby, quiescence is adopted as a 
surviving strategy to escape from different therapies. Current pharmacological strategies are aimed at 
eradicating quiescent cells, keeping them in a harmless, non-dividing state, or increasing their 
sensitivity to anti-proliferative drugs by reactivating them (Recasens and Munoz, 2019). If GDF11 
triggers the quiescent-dependent apoptosis in various cell types, treatment with the recombinant 
ligand could be a new therapeutic approach to eradicate quiescent cancer cells. 
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3.3 MATERIAL AND METHODS OF PART 2 
3.3.1 CELL LINES 
MCF10A cell lines were cultured in DMEM/F12 growth-medium (2.3.1). When required, the medium 
was supplemented with selective antibiotics to maintain transgene expression (400 μg/ml geneticin 
disulphate (G418, ROTH), 50 μg/ml hygromycin B (Thermo Fisher Scientific) or 5 μg/ml blasticidin S 
hydrochloride (ROTH)). The S2-R cell line has been previously described (Strasen et al., 2018). In short, 
lentiviral reporter constructs encoding SMAD2-YFP and H2B-CFP under the control of a constitutive 
human UbCp were generated using the MultiSite-Gateway recombination system (Invitrogen) and 
transduced utilizing lentiviral particles.  
HEK293 cells were grown in DMEM - High Glucose medium and U-2 OS cells in DMEM/F12 medium. 
Both media were supplemented with 10 % FBS (PAN-Biotech), 100 U/ml Penicilin, 100 μg/ml 
streptomycine and 2 mM GlutaMAX. 
3.3.2 GENERATING A FST KNOCKOUT CELL LINE 
A FST knockout cell line in MCF10A S2-R was created utilizing the CRISPR/Cas9 system. The knockout 
of FST has to affect both alleles of the gene to ensure a complete loss of the corresponding protein. To 
this end, a donor DNA and an sgRNA were cloned and transfected together with Cas9 endonuclease 
into S2-R cells. The donor DNA consists of a knock-in sequence (SV40-Blasticidin_R) surrounded by left 
and right homology arms. The arms are homologous to the genomic DNA upstream and downstream 
of the desired knock-in location. To create the homology arms, a template (HA-template) was amplified 
by PCR (3.3.5) from MCF10A genomic DNA using the primer pair FST_gen (listed below). The 
corresponding DNA fragment was purified from an agarose gel (3.3.6) and utilized as a template to 
amplify the homology arms with the primer pairs FST_HAL and FST_HAR. The lengths of the homology 
arms were as follows: 927 bp for the left and 800 bp for the right arm. For the knock-in sequence, the 
SV40 promotor in front of the blasticidin resistance gene was amplified from the pVE10 vector by 
utilizing the primer pair FST_Blast. All three PCRs were performed with the Q5 polymerase (New 
England BioLabs) and the resulting products were purified from an agarose gel. All primers were 
designed to create 15-35 bp overlapping DNA fragments to join the homology arms, the knock-in 
sequence and the expression vector pDONR221 (digested with EcoRV and AflII (both 
New England BioLabs)) together using NEbuilder (New England BioLabs). The resulting product 
(pDONR221-FST-Blast_R) was multiplied in E. coli (3.3.8) and afterwards validated by control digestion 
(3.3.10) and sequencing (3.3.11) to exclude any mutations. To clone the sgRNA, a 20 bp long guide 
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sequence (listed below) which is specific to the target gene was designed first. To ensure the smallest 
possible number of off-target sites, the sgRNA was designed with an online tool of Labun et al., 2019,  
(CHOPCHOP v3). The target sequence is located in exon 2 (chr5:53482891) near the start codon 
(chr5:53480791). Next, corresponding oligos were designed and annealed. To this end, 100 pmol of 
each oligo were diluted in 40 μl of 10 mM Tris-Buffer, denatured and annealed using a PCR machine 
(peqSTAR, VWR) (program listed at the end). For further use, 2 μl of the oligos were diluted in 38 μl of 
10 mM Tris-Buffer. Afterwards, the sgRNA_AL vector (6.4), which contains the crRNA and tracrRNA 
sequences, was digested with AgeI (New England BioLabs) and joined together with the annealed 
oligos utilizing NEbuilder. The final sgRNA was multiplied in E. coli and afterwards validated by control 
digestion and sequencing to exclude any mutations. Finally, 495 ng of sgRNA, 10 ng of donor DNA 
linearized by NotI (New England BioLabs) and 495 ng of Cas9 endonuclease were transfected into S2-R 
cells. Monoclonal colonies were achieved as described in 3.3.3. To analyze the corresponding clones 
and determine whether they are heterozygous, homozygous or negative for the insertion, genomic 
DNA was isolated from the clones using the QIAamp DNA Mini Kit. Afterwards, a PCR with two different 
primer pairs was performed. The FST_gen forward and reverse primers flank the target and amplify 
the genomic region containing the Cas9 endonuclease cleavage site. If the donor DNA was inserted 
into the FST locus, the PCR amplification will generate one fragment (3.4 kbp) for homozygous and two 
fragments (3.4 kbp + 2.2 kbp) for heterozygous genotypes. To check if the donor DNA was inserted 
correctly, the FST_gen reverse primer was exchanged with the direct-blast primer, which binds within 
the blasticidin sequence. By utilizing these two primers, the PCR amplification will generate a fragment 
of 1.7 kbp size upon successful integration. The program for oligo annealing was set up as follows: 
Temperature Time  Cycles 
95 °C 10 min 1 
95-85 °C, -2 °C /s   
85 °C 1 min 1 
85-75 °C, 0.3 °C/s   
75 °C 1 min 1 
75-65 °C, -0.3 °C /s   
65 °C 1 min 1 
65-55 °C, -0.3 °C /s   
55 °C 1 min 1 
55-45 °C, -0.3 °C /s   
45 °C 1 min 1 
45-35 °C, -0.3 °C /s   
35 °C 1 min 1 
35-25 °C, -0.3 °C /s   
25 °C 1 min 1 
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Guide sequence Sequence (5’-> 3’) 
FST_sgRNA_for CACCTGGCTCCGTCAAGCGAAGAAGTTTTAGAGCTAGAAATAGCA 
FST_sgRNA_rev AAACTTCTTCGCTTGACGGAGCCAGGTGTTTCGTCCTTTCC 
3.3.3 TRANSFECTION AND GENERATION OF MONOCLONAL CELL 
LINES 
For insertion of plasmid DNA into MCF10A cell lines, approximately 18-24 h before transfection 
2.5 × 105 cells were seeded in a 12-well plate and cultured in growth-medium. Afterwards, the 
corresponding DNA was diluted in 50 µl of preheated Opti-MEM I reduced-serum medium (Thermo 
Fisher Scientific) and 2 µl of P3000 (Lipofectamine 3000 Kit, Thermo Fisher Scientific) were added. The 
mixture was incubated for 5 min. Meanwhile, 3 µl of Lipofectamine 3000 (Lipofectamine 3000 kit) was 
added to another 50 µl of preheated Opti-MEM I reduced-serum medium. Afterwards, the two 
samples were mixed and incubated for 15 min at room temperature. The mixture was added dropwise 
to different areas of the wells and gently rocked for homogeneous distribution. After 3 days, the cells 
were trypsinized with 1× Trypsine-EDTA (Thermo Fisher Scientific) and transferred to 15 cm plates with 
antibiotic-containing medium. The medium was changed twice per week and after 14-21 days, colonies 
were picked. To this end, colonies were trypsinized, individually aspirated using a 1 ml pipette and 
transferred to a 12-well plate with antibiotic-containing medium. When confluent, cells were washed 
with PBS trypsinized and transferred to a 6-well plate. This process was repeated until cells were 
transferred to 10 cm plates. 
3.3.4 GENERATING A TGFBR3 OVEREXPRESSION CELL LINE 
To amplify the TGFBR3 level in S2-R cells, I followed the approach from Konermann et al., 2015, where 
a dead Cas9-VP64 complex was used to increase the expression of target genes. First, the target 
sequence was designed utilizing an online tool (sam.genome-engineering.org/database/) to avoid 
off-target effects and ensure that the target sequence (chr1:91886308) is located close to the TSS 
3 The Cell State and SMAD Signaling 
 
92 
(chr1:91886281). Next, corresponding oligos were denatured and annealed using a PCR machine. The 
annealed oligos with 4 bp overhangs were then joined together with the lentiviral vector lentiSAMv2 
(Addgene plasmid #75112) containing the dCas9-VP64 complex using Golden Gate cloning. The 
detailed reaction setups and programs are listed below. The final lentiviral vector 
(lentiSAMv2-TGFBR3) was multiplied in E. coli and afterwards validated by control digestion and 
sequencing to exclude any mutations. At the end, S2-R and wild-type MCF10A cells were infected with 
the corresponding lentiviral particles to create stable cell lines overexpressing TGFBR3. To achieve an 
even higher expression level of the target gene, cells were additionally infected with the vector 
lentiMPHv2 (Addgene plasmid #89308) containing the transcriptional activators p65 and HSF1. The 
reaction mixture and program for oligo annealing were set up as follows: 
Component Amount 
Each oligo [100 µM] 1 μl  
10x T4 ligase buffer (New England BioLabs) 1 μl  
T4 PNK (New England BioLabs) 0.5 μl  
ddH2O  6.5 μl  
 
Temperature Time  Cycles 
37 °C 30 min 1 
95 °C 5 min 1 
95-25 °C, -5° C/min  1 
 
Guide sequence Sequence (5’-> 3’) 
TGFBR3_sgRNA_for CACCGGAGAGGAGGCGGGAGGCGGG 
TGFBR3_sgRNA_rev AAACCCCGCCTCCCGCCTCCTCTCC 
The reaction mixture and program for the Golden Gate reaction were set up as follows: 
Component Amount 
2× T7 Ligase Reaction Buffer (New England BioLabs) 1 µl  
BSA [20 mg/ml] 0.125 µl  
Restriction enzyme BsmBI (New England BioLabs) 1 µl  
T7 ligase (New England BioLabs)  0.125 µl  
Diluted oligo anneal (1:10)  1 µl 
Backbone vector lentiSAMv2 1 µl 
ddH2O 9.25 µl 
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Temperature Time  Cycles 
37 °C 5 min 15 
20 °C 5 min 15 
3.3.5 POLYMERASE CHAIN REACTION 
The polymerase chain reaction (PCR) was used to amplify DNA fragments using specific primers listed 
in the respective sections. Q5 High-Fidelity DNA polymerase (New England BioLabs) was used with the 
following reaction setup and program: 
Component Amount 
5× Q5-Buffer (New England BioLabs)                                                                           10 µl  
dNTP mix (10 mM) (New England BioLabs) 1 µl  
Forward primer (10 pmol/μl)  1 µl  
Reverse primer (10 pmol/μl)  1 µl  
Q5® DNA polymerase  0.5 µl  
Template  10-200 ng  
ddH2O  up to 50 µl  
Program was adjusted to primers and product length. 
Step Temperature Time  Cycles 
Initial denaturation 98 °C 1.50 min 1 
Denaturation 98 °C 10 s 15 
Annealing 65 °C 30 s 15 
Elongation 72 °C 1.05 min 15 
Denaturation 98 °C 10 s 20 
Annealing 60 °C 30 s 20 
Elongation 72 °C 1.05 min  20 
Final elongation 72 °C 7.00 min 1 
3.3.6 ANALYSIS AND PURIFICATION OF DNA BY AGAROSE GELS 
For separation of DNA fragments, 1.0-1.5 % agarose gels with the fluorescent dye peqGREEN (Peqlab) 
were prepared. For a 1 % (w/v) agarose gel, 1 g of agarose was dissolved in 100 ml 1× TAE buffer by 
heating. After the mixture cooled down, 5 µl of peqGREEN were added. The DNA samples were 
supplemented with 6× loading dye (New England BioLabs). For molecular weight estimation, the 1 kb 
plus DNA Ladder (New England BioLabs) was used. Running time and used voltage were adjusted to 
the size of the DNA fragments (approximately 130 V for 30 min). If the DNA fragments were needed 
for further experiments, bands were extracted and purified with the QIAquick Gel Extraction Kit 
(Qiagen) according to the manufacturer’s instructions. The DNA was eluted with 30 µl EB buffer and 
quantified using the spectrophotometer NanoDrop 2000c (Thermo Fisher Scientific). 
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3.3.7 DNA FRAGMENT ASSEMBLY 
To assemble multiple overlapping DNA fragments in a single-tube isothermal reaction, NEbuilder 
assembly was used. The reaction mixture for cloning the donor DNA was set up as follows: 
Component Amount 
pDONR221×EcoRV+AflII  31.4 ng  
HAL  25 ng  
HAR  35 ng  
SV40-Blast_R  28.5 ng  
2× NEbuilder Master Mix 10 µl 
ddH2O up to 20 µl 
The reaction mixture for cloning the sgRNA was set up as follows: 
Component Amount 
sgRNA_AL×AgeI  50 ng  
Annealed oligos  2.8 ng  
2× NEbuilder Master Mix 5 µl  
ddH2O  up to 10 µl  
All reactions were performed at 50 °C for 1 h. 
3.3.8 ELECTROPORATION AND CULTIVATION OF ESCHERICHIA COLI 
For electroporation, electro competent E. coli cells (Top10) were thawed on ice and 1 µl of diluted 
NEbuilder assembly product (1:3) or 2 µl of Golden Gate reaction were added. The cells were 
transferred into an electroporation cuvette (Bulldog Bio, Inc.). Using an electroporator (Eppendorf AG), 
a charge of 1.8 kV was applied and afterwards, 1 ml of SOC medium (New England BioLabs) was added. 
The cells were incubated for 1 h at 37 °C. Subsequently, 50 µl were spread onto antibiotic-containing 
LB agar (Sigma) plates and incubated over night at 37 °C. The next day, single colonies were picked and 
grown in 5 ml LB medium (Carl Roth) with appropriate antibiotics (100 µg/ml Ampicillin (AppliChem) 
or 50 µg/ml Kanamycin (AppliChem)) at 37 °C O/N while shaking.  
3.3.9 GENOMIC DNA AND PLASMID DNA ISOLATION 
For the isolation and purification of plasmid DNA from overnight cultures, the QIAprep Spin Miniprep 
Kit (Qiagen) was used. For the isolation of genomic DNA from cultured MCF10A cells, the QIAamp Mini 
DNA Kit (Qiagen) was used. The isolations were performed according to the manufacturer’s 
instructions. Plasmid DNA was eluted with 30 µl EB buffer and genomic DNA was eluted with 200 µl EB 
buffer. 
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3.3.10 DIGESTION OF DNA SAMPLES 
To confirm the presence of the desired DNA fragments in plasmids or to prepare the DNA for other 
processes, a restriction digest was performed. By using appropriate restriction enzymes and associated 
buffers, DNA molecules were cleaved at selected sites. The reaction mixture was set up as follows: 
Component Amount 
DNA (200-1,000 ng)  10 µl  
10× Cutsmart Buffer (New England BioLabs)  2 µl  
Enzyme I (10 U/μl)  0.5 µl  
Enzyme II (10 U/μl)  0.5 µl  
ddH2O  up to 20 µl  
3.3.11 SEQUENCING 
SEQLAB Gmbh in Göttingen carried out the Sanger DNA sequencing. For this purpose, 60-100 ng/μl 
plasmid DNA and 2 pmol/μl of an appropriate primer were diluted in 15 μl pure water. 
3.3.12 LIVE-CELL TIME-LAPSE IMAGING 
For live-cell imaging experiments, I used 24-well imaging plates (ibidi). I seeded 3 × 104 cells per well 
and incubated them in growth-medium for 40 - 46 h. Afterwards, cells were incubated for at least 48 h 
in serum- and growth factor-free medium to ensure that cells go into a quiescent state. To compare 
proliferating and quiescent cells, additional cells were seeded and incubated in 
growth-medium. At least 1 h before the experiment, I changed medium to microscopy- or 
deprivation-microscopy-medium. Cells were imaged with the same setup as described in 2.3.2. Over 
24 h, images were taken every 6 min. For long-term experiments (120 h), images were taken every 
20 min and medium was exchanged every 48 h to ensure sustained ligand stimulation. 
3.3.13 LIGAND AND INHIBITOR TREATMENT 
Inhibitor and ligand treatments were performed in the appropriate medium. Recombinant TGFb, GDF8 
and GDF11 were stored at -80 °C in 4 mM HCl and 1 mg/ml bovine serum. Recombinant activin A and 
GDF3 were stored at -80 °C in 1 mg/ml bovine serum. If not indicated differently, inhibitors were 
diluted in DMSO and stored at -20 °C. Ligands and inhibitors were used as indicated below. Before the 
treatment, cells were imaged for 1 h. Usually, the ligands/inhibitors were prepared in 125 µl of medium 
and added to the cells to achieve the desired concentration in a final volume of 625 µl. Restimulations 
were carried out by aspirating the old medium and changing to new medium containing the desired 
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ligand/inhibitor concentration. Control cells were treated with medium only or medium containing 
DMSO. 
Inhibitors and ligands Used concentration  
Gefitinib EGFR inhibitor  10 µM 
Ly294002 PI3K inhibitor  50 µM 
Palbociclib CDK4/6 inhibitor in Sodium DL-Lactate  10 µM 
Selumetinib (AZD6244) MEK1/2 inhibitor  1 µM 
Activin A 1 nM and 20 nM 
GDF3 (Peprotech) 1 nM and 20 nM 
GDF8 (Peprotech) 1 nM and 20 nM 
GDF11 (Peprotech) various concentrations 
TGFb (Peprotech) various concentrations 
3.3.14 DATA ANALYSIS OF LIVE-CELL MICROSCOPY EXPERIMENTS 
Cells were tracked as described in 2.3.5. Afterwards, the integrated nuclear fluorescence intensity was 
quantified and the fluorescence intensity in the cytoplasm was measured using a 4-pixel wide annulus 
around the nucleus. To ensure that each annulus only measured the corresponding cytoplasm, the 
annulus was prevented from overlapping with neighboring cytoplasmic and nuclear regions. However, 
it could not be excluded that it contained extracellular areas. The median fluorescence intensity for 
each cell over time was measured within the area of the annulus. Together with the median 
fluorescence intensity of the nucleus, the nuc/cyt SMAD2 ratio was calculated.  
3.3.14.1 QUANTIFICATION OF CELL DIVISIONS 
To quantify divisions of individual cells, the shape and size of the nucleus as well as the integrated 
H2B-CFP fluorescence intensity were tracked and analyzed. If the size and intensity decrease by 
approximately 50 % within a certain time window, the event is considered a cell division. As nuclear 
envelope breakdown during mitosis could influence measurements of SMAD translocation, the data 
between 20 min before and 40 min after mitosis were removed by interpolation. To further minimize 
disturbing factors in the analysis, spikes which appear in all cells simultaneously were removed by 
interpolation as they usually indicate a flickering of the fluorescent lamp. 
3.3.14.2 QUANTIFICATION OF CELL MOTILITY 
To quantify the motility of individual cells, Euclidean distances between two subsequent positions of a 
single cell were calculated based on the x and y coordinates measured in pixels. When the distance 
covered between two time points exceeded a certain threshold (three times the average distance 
covered over all cells), the trajectories were ignored for the following analysis. In order to calculate the 
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motility score, the mean distance covered during two consecutive time points was determined for each 
cell. 
3.3.15 IMMUNOFLUORESCENCE 
For immunofluorescence experiments, 2 × 105 wild-type MCF10A cells were seeded on coverslips 
coated with poly-L-lysine (Sigma) and incubated in growth-medium for 2 days. After a 48-h growth 
factor and serum deprivation, cells were stimulated with TGFb or GDF11 and fixed at indicated time 
points with 2 % paraformaldehyde in PBS for 10 minutes. Permeabilization, antibody staining, and 
Hoechst staining were performed as described in 2.3.8. Coverslips were embedded in Prolong Antifade 
(Thermo Fisher Scientific) and stored over night at room temperature. The next day, images were 
acquired with the same objective and filter sets as described in 2.3.2. Again, automated segmentation 
was performed in MATLAB (MathWorks) with algorithms from CellProfiler (Carpenter et al., 2006). 
Antibody  
Rabbit monoclonal anti-total SMAD2 (Cell Signaling Technology) 




3.3.16 CELL CYCLE ANALYSIS 
Cells were seeded and treated as described in 3.3.12. Proliferating and quiescent cells were incubated 
with 10 mM EdU (EdU Click-647) for 1 h. EdU was washed off with PBS and cells were fixed with 
2 % paraformaldehyde in PBS for 10 min at room temperature. Afterwards, cells were washed with 
PBS, permeabilized with 0.1 % Triton X-100 in PBS and blocked with 10 % goat serum in PBS. For EdU 
detection, a reaction cocktail was prepared according to the manufacturer’s instructions and added to 
the cells. After 30 min incubation at room temperature, cells were washed and counterstained with 
0.4 mg/ml DAPI in deionized water for 5 min. Cells were washed with deionized water and imaged with 
a widefield microscope (Axiovert 200M with a 10× objective, Zeiss). Cells were automatically scanned 
and the EdU signal intensity was plotted against the DAPI signal intensity by utilizing the program 
MetaCyte (MetaSystems). To determine the number of cells in G1-, S-, and G2-phase, the cell cycle 
distribution generated by MetaCyte was used.  
3.3.17 WESTERN BLOT ANALYSIS 
For quantification of protein levels, 6 × 105 wild-type MCF10A or S2-R cells were seeded on 6 cm tissue 
culture plates and incubated in growth-medium for 2 days. After a 48-h growth factor and serum 
deprivation, cells were stimulated for the indicated time points and then harvested in 2 ml PBS by 
scraping. Cells were centrifuged and frozen in liquid nitrogen. For protein extraction, cells were lysed 
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on ice with 50 μl lysis buffer (RIPA) containing 1 % protease inhibitor (Carl Roth), 1 % phosphatase 
inhibitor (Sigma), 50 mM Tris (Carl Roth), 100 mM NaCl (Carl Roth), 1 % Triton X-100, 0.5 % 
Na-Deoxycholate (Carl Roth) and 0.1 % SDS (Carl Roth). Cell debris was removed by centrifugation at 
4 °C and protein concentration was determined by Bradford protein assay (Roti-Nanoquant, Carl Roth). 
Afterwards, proteins were denatured with NuPAGE 4× Sample buffer (Invitrogen) and 50 mM reducing 
agent (DTT, Sigma) for 10 min at 70 °C. Each protein sample (10-20 μg) was loaded on a 10 % SDS-PAGE 
gel and separated for 1 h at 180 V using the Mini Trans-Blot® Cell System (Biorad) with running buffer 
containing 25 mM Tris/HCl (Carl Roth), 0.2 M glycine (Carl Roth) and 0.5 % SDS. For molecular weight 
estimation 7 μl of Precision Plus ProteinTM Dual Color Standards (Biorad) were loaded on the gel. After 
the run was finished, proteins were transferred to a polyvinylidene difluoride (PVDF) membrane 
(Carl Roth) for 1.5 h at 200 mA using the same chamber with transfer buffer containing 25 mM Tris, 
192 mM glycine and 20 % methanol. To cover unspecific reaction sites, the membrane was blocked 
with 5 % nonfat-dried milk or BSA in TBS-T for 1 h at room temperature. In the next step, the primary 
antibodies (listed below) were diluted in the respective blocking solution and incubated with the 
membrane overnight at 4° C. The next day the membrane was washed with TBS-T and incubated with 
an HRP (horseradish peroxidase) conjugated goat anti-rabbit/mouse secondary antibody for 1 h at 
room temperature. Washing steps were performed as before and finally the detection of the 
transferred proteins was carried out by using the Amersham ECL Prime Western Blotting Detection Kit 
(GE Healthcare). Chemiluminescent images were captured with a Fusion Fx documentation system 
(Vilber Lourmat). Western blot bands were quantified with Image J’s gel analysis tool. 
Antibody 
Mouse monoclonal anti-Actin (Thermo Fisher Scientific) 
Mouse monoclonal anti-FST (Santa Cruz) 
Rabbit monoclonal anti-GAPDH (Sigma Aldrich) 
Rabbit monoclonal anti-pSMAD2 (Cell Signaling Technology) 
Rabbit monoclonal anti-TGFBR3 (Cell Signaling Technology) 
Rabbit monoclonal anti-cleaved caspase 7 (Cell Signaling Technology) 
Goat polyclonal anti-mouse, HRP conjugated (Thermo Fisher Scientific) 










3.3.18 RNA ISOLATION AND CDNA SYNTHESIS 
For RNA isolation, S2-R cells were seeded, stimulated and harvested as described in 3.3.17. Total RNA 
was isolated from the cells using the High Pure RNA Isolation Kit by Roche according to the 
manufacturer´s instructions. The RNA was eluted in 30 µl EB buffer and the concentration was 
determined using the spectrophotometer NanoDrop 2000c. For each sample, 1 µg of RNA was 
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converted into cDNA by using the reverse transcriptase and oligo dT primer (NEB First Strand cDNA 
Synthesis Kit). To this end, the following components were mixed and heated for 5 min at 70 °C. 
Component Amount 
RNA  1 µg  
dNTP mix (10 mM)  1 µl  
Oligo dT  2 µl  
DEPC-treated H2O  8 µl  
Afterwards, the components listed below were added and the resulting mixture was incubated for 1 h 
at 42 °C. 
Component Amount 
5× Reaction Buffer  4 µl  
DTT (1 M)  2 µl  
RNase inhibitor  1 µl  
Reverse transcriptase  1 µl  
Enzymes were inactivated at 80 °C for 5 min and 180 µl DEPC-treated H2O were added for dilution. 
3.3.19 REAL-TIME QUANTITATIVE PCR 
The RT-qPCR was performed in the StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific) 
using a 96-well plate (Applied Biosystems) and an adhesive foil (Biozym). All samples were carried out 
in triplicates. The real-time PCR was performed with the following reaction setup and program: 
Component Amount 
cDNA  3 µl  
SYBR Green Master Mix (Roche)  12.5 µl  
forward primer (640 nM)  4.75 µl  
reverse primer (640 nM)  4.75 µl  
 
Step Temperature  Time  Cycles  
Holding stage 95 °C  10 min  1  
Cycling stage 1 95 °C  15 s  40  
Cycling stage 2 60 °C  1 min  40  
Melt curve stage 1 95 °C  15 s  1  
Melt curve stage 2 60 °C  1 min  1  
Melt curve stage 3 60-95 °C, +0.3 °C  15 s  10  
To determine the level of expression for each gene of interest, the comparative CT (ΔΔCT) method was 
used. First, the difference between the CT value of a housekeeping gene (Actin) and the CT value of 
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the gene of interest was calculated resulting in the ΔCT value. Then, the difference in the ΔCT values 
between the experimental and control samples is calculated resulting in the ΔΔCT value.  













3.3.20 RNA SEQUENCING 
For the RNA sequencing, S2-R cells were seeded, stimulated and harvested as described in 3.3.17. 
Afterwards, RNA was isolated as described in 3.3.18. Two biological replicates for each condition were 
prepared. The RNA sequencing itself and subsequent data processing were performed by the IMB 
Genomics Core Facility (Mainz). Further data evaluation was carried out by Lorenz Ripka (IMB Mainz). 
To generate the next generation sequencing (NGS) libraries the TruSeq stranded mRNA LT Sample Prep 
Kit (Illumina) was used according to the manufacturer’s instructions. Libraries were prepared with a 
starting amount of 500 ng RNA, amplified in 11 PCR cycles, and profiled using a DNA 1000 kit and a 
2100 Bioanalyzer (both Agilent). Afterwards, the libraries were quantified in a Qubit 2.0 Fluorometer 
using the dsDNA HS Assay Kit (both Thermo Fisher). All libraries were pooled in equimolar ratios and 
sequenced on the NextSeq 500 sequencing system (Illumina) with the following parameters: 
high-output flow cell, single-read mode and 84 cycles plus 7 cycles index read. The poly(A) RNA 
sequencing was conducted in a non-strand specific mode with a coverage of 50 bp reads. Utilizing the 
software bcl2fastq (v.2.19.1.403, Illumina), samples were demultiplexed and FastQ files were 
generated. The raw sequence reads were assessed with FastQC (v.0.11.5, Babraham Bioinformatics) 
and then aligned to the human reference genome GRCh38.p7 (GTF annotation file from Gencode 
human release 25) using the STAR aligner (Dobin et al., 2013, v.2.5.2b). The mapped data were 
summarized on the gene level using the software featureCounts (v.1.6.2, Subread). Further data 
evaluation, normalization and pairwise differential expression analyses were carried out in R (v.3.5.0) 
using the Bioconductor package DESeq2 (v.1.20.0) following the recommended analysis workflow. To 
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calculate the robust reads per kilobase of transcript per million mapped reads (RPKMs) for each gene, 
the Bioconductor packages GenomicRanges (v.1.32.1) and rtracklayer (v.1.40.6) with the 
above-mentioned GTF annotation file and robust fragments per million (FPM) data computed by 
DESeq2 were used. To calculate fold changes, this package uses a maximum likelihood model with the 
assumption of a negative binomial distribution of reads fitted to the read counts of all samples 
available for a given combination of conditions. Additionally, based on those models, p-values were 
calculated for each fold change that refer to the differential expression compared to a reference 





The overall objective of this study was to gain an improved understanding of the interplay between 
different signaling pathways through quantitative and time-resolved dissection of the MEK/ERK, 
PI3K/AKT and SMAD networks at the single-cell level. With this approach, I was able to disentangle the 
contributions of the MAPK and PI3K/AKT pathways to mitogenic signaling during different cell cycle 
phases. Furthermore, I discovered that MAPK signaling strongly affected the SMAD network and 
shaped ligand-specific signaling dynamics of SMAD2, which is most likely mediated through gene 
expression changes. Interestingly, these dynamics are more decisive for cellular responses than the 
ligands themselves, suggesting a quantitative rather than qualitative signaling pathway. Thus, MAPK 
activity not only affected activation patterns of SMAD molecules but also SMAD-associated cell fate 
decisions such as apoptosis and EMT. Conversely, SMAD signaling decreased the expression of cell 
cycle regulators like MYC and thereby counteracted the pro-mitotic signals mediated by MEK/ERK and 
PI3K/AKT pathways. This shows how tightly different signaling pathways are connected and how they 
interact to orchestrate changes in gene expression and signaling dynamics to ultimately control 
important cellular outcomes such as proliferation, quiescence, migration and apoptosis. 
The interplay between MAPK and SMAD pathways has been investigated before and there is broad 
evidence that SMAD signaling is integrated in a complex network with other signaling pathways that 
modify initial SMAD signals (Javelaud and Mauviel, 2005). For example, it has been shown that ligands 
like TGFb not only signal through SMAD proteins but also activate signaling networks involving MAPK 
and PI3K. Conversely, these pathways can modulate the outcome of ligand-induced SMAD signaling by 
regulating R-SMADs through phosphorylation of the corresponding linker-regions, regulating I-SMADs 
or altering gene expression (Zhang and Derynck, 1999; Lutz and Knaus, 2002; Wakefield and Roberts, 
2002; Derynck and Zhang, 2003). Many studies have shown that the expression of SMAD 
pathway-associated genes can be modified through other networks. For instance, MEK activity is 
required for the expression of TGFB1 and positively regulates SMAD3 gene transcription (Yue and 
Mulder, 2000; Ross et al., 2007). Furthermore, EGF can induce the expression of I-SMADs and the 
kinase JNK has a repressive effect on the TGFB1 gene (Afrakhte et al., 1998; Ventura et al., 2004). These 
observations are compatible with my results that showed that multiple SMAD pathway-associated 
genes are differentially expressed without sustained MAPK activity. 
Although there are already numerous studies showing crosstalk between the SMAD and MAPK 
signaling pathways, my work additionally provides time-resolved single-cell measurements of SMAD 




leads to an increase or decrease in SMAD2 signaling dynamics depending on the ligand. These results 
highlight how simple and straight forward pathways gain complexity by interacting with other signaling 
networks. While I shed some light on the interplay between the MEK/ERK, PI3K/AKT and SMAD 
pathways, it should be mentioned that further studies need to follow in order to grasp signaling 
crosstalk in its entirety. As there are many more pathways affecting SMAD signaling such as the WNT, 
Notch, p53 and NF-κB pathways (Elston and Inman, 2012; Luo, 2017), which can additionally influence 
one another (Dotto, 2009; Kim et al., 2011; Konrath et al., 2020), a complete understanding of the 
convoluted interplay constitutes a great challenge. Nonetheless, since comprehending complex 
biological systems provides valuable knowledge and should be the ambition of systems biology, it is 
crucial to further research pathway interactions to ultimately understand the larger picture. But why 
is it important to gain a profound knowledge of the interplay of signaling networks? A good example 
to answer this question is the interaction of the SMAD and MAPK pathways in cancer progression. 
Usually, in healthy tissues these pathways operate in opposite directions, however, in different cancers 
the corresponding pathways are simultaneously activated and promote the malignant state (Chapnick 
et al., 2011). For instance, the crosstalk between SMAD and MAPK pathways is required for the 
formation of metastasis. Consistent with my results, it has been reported that none of the two 
pathways is capable of inducing the transition from an epithelial to mesenchymal phenotype alone 
(Janda et al., 2002). Interestingly, Janda et al., 2002, also showed that TGFb-induced apoptosis requires 
a sustained lack of PI3K signaling. Although my results also only showed apoptosis in 
growth factor-deprived cells and thus without active PI3K, I did not observe an increase in cell death 
when cells were treated for 48 h with a PI3K inhibitor and subsequently with TGFb or GDF11 (data not 
shown). Therefore, further pathway interactions may regulate the induction of apoptosis in MCF10A 
cells. Understanding such molecular details and the relative contributions of each signaling pathway 
to cell fate decisions is thereby essential to devise therapeutic interventions that counteract altered 
cellular outcomes. While there are already plenty of inhibitors and antagonistic antibodies of the ERK 
and SMAD pathways under evaluation in clinical trials (Yingling et al., 2004; Arteaga, 2006; Roberts and 
Der, 2007), it may be advantageously to utilize a combinatorial approach when considering the 
interplay between the different pathways. The information provided by my work, such as that MAPK 
and PI3K/AKT activity are required for proper cell cycle entry and progression, or that the cell state 
changes SMAD-associated dynamics and cellular responses, may be of use in the development of such 
combinatorial therapies.  
Simultaneously targeting mitogenic signals and the SMAD pathway could be of particular interest in 




often exhibit dysregulations of both signaling networks in cancer. The mammary gland is a perfect 
example for such a tissue, as it constantly employs the corresponding pathways to facilitate the switch 
between proliferation states and as approximately 90 % of breast cancer deaths are associated with 
invasion and distant metastasis (Wang and Zhou, 2011).  
The results of this study were all obtained in breast epithelial cells and thereby most relatable to the 
mammary tissue. However, it should be kept in mind that all experiments in this work were performed 
in vitro under isolated conditions. Therefore, as a next step it would be intriguing to put my 
observations into context with the mammary gland in vivo, where many other factors interact to 
regulate biological mechanisms. While I have already included different proliferation states into the 
equation by investigating pathways in quiescent cells without abundant growth factors, there are 
many more parameters to consider. For instance, the development of the mammary gland is mainly 
controlled by signals from the mesenchyme and circulating hormones such as estrogen, progesteron 
and growth hormones (Macias and Hinck, 2012). In my experimental approach, growth control was 
primarily regulated by EGF. Thus, it would be interesting to see how hormonal cues affect the interplay 
between different pathways and ultimately cell fate decisions. Furthermore, examining the activity of 
MAPK, PI3K/AKT, SMAD or other pathways during the development of the mammary gland could give 
deeper insight into how different networks interact to precisely regulate proliferation, quiescence, 
migration and apoptosis.  
Taken together, although extensive biochemical and genetic studies already characterized most 
signaling pathways in molecular detail, their relative contribution and interplay in governing cell fate 
decisions remain largely unexplored. The present thesis shows how important the crosstalk between 
pathways is, since interfering with different interactions can lead to a strong delay in cell cycle 
progression or even trigger completely different cell fates. Further studies combining time-resolved 
quantitative experiments with computer-aided analysis and correlating the data to cellular outcomes 
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6.1 LIST OF ABBREVIATIONS 




µg micrograms  





ACVR1B activin A receptor 1B  
ACVR1C  activin A receptor 1C  
ACVR2A activin A receptor 2A  
ACVR2B activin A receptor 2B 
 AKTi AKT inhibitor  
AMH anti-Muellerian hormone   
Amp amplitude  
APC anaphase-promoting complex  
APS ammonium persulfate  
au arbitrary unit   




BAM binary sequencing alignment map  
BIM Bcl-2-like protein 11  
Blast_R blasticidin resistance  
BMP bone morphogenetic protein  
BMPR2  BMP receptor 2  
bp base pairs  




Cas9 CRISPR-associated 9  
CDH1 E-cadherin  
CDH2 N-cadherin  
CDK cyclin-dependent kinases  
 CDK1i CDK1 inhibitor 
 CDK4/6i CDK4/6 inhibitor  
CDKN1A  cyclin-dependent kinase inhibitor 1A (p21)  
CDKN1B cyclin-dependent kinase inhibitor 1B (p27)  
CDKN2B  cyclin-dependent kinase inhibitor 2B (p15)  
cDNA complementary DNA  
CFP cyan fluorescent protein  
CKIs CDK inhibitors   
cm centimeter  
CMV cauliflower mosaic virus  
Co-SMAD common-mediator SMAD; isoform 4  





crRNA  CRISPR RNA  




DAPI  4ʹ,6-diamidino-2-phenylindole  
dCas9 dead Cas9  
ddH2O  double-distilled water  
DEPC-treated H2O  diethyl pyrocarbonate treated water  
DMEM/F12 Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12  
DMSO dimethyl sulfoxide  
DNA deoxyribonucleic acid  
dNTP deoxyribose nucleotide triphosphate  
DPBS Dulbecco's phosphate buffered saline  
DRB 5,6-dichlorobenzimidazole 1-β-D-ribofuranoside  
DSB double-strand breaks  





ECL enhanced chemiluminescence  
EDTA ethylenediaminetetraacetic acid  
EdU 5-Ethynyl-2ʹ-deoxyuridine  
EGF epidermal growth factors   
EGFR EGF receptor  
 EGFRi EGFR inhibitor  
EGR1 early growth response protein 1  
EMT epithelial to mesenchymal transition  




FC fold change  
FIRE fra-1-based integrative reporter of ERK  
FOXH1 forkhead box protein H1   
FOXO forkhead box protein O  
FPM fragments per million   
FRA1/FOSL1 fos-related antigen 1  
FRET fluorescence resonance energy transfer  
FST follistatin  




G1-phase first gap phase (cell cycle)  
G2-phase second gap phase (cell cycle)  
GAPDH glyceraldehyde 3-phosphate dehydrogenase  
GASP1 GDF-associated serum protein 1  
GASP2 GDF-associated serum protein 2  
GDF3 growth differentiation factor 3  
GDF8 growth differentiation factor 8; also called myostatin 
 GDF11 growth differentiation factor 11  





GO gene ontology   
GSK3beta glycogen synthase kinase 3 beta 
 GSK3i GSK3 inhibitor  




h hours  
H2B histone 2b  
HA homology arm  
HAL homology arm left  
HAR homology arm right  
HCl  hydrogen chloride  
HDAC1 histone deacetylase 1  
HDAC2 histone deacetylase 2  
HDR homology-directed repair  
HEK293T human embryonic kidney cells expressing SV40 large T antigen  




ID2 inhibitor of DNA binding 2  
IGF insulin-like growth factor  




JNK c-Jun N-terminal kinase 




kDa kilodalton  
KEGG Kyoto Encyclopedia of Genes and Genomes  
KLF krueppel-like factors    









m slope of linear model   
mA milliampere  
MAPK mitogen-activated protein kinase  
MCF10A immortalized human breast epithelial cell line (Michigan Cancer 
Foundation-10A)  
MEK MAPK kinase  
MEKi MEK inhibitor  
mg milligrams  
MH1 mad homology 1  
MH2 mad homology 2  
min minutes  
ml milliliter  
mM millimolar  





mRNA messenger RNA  
MSCV LTR  murine stem cell virus long terminal repeat  
mTOR mechanistic target of rapamycin kinase   
MYC myelocytomatosis oncogene 
N 
  
 NF-κB  nuclear factor 'kappa-light-chain-enhancer' of activated B-cells  
ng nanograms  
NGF nerve growth factors   
NGS next generation sequencing  
NLS nuclear localization sequence   









 p38i p38 inhibitor  
PBS phosphate buffered saline  
PC principal components  
PCA principal component analysis   
PCR polymerase chain reaction  
PDK1 phosphoinositide-dependent kinase 1   
PDP pyruvate dehydrogenase phosphatase   
PI3K phosphatidylinositol 3-kinase  
PI3Ki PI3K inhibitor  
PIP2 phosphatidylinositol-4,5-bisphosphate   
PIP3 phosphatidylinositol-3,4,5-triphosphate   
pM picomolar  
poly(A) polyadenylation  
PPM1A protein phosphatase 1A  
PROGENy Pathway RespOnsive GENes for activity inference  
pSMAD2 phosphorylated SMAD2  
PTEN phosphatase and tensin homologue   
PTM post-translational modification   




r correlation coefficient   
RAF rapidly accelerated fibrosarcoma   
RB retinoblastoma protein  
RFP red fluorescent protein   
RNA ribonucleic acid  
RNase ribonuclease  
RPKM reads per kilobase of transcript per million mapped reads   
R-SMADs receptor-regulated SMADs; isoforms 1, 2, 3, 5, 8  
RT-qPCR real-time quantitative PCR  







s seconds  
S2-R  MCF10A SMAD2 reporter cell line  
SA-bG senescence-associated beta-galactosidase  
scRNA-seq single-cell RNA sequencing  
 sd standard deviation  
SDS sodium dodecyl sulfate  
sgRNA single guide RNA   
SMAD SMA ('small') and MAD ('mothers against decapentaplegic')  
SOC  super optimal broth with catabolite repression  
SOX4 SRY-box transcription factor 4  
S-phase synthesis phase (cell cycle)  




TAE tris-acetate-EDTA  
TBS-T  tris-buffered saline with Tween20  
TEMED tetramethylethylenediamine  
TGFb transforming growth factor beta   
TGFBR1 TGFb receptor 1  
TGFBR2 TGFb receptor 2  
TGFBR3 TGFb receptor 3  
tracrRNA trans-activating crRNA  




U/ml units per milliliter  
U-2 OS  human bone osteosarcoma cells  
UbCp ubiquitin C promoter   
UMAP uniform manifold approximation and projection  









w/v weight per volume 
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6.3 NUMBER OF TRACKED CELLS IN TIME-LAPSE 
























































































Related to Figure 8-10  
Stimulation 0 control 
   
1147 
Stimulation 0,5 control 
   
1137 
Stimulation 1 control 
   
1062 
Stimulation 2,5 control 
   
1248 
Stimulation 5 control 
   
1022 
Stimulation 7,5 control 
   
1013 
Stimulation 10 control 
   
876 
Stimulation 12,5 control 
   
877 
Stimulation 15 control 
   
1061 
Stimulation 17,5 control 
   
920 
Stimulation 20 control 
   
905 
Stimulation 50 control 
   
1175 
Related to Figure 9 and 10 
EDU costaining 0 control 
   
2821 
EDU costaining 0 control 
  
20 3501 
EDU costaining 0,5 control 
   
2531 
EDU costaining 0,5 control 
  
20 3206 
EDU costaining 1 control 
   
2356 
EDU costaining 1 control 
  
20 3119 
EDU costaining 2,5 control 
   
2127 
EDU costaining 2,5 control 
  
20 2575 
Related to Figure 11 
MAPK 0 AZD6244 
   
1324 
MAPK 0 control 
   
995 
MAPK 0 gefitinib 
   
1373 
MAPK 0 sorafenib 
   
1423 
MAPK 1 AZD6244 
   
1550 
MAPK 1 control 
   
1097 
MAPK 1 gefitinib 
   
1601 
MAPK 1 sorafenib 
   
1565 
MAPK 7,5 AZD6244 
   
1603 
MAPK 7,5 control 
   
1264 
MAPK 7,5 gefitinib 





MAPK 7,5 sorafenib 
   
1441 
Related to Figure 11 
PI3K-IKK2 0 control 
   
1403 
PI3K-IKK2 0 IKK2 
   
2009 
PI3K-IKK2 0 PI3K 
   
1575 
PI3K-IKK2 1 control 
   
1580 
PI3K-IKK2 1 IKK2 
   
1810 
PI3K-IKK2 1 PI3K 
   
1810 
PI3K-IKK2 7,5 control 
   
1338 
PI3K-IKK2 7,5 IKK2 
   
1780 
PI3K-IKK2 7,5 PI3K 
   
1825 
Related to Figure 11 
p38 0 control 
   
1071 
p38 0 p38 
   
1779 
p38 1 control 
   
1398 
p38 1 p38 
   
1760 
p38 7,5 control 
   
1255 
p38 7,5 p38 
   
1648 
Related to Figure 11 
AKT 0 AKT 
   
1779 
AKT 0 control 
   
1817 
AKT 1 AKT 
   
2075 
AKT 1 control 
   
2137 
AKT 7,5 AKT 
   
1721 
AKT 7,5 control 
   
1805 
Related to Figure 11 
JNK-GSK 0 control 
   
1765 
JNK-GSK 0 GSK3 
   
2027 
JNK-GSK 0 JNK 
   
1862 
JNK-GSK 1 control 
   
1386 
JNK-GSK 1 GSK3 
   
1837 
JNK-GSK 1 JNK 
   
2082 
JNK-GSK 7,5 control 
   
1621 
JNK-GSK 7,5 GSK3 
   
1753 
JNK-GSK 7,5 JNK 
   
1796 
Related to Figure 12 
CDK 0 CDK4/6 (10 uM 
Palbocyclin) 
   
2110 
CDK 0 CDK1 (10 uM RO3306) 
   
2336 
CDK 0 control 
   
2067 
CDK 1 CDK4/6 (10 uM 
Palbocyclin) 
   
2365 
CDK 1 CDK1 (10 uM RO3306) 
   
2386 
CDK 1 control 





CDK 7,5 CDK4/6 (10 uM 
Palbocyclin) 
   
2155 
CDK 7,5 CDK1 (10 uM RO3306) 
   
2595 
CDK 7,5 control 
   
1801 
Related to Figure 13 
Pulse_02 0 control 0 
  
3108 
Pulse_02 7,5 AZD6244 0 
  
2245 
Pulse_02 7,5 AZD6244 10 
  
2291 
Pulse_02 7,5 AZD6244 15 
  
2429 
Pulse_02 7,5 AZD6244 20 
  
1839 
Pulse_02 7,5 control 0 
  
1568 
Pulse_02 7,5 control 10 
  
1713 
Pulse_02 7,5 control 15 
  
1842 
Pulse_02 7,5 control 20 
  
1749 
Pulse_02 7,5 gefitinib 0 
  
2854 
Pulse_02 7,5 gefitinib 10 
  
2668 
Pulse_02 7,5 gefitinib 15 
  
3018 
Pulse_02 7,5 gefitinib 20 
  
2507 
Pulse_02 7,5 PI3K 0 
  
2778 
Pulse_02 7,5 PI3K 10 
  
2998 
Pulse_02 7,5 PI3K 15 
  
3101 
Pulse_02 7,5 PI3K 20 
  
3092 
Related to Figure 13 and 17 
EdU_pulse 0 gefitinib 
   
2227 





EdU_pulse 7,5 control 
  
15 1985 
EdU_pulse 7,5 control 
  
22.5 1775 
EdU_pulse 7,5 control 
  
32.5 1819 
EdU_pulse 7,5 control 15 
  
1918 
EdU_pulse 7,5 AZD6244 15 
 
22.5 2394 
EdU_pulse 7,5 AZD6244 15 
 
32.5 2155 
EdU_pulse 7,5 PI3K 15 
 
22.5 2646 
EdU_pulse 7,5 PI3K 15 
 
32.5 2443 
EdU_pulse 7,5 AZD6244 20 
  
1877 
EdU_pulse 7,5 PI3K 20 
  
2609 
Related to Figure 13 




































































Related to Figure 14 
IGF expanded 0 control 
   
3186 
IGF expanded 0,1 IGF (2.5 µg/ml) 
   
2287 
IGF expanded 0,1 control 
   
2584 
IGF expanded 0,175 IGF (2.5 µg/ml) 
   
2528 
IGF expanded 0,175 control 
   
2519 
IGF expanded 0,25 IGF (2.5 µg/ml) 
   
2402 
IGF expanded 0,25 control 
   
2402 
IGF expanded 0,5 IGF (2.5 µg/ml) 
   
2815 
IGF expanded 0,5 control 
   
2212 
Related to Figure 14 
Insulin 0 control 
   
1811 
Insulin 1 Insulin (5 µg/ml) 
   
1681 
Insulin 1 control 
   
1601 
Insulin 7,5 control 
   
1504 
Related to Figure 14 
IGF rescue 0 control 
  
20 3545 
IGF rescue 0 IGF 
  
20 3710 
IGF rescue 0,1 control 
  
20 3853 
IGF rescue 0,1 IGF 
  
20 3935 
IGF rescue 0,25 control 
  
20 3678 
IGF rescue 0,25 IGF 
  
20 4095 
IGF rescue 0,5 control 
  
20 4107 
IGF rescue 0,5 IGF 
  
20 4365 
Related to Figure 14 
IGF 0 control 
   
2242 
IGF 0,5 IGF (2.5 µg/ml) 
   
2047 
IGF 0,5 control 
   
2148 
IGF 50 control 
   
1379 
IGF 0 IGF (0.5 µg/ml) 
   
1874 
IGF 0 IGF (1 µg/ml) 
   
2388 
IGF 0 IGF (2.5 µg/ml) 







6.4 PLASMID MAPS 
 
Figure 28: Plasmid map of sgRNA_AL. 





Figure 29: Plasmid map of pDONR221. 





Figure 30: Plasmid map of pVE10. 





Figure 31: Plasmid map of pDONR221-Blast_R. 





6.5 SEQUENCING OF FST KNOCKOUT CLONES 
 
 
Figure 32: Sequencing results of FST-KO clones 1 and 26. 






6.6 DATABASE RESOURCES USED FOR SMAD 
PATHWAY-ASSOCIATED GENES 
Database resource Reference 
TGF-beta signaling pathway (KEGG)  [1] 
TGF-beta signaling pathway  [2] 
TGF-beta Receptor Signaling  [2] 
ALK1 signaling (GDF11)  [2] 
TGF-beta receptor signaling activates SMADs  [2] 
SMAD Signaling Network  [2] 
TGF-beta Signaling Pathways  [2] 
Transcriptional feedback regulation of TGFb signaling [3] 
[1] Kanehisa et al., 2016 ; [2] Belinky et al., 2015 ; [3] Legewie, 2009 
6.7 NUMBER OF TRACKED CELLS IN TIME-LAPSE 
MICROSCOPY EXPERIMENTS (PART 2) 
Condition Number of tracked cells 
Figure 18D + E + G + H  
Quiescent control 1092 
Quiescent TGFb 1256 
Proliferating control 924 
Proliferating TGFb 912 
Figure 19A  
Quiescent control 790 
Quiescent + EGF 899 
Quiescent TGFb 815 
Quiescent 4 h EGF 789 
Quiescent 6 h EGF 811 
Quiescent 8 h EGF 793 
Figure 19C  
Quiescent control 235 
Quiescent TGFb 303 
Quiescent CDK4/6 + TGFb 402 
Quiescent EGF + TGFb 478 
Quiescent CDK4/6 + EGF + TGFb 779 
Figure 19D + 20H  
Quiescent control 764 
Quiescent TGFb 781 




Proliferating TGFb 704 
EGFRi + TGFb 912 
MEKi + TGFb 986 
Quiescence GDF11 719 
EGFRi + GDF11 891 
MEKi + GDF11 907 
Proliferating GDF11 697 
PI3K + TGFb 2694 
PI3K + GDF11 3183 
Proliferating Control 4076 
Figure 20A  
Quiescent control 1136 
Quiescent 100 pM TGFb 1515 
Quiescent 1 nM GDF11 2081 
Quiescent 20 nM GDF11 1801 
Quiescent 1 nM GDF8 2065 
Quiescent 20 nM GDF8 1726 
Quiescent 1 nM GDF3 2006 
Quiescent 20 nM GDF3 2019 
Quiescent 1 nM activin A 2165 
Quiescent 20 nM activin A 2005 
Proliferating control 1054 
Proliferating 100 pM TGFb 895 
Proliferating 1 nM GDF11 851 
Proliferating 20 nM GDF11 971 
Proliferating 1 nM GDF8 953 
Proliferating 20 nM GDF8 1025 
Proliferating 1 nM GDF3 925 
Proliferating 20 nM GDF3 982 
Proliferating 1 nM activin A 1054 
Proliferating 20 nM activin A 965 
Figure 20B-E + Figure 18A  
Quiescent control 1635 
Quiescent 1 pM TGFb 1447 
Quiescent 2.5 pM TGFb 1424 
Quiescent 5 pM TGFb 1410 
Quiescent 25 pM TGFb 1413 
Quiescent 100 pM TGFb 1576 
Quiescent 100 pM GDF11 1522 
Quiescent 500 pM GDF11 1682 




Quiescent 2.5 nM GDF11 1380 
Quiescent 10 nM GDF11 1379 
Proliferating Control 739 
Proliferating 1 pM TGFb 744 
Proliferating 2.5 pM TGFb 768 
Proliferating 5 pM TGFb 702 
Proliferating 25 pM TGFb 671 
Proliferating 100 pM TGFb 649 
Proliferating 100 pM GDF11 763 
Proliferating 500 pM GDF11 649 
Proliferating 1 nM GDF11 869 
Proliferating 2.5 nM GDF11 803 
Proliferating 10 nM GDF11 769 
Figure 20F + 18F  
Proliferating control 1103 
Proliferating GDF11 1128 
Proliferating TGFb 1080 
Quiescent control 1249 
Quiescent GDF11 1248 
Quiescent TGFb 1386 
Figure 24B + C  
DRB + GDF11 1479 
GDF11 1651 
TGFb 1049 
TGFBR3-OE TGFb 865 
Figure 25 + 26 two biological replicates  
Quiescent control 5185 
Quiescent 5 pm TGFb 4713 
Quiescent 250 pM TGFb 2651 
Quiescent 100 pM GDF11 3749 
Quiescent 10 nM GDF11 572 
Proliferating Control 4478 
Proliferating 5 pM TGFb 1230 
Proliferating 250 pM TGFb 355 
Proliferating 100 pM GDF11 4901 
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